学术周报 · IF≥10 或专科旗舰刊
急重症领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Critical care medicine | 20 | IF 7.5 |
| Annals of emergency medicine | 8 | IF 6.5 |
| British journal of anaesthesia | 7 | IF 10.3 |
| JAMA network open | 5 | IF 11.7 |
| Intensive care medicine | 4 | IF 22.0 |
| European heart journal | 3 | IF 45.3 |
| Archives of toxicology | 3 | IF 10.9 |
| Pharmacological research | 3 | IF 12.2 |
| JAMA internal medicine | 3 | IF 26.3 |
| JAMA pediatrics | 3 | IF 17.1 |
1急诊医学与院前急救 (25篇)
临床研究 (23篇)
Acute cholangitis (AC) is a potentially fatal biliary tract infection most commonly caused by gallstones. While modern-day treatments with antibiotics and biliary decompression have drastically decreased mortality rates, AC still requires prompt intervention. Diagnosis of AC traditionally relied on the presence of the Charcot triad, which has since proven to incompletely capture the complexity of this condition. Modern-day diagnosis, severity grading, and management guidelines provide a more holistic approach. Tokyo Guidelines (TG) are widely used, though newer guidelines, namely the BILE criteria, have recently emerged. These criteria include demonstration of inflammation, cholestasis, and biliary obstruction. Ultrasound is first-line imaging modality with computed tomography or magnetic resonance cholangiopancreatography often used for diagnostic dilemmas. Treatment is dependent on severity, though guidelines generally recommend early decompression (most commonly with endoscopic retrograde cholangiopancreatography [ERCP]) for moderate to severe cases. The optimal timing of biliary drainage remains unclear, with mixed evidence from observational studies and no universal definition of what constitutes "early" vs "urgent" drainage. Laparoscopic cholecystectomy should be performed during index hospitalization, when possible, with multiple studies demonstrating lower morbidity and mortality rates when compared with interval procedures. The prognosis of AC is favorable if treated swiftly and appropriately; in turn, mortality rates increase with severity and delays in diagnosis. AC can be challenging to diagnose and the precise timing of biliary drainage and cholecystectomy is debated. This comprehensive review reflects the most recent evidence and recommendations on severity grading, resuscitation, and timing of ERCP and cholecystectomy to assist clinicians who manage these complex patients.
中文摘要:急性胆管炎(AC)是一种可能致命的胆道感染,最常见由胆结石引起。抗生素和胆道减压等现代治疗已大幅降低死亡率,但AC仍需要及时干预。传统诊断依赖Charcot三联征,后来发现其不能完整反映该病的复杂性。现代诊断、严重程度分级和管理指南提供了更全面的方法。东京指南(TG)应用广泛,新近出现了BILE标准等新指南。这些标准包括炎症、胆汁淤积和胆道梗阻的证据。超声是一线影像学检查,诊断困难时常用计算机断层扫描或磁共振胰胆管成像。治疗取决于严重程度,指南通常建议中重度病例尽早减压(最常用内镜逆行胰胆管造影[ERCP])。胆道引流的最佳时机仍不明确,观察性研究证据不一,且对「早期」与「紧急」引流没有统一定义。条件允许时,应在本次住院期间行腹腔镜胆囊切除术,多项研究显示与延期手术相比,其并发症发生率和死亡率更低。若治疗及时恰当,AC预后良好;反之,死亡风险随严重程度和诊断延误而升高。AC的诊断可能具有挑战性,胆道引流和胆囊切除术的确切时机仍有争议。这篇综合综述反映最新证据和建议,涵盖严重程度分级、复苏以及ERCP和胆囊切除术的时机,以帮助临床医生管理这类复杂患者。
Generative artificial intelligence (AI) chatbots are increasingly used to support maternal health, but randomized evidence is limited. To evaluate whether access to a generative AI maternal health chatbot improved 12-month maternal health outcomes. This 2-group randomized clinical trial enrolled 400 participants from October 2023 to December 2024, with 12-month follow-up completed in December 2025. Participants were recruited online across 49 US states and the District of Columbia. Eligible participants were English-speaking, aged 14 years or older, pregnant or parenting an infant younger than 6 months, and self-identified as members of racial and/or ethnic minoritized groups. Participants were randomized 1:1 to receive access to the chatbot or an active control consisting of monthly children's books. Primary outcomes were anxiety and depression symptoms at 12 months measured using the Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9. Secondary outcomes included emergency department visits, pregnancy-related complications, postpartum care checkups, effective contraception use, and sleep duration. Among 400 randomized participants, the mean (SD) age was 32.6 (5.1) years; 200 (50%) were parenting an infant at enrollment; and 10 (2%) identified as American Indian or Alaska Native, 80 (20%) Asian, 188 (47%) Black or African American, 57 (14%) multiracial, and 65 (16%) Hispanic or Latino. The AI chatbot was not associated with differences in anxiety scores (adjusted mean difference, 0.10; 95% CI, -0.77 to 0.96) or depression scores (adjusted mean difference, -0.23; 95% CI, -1.05 to 0.59), nor with emergency department visits, postpartum care, contraception use, or sleep duration. Among participants pregnant at enrollment, the chatbot was associated with more self-reported pregnancy-related complications in the secondary 12-month end point analysis, but not in longitudinal analyses. Higher chatbot engagement was associated with longer sleep duration and higher anxiety scores in exploratory within-group analyses. In this randomized clinical trial of pregnant and postpartum individuals from racial and ethnic minoritized groups, access to a generative artificial intelligence maternal health chatbot did not improve maternal anxiety or depression at 12 months compared with an active control. Secondary and exploratory findings should be interpreted cautiously. ClinicalTrials.gov Identifier: NCT06053515.
中文摘要:生成式人工智能聊天机器人越来越多用于支持孕产妇健康,但随机证据有限。评估获得生成式人工智能孕产妇健康聊天机器人使用权限是否改善12个月孕产妇健康结局。这项2组随机临床试验于2023年10月至2024年12月入组400名参与者,12个月随访于2025年12月完成。参与者通过美国49个州和哥伦比亚特区在线招募。合格参与者为英语使用者、年龄14岁及以上、怀孕或正在抚养小于6月龄婴儿,并自我认同为种族和/或族裔少数群体成员。参与者按1:1随机分配至获得聊天机器人使用权限组或主动对照组,主动对照为每月儿童书籍。主要结局为12个月时使用广泛性焦虑障碍量表-7和患者健康问卷-9测量的焦虑和抑郁症状。次要结局包括急诊科就诊、妊娠相关并发症、产后保健检查、有效避孕措施使用和睡眠时长。400名随机参与者平均(SD)年龄为32.6(5.1)岁;入组时200名(50%)正在养育婴儿;10名(2%)为美洲印第安人或阿拉斯加原住民,80名(20%)为亚裔,188名(47%)为黑人或非裔美国人,57名(14%)为多种族,65名(16%)为西班牙裔或拉丁裔。AI聊天机器人未带来焦虑评分差异(调整后平均差,0.10;95%CI,-0.77至0.96)或抑郁评分差异(调整后平均差,-0.23;95%CI,-1.05至0.59),也未带来急诊科就诊、产后保健、避孕措施使用或睡眠时长差异。在入组时怀孕的参与者中,聊天机器人在12个月次要终点分析与更多自我报告的妊娠相关并发症相关,但在纵向分析中未见此关联。在探索性组内分析中,聊天机器人使用参与度较高与睡眠时长较长和焦虑评分较高相关。在这项针对种族和族裔少数群体孕妇和产后个体的随机临床试验中,与主动对照相比,获得生成式人工智能孕产妇健康聊天机器人使用权限未改善12个月时的孕产妇焦虑或抑郁。次要和探索性发现应谨慎解读。ClinicalTrials.gov Identifier: NCT06053515。
Hospitalizations are costly and may lead to adverse events. Some health systems offer treatment in alternative venues of care for select patients. To describe use and short-term outcomes of emergency department (ED) patients transitioned to noninpatient care settings (ambulatory treatment center [ATC], advanced care at home [ACAH], or emergency department observation unit [EDOU]) compared with inpatient care. This retrospective cohort study of ED patients aged 19 years or older was conducted from January 1, 2024, to June 30, 2025, at multisite community ED and inpatient medical centers within an integrated delivery system (Kaiser Permanente Northern California). Included patients had active health plan membership; had an ED visit for heart failure, pneumonia, cellulitis, urinary tract infection, COVID-19, or anemia; and had their care transitioned to an ATC, ACAH program (Kaiser Permanente Advanced Care at Home), EDOU, or inpatient bed. Treatment venue. The main outcomes were care escalation (inpatient admission) for patients treated in an ATC, ACAH program, or EDOU, as well as 7-day ED return visits, 30-day hospitalizations, and 30-day mortality following care completion across all venues. Unadjusted outcome rates are reported. This study included 26 618 ED encounters (median patient age, 77 years [IQR, 65-85 years]; 52.6% female). Among 22 755 unique patients, 87.4% had 1 encounter, 9.8% had 2 encounters, and 2.8% had more than 2 encounters. There were 728 (2.7%), 880 (3.3%), 5133 (19.3%), and 19 877 (74.7%) encounters in ATC, ACAH, EDOU, and hospital settings, respectively. One-quarter of patients (25.3%) received care in an ATC, ACAH program, or EDOU. Inpatient admission rates were lower for ATC and ACAH encounters than for EDOU encounters (4.3% [95% CI, 2.7%-5.8%], 5.3% [3.8%-6.8%], and 28.0% [26.8%-29.2%], respectively). Rates of 7-day ED visits were similar across venues (ATC: 10.4% [95% CI, 7.8%-12.9%]; ACAH: 5.3% [3.8%-6.8%]; EDOU: 9.2% [8.4%-10.0%]; and hospital: 8.5% [8.1%-8.9%]). In contrast, 30-day mortality and hospitalization rates were lower among ATC, ACAH, and EDOU encounters than in hospital encounters (30-day mortality: 2.1% [95% CI, 1.0%-3.2%], 1.7% [0.8%-2.6%], 2.8% [2.3%-3.2%], and 5.3% [5.0%-5.6%]; and 30-day hospitalization: 11.4% [95% CI, 8.8%-14.1%], 8.3% [6.3%-10.2%], 12.7% [11.7%-13.7%], and 15.3% [14.7%-15.8%], respectively). In this cohort study of patients treated in alternative venues of care, one-quarter received care in an ATC, ACAH program, or EDOU. These findings suggest that adoption of novel treatment spaces for appropriately selected patients may allow health systems to focus hospital resources on the patients with the most complex needs.
中文摘要:住院治疗费用高,并可能带来不良事件。部分医疗系统对经过选择的患者在替代场所提供治疗。该研究描述急诊科患者转入非住院治疗场所(门诊治疗中心ATC、居家高级照护ACAH或急诊科观察病房EDOU)与住院治疗相比的使用情况和短期结局。这项回顾性队列研究纳入2024年1月1日至2025年6月30日在Kaiser Permanente Northern California整合医疗系统内多个社区急诊科和住院医疗中心就诊、年龄19岁及以上的急诊患者。纳入患者为健康计划有效成员,因心力衰竭、肺炎、蜂窝织炎、尿路感染、COVID-19或贫血就诊,并转入ATC、ACAH项目、EDOU或住院床位。主要结局为在ATC、ACAH项目或EDOU治疗患者的照护升级(住院),以及所有场所在照护完成后7天内急诊回访、30天内住院和30天内死亡。报告未校正结局率。研究纳入26618次急诊就诊(患者年龄中位数77岁[IQR 65-85岁],女性52.6%)。在22755名唯一患者中,87.4%有1次就诊,9.8%有2次就诊,2.8%有超过2次就诊。ATC、ACAH、EDOU和医院场所的就诊次数分别为728次(2.7%)、880次(3.3%)、5133次(19.3%)和19877次(74.7%)。四分之一患者(25.3%)在ATC、ACAH项目或EDOU接受照护。ATC和ACAH就诊的住院率低于EDOU就诊(分别为4.3%[95% CI 2.7%-5.8%]、5.3%[3.8%-6.8%]和28.0%[26.8%-29.2%])。各场所7天内急诊就诊率相近(ATC 10.4%[95% CI 7.8%-12.9%];ACAH 5.3%[3.8%-6.8%];EDOU 9.2%[8.4%-10.0%];医院8.5%[8.1%-8.9%])。相比之下,ATC、ACAH和EDOU就诊的30天死亡率和住院率低于医院就诊(30天死亡率分别为2.1%[95% CI 1.0%-3.2%]、1.7%[0.8%-2.6%]、2.8%[2.3%-3.2%]和5.3%[5.0%-5.6%];30天住院率分别为11.4%[95% CI 8.8%-14.1%]、8.3%[6.3%-10.2%]、12.7%[11.7%-13.7%]和15.3%[14.7%-15.8%])。在这项接受替代场所治疗患者的队列研究中,四分之一患者在ATC、ACAH项目或EDOU接受照护。这些发现提示,对经过适当选择的患者采用新的治疗空间,可能使医疗系统将医院资源集中于需求最复杂的患者。
Delirium is a state of acute confusion characterized by deficits in attention that occurs commonly during hospitalization and is associated with adverse outcomes; however, the association of delirium with longitudinal cognitive trajectories is not fully understood. To evaluate the association of delirium during hospitalization with subsequent development of mild cognitive impairment (MCI), dementia, and longitudinal cognitive trajectories. This cohort study used data from participants with hospitalizations in the Mayo Clinic Study of Aging (MCSA) from October 2004 to December 2023. The MCSA is a prospective, population-based longitudinal study of cognitive aging among residents of Olmsted County, Minnesota. Of participants enrolled in the MCSA between 2004 and 2023, individuals who experienced 1 or more hospitalization prior to their last MCSA encounter were included in this study. Participants with dementia at MCSA enrollment or prior to first hospitalization were excluded. Follow-up continued until development of MCI or dementia, last MCSA visit, or the end of the study. Delirium was identified using a validated natural language processing algorithm applied to clinical notes from hospitalizations, associated emergency department visits, and follow-up within 30 days after hospitalization. Delirium status was modeled as a time-dependent exposure. Incident MCI and dementia were assigned through MCSA expert consensus evaluations, including neuropsychological testing performed every 15 months. Association between delirium and development of MCI or dementia was assessed using Cox proportional hazards regression, adjusted for patient age, sex, level of education, and apolipoprotein E (APOE) ε4 allele carrier status; cognitive trajectories were assessed with linear mixed-effects models. Of 7030 participants enrolled in the MCSA, 3542 individuals experienced 1 or more hospitalization prior to their last MCSA encounter and were included, and 41 participants with dementia at enrollment or prior to first hospitalization were excluded. The cohort included 3501 participants with at least 1 hospitalization. Median (IQR) age was 74.1 (66.6-80.9) years, 1676 participants (47.9%) were female, median (IQR) level of education was 14 (12-16) years, and 910 participants (26.0%) were APOE ε4 carriers. During a median (IQR) follow-up of 7.2 (4.1-10.4) years, 75 participants (2.1%) had delirium documented within 30 days of hospitalization. Delirium was associated with increased risk of MCI (adjusted hazard ratio [aHR], 3.67; 95% CI, 2.19-6.15) and dementia (aHR, 5.39; 95% CI, 2.94-9.85) and with accelerated decline in longitudinal cognitive testing. In this cohort study among adults in the MCSA, including those with unimpaired cognition at baseline, delirium during hospitalization was strongly associated with increased risk of MCI and dementia and accelerated cognitive decline in subsequent years.
中文摘要:谵妄是一种以注意力缺陷为特征的急性意识混乱状态,常发生于住院期间,并与不良结局相关;但谵妄与纵向认知轨迹的关系尚未完全明确。评估住院期间谵妄与随后发生轻度认知障碍(MCI)、痴呆及纵向认知轨迹的关系。本队列研究使用2004年10月至2023年12月在Mayo Clinic Study of Aging(MCSA)中住过院的参与者数据。MCSA是一项前瞻性、基于人群的纵向认知老化研究,对象为明尼苏达州奥姆斯特德县居民。2004年至2023年纳入MCSA的参与者中,纳入在末次MCSA访视前经历1次或以上住院者。排除MCSA入组时或首次住院前已患痴呆者。随访持续至发生MCI或痴呆、末次MCSA访视或研究结束。谵妄通过经验证的自然语言处理算法识别,应用于住院、相关急诊就诊及住院后30天内随访的临床记录。谵妄状态作为时间依赖暴露建模。新发MCI和痴呆由MCSA专家共识评估判定,包括每15个月进行的神经心理测试。采用Cox比例风险回归评估谵妄与MCI或痴呆发生的关系,校正年龄、性别、教育程度和载脂蛋白E(APOE)ε4等位基因携带状态;认知轨迹采用线性混合效应模型评估。7030名纳入MCSA的参与者中,3542人在末次MCSA访视前经历1次或以上住院并纳入,41名入组时或首次住院前已患痴呆者被排除。队列包括3501名至少住院1次的参与者。中位(IQR)年龄74.1(66.6-80.9)岁,1676名参与者(47.9%)为女性,中位(IQR)教育年限14(12-16)年,910名参与者(26.0%)为APOE ε4携带者。中位(IQR)随访7.2(4.1-10.4)年期间,75名参与者(2.1%)在住院30天内记录到谵妄。谵妄与MCI风险升高相关(校正风险比[aHR],3.67;95% CI,2.19-6.15)和痴呆风险升高相关(aHR,5.39;95% CI,2.94-9.85),并与纵向认知测试的加速下降相关。在这项MCSA成人队列研究中,包括基线认知未受损者,住院期间谵妄与随后数年MCI和痴呆风险升高及认知加速下降强烈相关。
Actinic keratosis (AK) is a dynamic manifestation of chronic ultraviolet injury and a marker of field cancerization, but individual lesions and patients differ substantially in risk. Contemporary management therefore requires lesion-level triage, assessment of field burden, selection of a regimen the patient can complete, and longitudinal prevention rather than a uniform preference for either lesion- or field-directed therapy. This narrative review evaluates advances reported primarily from 2024 through June 2026. Recent evidence supports expanded treatment-area labeling and growing real-world experience with tirbanibulin; indoor and simulated-daylight photodynamic therapy (PDT); laser-assisted PDT; and low-irradiance, abbreviated-incubation, or simultaneous-illumination protocols designed to reduce pain. Short-course topical fluorouracil/calcipotriene has gained mechanistic and expert-consensus support, whereas diclofenac remains a slower and generally less efficacious option for selected patients. Nicotinamide, previously shown to be effective in immunocompetent patients, has not demonstrated benefit in solid organ transplant recipients, and systemic retinoids or capecitabine remain reserved for carefully selected high-risk populations. Senescence-directed glutathione peroxidase 4 (GPX4) modulation, interleukin-1 pathway targets, immune checkpoint blockade, and human papillomavirus vaccination are scientifically important but remain investigational for routine AK prevention. A risk-adapted blended strategy-biopsy when invasion is suspected, lesion-directed treatment for appropriate confirmed AKs, field treatment when subclinical burden is clinically meaningful, and cyclical therapy to aid prevention and provide surveillance for high-risk patients-best reflects current evidence.
中文摘要:日光性角化病(AK)是慢性紫外线损伤的动态表现,也是区域癌化的标志,但单个皮损与患者之间的风险差异很大。当代管理需要皮损层面的分诊、区域负荷评估、选择患者能够完成的方案以及长期预防,而不是统一偏向皮损导向或区域导向治疗。本叙述性综述评估了主要报道于2024年至2026年6月的进展。近期证据支持替巴尼布林扩大治疗面积标签及不断增长的真实世界经验;室内与模拟日光光动力疗法(PDT);激光辅助PDT;以及为减轻疼痛而设计的低辐照度、缩短孵育或同步照射方案。短程外用氟尿嘧啶/卡泊三醇获得机制与专家共识支持,而双氯芬酸仍是较慢且通常疗效较低的选择,适用于特定患者。烟酰胺此前在免疫功能正常患者中显示有效,但在实体器官移植受者中未显示获益,系统性维A酸类或卡培他滨仍保留给经仔细选择的高危人群。针对衰老的谷胱甘肽过氧化物酶4(GPX4)调控、白细胞介素-1通路靶点、免疫检查点阻断以及人乳头瘤病毒疫苗接种具有科学重要性,但对于常规AK预防仍处于研究阶段。风险适配的混合策略——怀疑侵袭时活检、对合适的已确认AK行皮损导向治疗、当亚临床负荷具有临床意义时行区域治疗,以及循环治疗以帮助预防并为高危患者提供监测——最能反映当前证据。
Chest pain is a leading reason for emergency department (ED) visits, with most cases classified as low-risk chest pain (LRCP) after excluding acute coronary syndrome. Many patients with LRCP experience undiagnosed or undertreated anxiety. To determine if 2 types of telehealth-delivered cognitive behavioral therapy (CBT) interventions were superior to primary care referral for patients with LRCP and anxiety. The Patient-Centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room (PACER) trial was a randomized, 3-group comparative effectiveness trial conducted across 6 university health systems EDs that enrolled adults with LRCP who were discharged from the ED and had at least moderate anxiety (Generalized Anxiety Disorder-7 [GAD-7] score ≥8 or Patient Health Questionnaire [PHQ] panic screener score ≥2) from April 2021 to July 2024 (12-month follow-up was completed by July 2025). Data analysis began in July 2025 and was completed by January 2026. All 3 groups received psychoeducation. The 3 interventions compared were (1) recommended primary care follow-up, (2) peer-supported internet-based CBT (iCBT), and (3) therapist-delivered CBT via telehealth. The primary outcome was change over 12 months in the GAD-7 anxiety score. Secondary outcomes included global anxiety improvement, PHQ-8 depression scores, PHQ-14 somatization scores, and Sheehan Disability Scale scores. Outcomes were assessed at 3, 6, 9, and 12 months. A total of 375 patients were enrolled (265 female individuals [70.7%] and 109 male individuals [29.1%]; 125 Black individuals [33.3%], 28 Hispanic individuals [7.5%], 226 White individuals [60.3%], and 22 individuals [5.9%] of other race; mean [SD] age, 39.9 [13.1] years). Adjusted mean improvement in GAD-7 over 12 months was significant within all arms (4.32, 5.54, and 5.13 points in the primary care referral, peer-supported iCBT, and therapist-delivered CBT groups, respectively, for which the baseline SD pooled over groups that was used to calculate all effect sizes was 4.83). Improvement with peer-supported iCBT was 1.22 points greater (95% CI, 0.01-2.43; effect size = 0.25) than primary care referral, and this effect was strongest (2.8 points) among patients with severe anxiety. Depression, somatization, and disability improved moderately within groups, with no significant between-group differences. Odds of patient-reported global anxiety improvement were 3 times higher in the 2 CBT groups compared with primary care referral. Higher engagement was associated with greater anxiety reduction. Therapeutic alliance and program satisfaction were high in both CBT groups. The results of this randomized clinical trial suggest that peer-supported iCBT significantly reduces anxiety in ED patients with LRCP and elevated anxiety, with the greatest improvement occurring in patients with severe anxiety. ClinicalTrials.gov Identifier: NCT04811521.
中文摘要:胸痛是急诊就诊的主要原因之一,排除急性冠脉综合征后多数病例被归为低风险胸痛(LRCP)。许多LRCP患者存在未诊断或治疗不足的焦虑。研究旨在判断两种远程医疗递送的认知行为治疗(CBT)干预是否优于转诊初级保健。PACER试验即急诊低风险胸痛后以患者为中心的焦虑治疗试验,为随机、3组比较效果试验,在6个大学医疗系统急诊科开展,纳入2021年4月至2024年7月从急诊出院且至少中度焦虑的LRCP成人,焦虑标准为广泛性焦虑障碍7项量表(GAD-7)评分≥8或患者健康问卷(PHQ)惊恐筛查评分≥2,12个月随访于2025年7月完成。数据分析于2025年7月开始,2026年1月完成。3组均接受心理教育。比较的3种干预为:推荐初级保健随访、同伴支持的网络CBT(iCBT)、治疗师通过远程医疗实施的CBT。主要结局为12个月内GAD-7焦虑评分变化。次要结局包括整体焦虑改善、PHQ-8抑郁评分、PHQ-14躯体化评分和Sheehan残疾量表评分,在3、6、9、12个月评估。共纳入375例患者,其中女性265例(70.7%)、男性109例(29.1%);黑人125例(33.3%)、西班牙裔28例(7.5%)、白人226例(60.3%)、其他种族22例(5.9%);平均年龄39.9岁(SD 13.1)。12个月内GAD-7调整后平均改善在所有组内均显著:初级保健转诊组4.32分、同伴支持iCBT组5.54分、治疗师实施CBT组5.13分;用于计算所有效应量的组间合并基线SD为4.83。同伴支持iCBT较初级保健转诊多改善1.22分(95% CI 0.01-2.43;效应量0.25),在重度焦虑患者中该效应最强,为2.8分。抑郁、躯体化和残疾在各组内中度改善,组间无显著差异。两个CBT组患者报告的整体焦虑改善几率是初级保健转诊组的3倍。参与度越高,焦虑下降越大。两个CBT组的治疗联盟和项目满意度均较高。该随机临床试验结果提示,同伴支持iCBT可显著降低急诊LRCP且焦虑升高患者的焦虑,重度焦虑患者改善最大。ClinicalTrials.gov标识符:NCT04811521。
Timely integration of palliative care is critical in the management of patients with glioblastoma. This study evaluated the frequency and determinants of potentially inappropriate care in the final 3 months of life on population level. Patient characteristics and healthcare utilization were extracted from medical records for deceased patients diagnosed with glioblastoma, who survived at least 3 months after diagnosis and received routine care at a single tertiary hospital between January 2015 and February 2026. Potentially inappropriate care was defined as the proportion of patients with any of these indicators in the final 3 months of life: ≥2 emergency department visits, ≥2 hospital admissions, >14 consecutive hospitalization days, intensive care unit admission, chemotherapy administration, or in-hospital death. Logistic regression analyses were performed to identify factors associated with receiving potentially inappropriate care. The cohort included 310 patients (median age 66 [IQR 56-72], 60% male), of whom 22% (n = 67/310) received potentially inappropriate care in the final 3 months of life. Chemotherapy was the main driver (n = 58/67, 87%), followed by ≥2 hospital admissions (n = 10/67, 15%) and in-hospital death (n = 9/67, 13%). Older patients (OR 0.97, 95% CI, 0.94-0.99) or those with an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter (OR 0.42, 95% CI, 0.23-0.75) were less likely to receive potentially inappropriate care. One in 5 patients with glioblastoma received potentially inappropriate care at the end of life, predominantly through chemotherapy. Younger patients and those with methylated MGMT promoters were most affected. Identification of patients at risk may support targeted palliative care interventions.
中文摘要:在胶质母细胞瘤患者的管理中,及时整合姑息治疗十分关键。本研究在人群层面评估生命最后3个月内潜在不适当照护的发生频率及其决定因素。研究者从病历中提取2015年1月至2026年2月在一家三级医院接受常规诊疗、诊断后生存至少3个月的已故胶质母细胞瘤患者的特征和医疗资源使用情况。潜在不适当照护定义为生命最后3个月内出现以下任一指标的患者比例:急诊就诊≥2次、住院≥2次、连续住院>14天、入住重症监护病房、接受化疗或院内死亡。采用逻辑回归分析识别与接受潜在不适当照护相关的因素。队列纳入310例患者(中位年龄66岁[IQR 56-72],男性60%),其中22%(67/310)在生命最后3个月接受了潜在不适当照护。化疗是主要驱动因素(58/67,87%),其次是住院≥2次(10/67,15%)和院内死亡(9/67,13%)。年龄较大(OR 0.97,95% CI 0.94-0.99)或O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子未甲基化的患者(OR 0.42,95% CI 0.23-0.75)接受潜在不适当照护的可能性较低。每5例胶质母细胞瘤患者中约有1例在生命终末期接受潜在不适当照护,主要形式为化疗。较年轻患者和MGMT启动子甲基化患者受影响最大。识别高危患者可能有助于开展有针对性的姑息治疗干预。
Acute ischemic stroke (AIS) survivors are at high risk of major adverse cardiovascular events (MACE), highlighting the need to identify modifiable secondary prevention targets. We assessed whether postacute discharge destination is associated with 1-year MACE risk among AIS survivors. In this retrospective cohort study, adult AIS survivors were identified from the state inpatient and emergency department databases of 5 US states (2016-2019) and categorized by discharge destination: home, inpatient rehabilitation facility (IRF), or skilled nursing facility (SNF). Other destinations were excluded. The primary outcome was 1-year MACE, defined as recurrent stroke, acute myocardial infarction, systemic embolism, or vascular death. Multivariable Cox models, adjusted for demographic and clinical factors, were used to evaluate the association between discharge disposition and MACE risk. Fine-Gray models were used for nonfatal secondary outcomes, and restricted mean survival time analyses were used to estimate absolute risk. Effect modification by age (<65 versus ≥65 years) was examined. Confounder-adjusted number-needed-to-be-exposed was estimated by marginal standardization. Among 213 511 AIS survivors (median age, 71 years), 16 237 (7.6%) experienced MACE within 1-year. MACE incidence was lowest after IRF discharge (6.6%) versus home (7.6%) or SNF (8.3%). In adjusted analyses, IRF discharge was associated with lower MACE risk versus home (adjusted hazard ratio, 0.88 [95% CI, 0.83-0.93]) and SNF (0.84 [95% CI, 0.79-0.89]). The association persisted across age strata but was more pronounced in patients <65 years (Pinteraction=0.014). Restricted mean survival time analyses indicated that IRF discharge was associated with 3.47 and 3.87 additional MACE-free days versus home and SNF discharge, respectively (both P<0.001). Adjusted number-needed-to-be-exposed were 115 (95% CI, 80-207) for IRF versus home and 87 (95% CI, 64-136) for IRF versus SNF. Postacute IRF discharge is associated with a lower 1-year MACE risk after AIS, highlighting the postacute care setting as a potentially modifiable system-level target for secondary prevention of long-term vascular outcomes.
中文摘要:急性缺血性卒中存活者发生主要不良心血管事件的风险较高,识别可干预的二级预防目标具有重要价值。研究评估急性缺血性卒中存活者出院后去向是否与1年主要不良心血管事件风险相关。这项回顾性队列研究从美国5个州2016至2019年的住院和急诊数据库识别成人急性缺血性卒中存活者,按出院去向分为家庭、住院康复机构或熟练护理机构,其他去向被排除。主要结局为1年主要不良心血管事件,定义为复发性卒中、急性心肌梗死、系统性栓塞或血管性死亡。采用多变量Cox模型校正人口学和临床因素,评估出院去向与主要不良心血管事件风险的关联;非致死性次要结局采用Fine-Gray模型,绝对风险采用限制平均生存时间分析估计;并检验年龄(<65岁与≥65岁)的效应修饰。通过边际标准化估计校正混杂因素后的需暴露人数。213511例急性缺血性卒中存活者中位年龄71岁,16237例(7.6%)在1年内发生主要不良心血管事件。住院康复机构出院后的发生率最低(6.6%),家庭出院为7.6%,熟练护理机构出院为8.3%。校正分析中,与家庭出院相比,住院康复机构出院与较低的主要不良心血管事件风险相关(校正风险比0.88,95%置信区间0.83-0.93);与熟练护理机构出院相比亦较低(0.84,95%置信区间0.79-0.89)。该关联在各年龄层中持续存在,在<65岁患者中更明显(交互作用P=0.014)。限制平均生存时间分析显示,与家庭出院和熟练护理机构出院相比,住院康复机构出院分别与多3.47个和3.87个无主要不良心血管事件天数相关(两者P<0.001)。校正后的需暴露人数为住院康复机构出院相对家庭出院115(95%置信区间80-207),住院康复机构出院相对熟练护理机构出院87(95%置信区间64-136)。急性缺血性卒中后住院康复机构出院与较低的1年主要不良心血管事件风险相关,提示出院后照护环境可能是长期血管结局二级预防中可干预的系统层面目标。
The respiratory syncytial virus (RSV) bivalent prefusion F protein vaccine (RSVpreF) administered during pregnancy has demonstrated efficacy in protecting infants against early-life RSV disease in the pivotal clinical trial. To conduct a systematic review and meta-analysis to synthesize real-world evidence on the effectiveness of RSVpreF in preventing RSV-associated lower respiratory tract infection (LRTI) in infants. PubMed, Scopus, and Europe PMC were searched from January 1, 2020, through January 30, 2026. A total of 1144 studies were initially identified. Eligible were nonrandomized studies reporting the effectiveness of RSVpreF vaccine in pregnancy in the prevention of RSV-associated LRTI in infants. All studies were screened independently by 2 reviewers. Data were extracted on RSV-associated outcomes among infants born to women who received RSVpreF vaccination during pregnancy and infants born to unvaccinated women. The primary outcome was RSV-associated LRTI hospitalization. Odds ratios (ORs) were pooled using random-effects meta-analysis with the Hartung-Knapp adjustment and Sidik-Jonkman estimator. Vaccine effectiveness against RSV-associated LRTI hospitalization was calculated as (1 - OR) × 100% and assessed in infants from birth to age 3 months and from birth to 6 months, separately. The limited available data precluded meta-analysis of effectiveness against the secondary outcomes of RSV-associated emergency department visits, intensive care unit admissions, and death. A total of 7 studies were included, comprising 7112 infants, of whom 2684 were born to vaccinated mothers. The studies collected data from January 2024 through April 2025 from Argentina, the UK, and the US. Pooled vaccine effectiveness against RSV-associated LRTI hospitalization was 82% (95% CI, 81%-82%; 3 studies, 4397 participants; I2 = 0%) in infants from birth to 3 months and 78% (95% CI, 70%-84%; 6 studies, 3008 participants; I2 = 18.7%) in infants from birth to 6 months, when mothers were vaccinated 14 days or more before delivery. The results of this systematic review and meta-analysis suggest that postimplementation data support the effectiveness of RSVpreF in pregnancy for the prevention of RSV-associated LRTI hospitalization during the first 6 months of life. The results support the introduction of RSVpreF into routine antenatal immunization programs.
中文摘要:妊娠期接种RSV双价预融合F蛋白疫苗(RSVpreF)在关键临床试验中显示可保护婴儿免于生命早期RSV疾病。为开展系统综述和Meta分析,综合真实世界证据,评估RSVpreF预防婴儿RSV相关下呼吸道感染(LRTI)的有效性。检索PubMed、Scopus和Europe PMC,时间2020年1月1日至2026年1月30日,初检1144项研究。纳入报告妊娠期RSVpreF疫苗预防婴儿RSV相关LRTI有效性的非随机研究。所有研究由2名评审员独立筛选。提取妊娠期接种RSVpreF疫苗女性所生婴儿与未接种女性所生婴儿的RSV相关结局数据。主要结局为RSV相关LRTI住院。采用随机效应Meta分析合并比值比(OR),使用Hartung-Knapp校正和Sidik-Jonkman估计量。疫苗对RSV相关LRTI住院的有效性按(1−OR)×100%计算,并分别评估出生至3月龄和出生至6月龄婴儿。因可用数据有限,未对RSV相关急诊就诊、重症监护病房入住和死亡等次要结局的有效性进行Meta分析。共纳入7项研究,包含7112名婴儿,其中2684名由接种疫苗的母亲所生。研究数据收集时间为2024年1月至2025年4月,来自阿根廷、英国和美国。当母亲在分娩前14天或更早接种疫苗时,合并疫苗对RSV相关LRTI住院的有效性在出生至3月龄婴儿中为82%(95% CI,81%-82%;3项研究,4397名参与者;I2=0%),在出生至6月龄婴儿中为78%(95% CI,70%-84%;6项研究,3008名参与者;I2=18.7%)。该系统综述和Meta分析结果提示,实施后数据支持妊娠期RSVpreF预防生命最初6个月内RSV相关LRTI住院的有效性。结果支持将RSVpreF纳入常规产前免疫规划。
This study aims to evaluate a triage approach prioritising assessment of patients with inflammatory rheumatic and musculoskeletal disease (iRMD) among rheumatology referrals. In this prospective study, 1180 consecutive referrals to a tertiary rheumatology centre underwent a telephone interview (step 1), followed by a 10-minute rheumatologist consultation within 4 weeks (step 2), during which patients were scheduled for comprehensive inpatient assessment (step 3) immediately, within 4 weeks or later. Diagnostic performance and wait times were analysed. Machine learning (ML) models for steps 1 and 2 were retrospectively investigated. Among 1180 referred patients, iRMD was suspected in 413 patients (35%) and not suspected in 767 (65%), of whom 52 (4.4%) were considered sufficiently unlikely to have an iRMD to forgo further evaluation. The remaining 1128 patients were scheduled for comprehensive assessment (step 3). Of these, 148 (13.1%) dropped out, whereas 980 patients proceeded. iRMD was diagnosed in 314 patients (32%); 666 (68%) had noninflammatory conditions. Step 2 correctly identified 211 patients with iRMD (sensitivity 67.2%) and 502 patients without iRMD (specificity 75.4%). Mean (SD) time from telephone interview to final assessment was shorter for patients with iRMD than for those without iRMD (33 [30] vs 55 [24] days). The step 1 and step 2 ML models achieved area under the receiver operating characteristic curve (AUC-ROC) values of 0.73 (95% CI: 0.65-0.80) and 0.78 (95% CI: 0.70-0.86), respectively. The triage approach accelerated assessment for more than two-thirds of patients with iRMD, while highlighting the necessity of a full workup to capture the one-third of cases otherwise missed. Using ML may further improve triage performance.
中文摘要:本研究评估一种在风湿科转诊患者中优先识别炎症性风湿与肌肉骨骼疾病(iRMD)患者的分诊方法。这项前瞻性研究纳入连续转诊至三级风湿病中心的1180例患者,先接受电话访谈(第1步),随后在4周内接受10分钟风湿科医生会诊(第2步),并据此时安排在立即、4周内或更晚进行综合住院评估(第3步)。研究分析诊断性能与等待时间,并回顾性探讨第1步和第2步的机器学习(ML)模型。1180例转诊患者中,413例(35%)怀疑iRMD,767例(65%)不怀疑iRMD,其中52例(4.4%)被认为iRMD可能性足够低而可不再进一步评估。其余1128例安排综合评估(第3步),其中148例(13.1%)退出,980例继续完成。314例(32%)诊断为iRMD,666例(68%)为非炎症性疾病。第2步正确识别211例iRMD患者(敏感度67.2%)和502例无iRMD患者(特异度75.4%)。iRMD患者从电话访谈到最终评估的平均(标准差)时间短于无iRMD患者(33[30]天对55[24]天)。第1步和第2步ML模型的受试者工作特征曲线下面积(AUC-ROC)分别为0.73(95% CI:0.65-0.80)和0.78(95% CI:0.70-0.86)。该分诊方法加快了超过三分之二iRMD患者的评估,同时提示需要完整检查以发现否则会漏诊的三分之一病例。使用ML可能进一步提高分诊性能。
Sepsis is a leading cause of morbidity and mortality for critically ill children, yet the pattern of healthcare use before admission for sepsis remains unknown. We measured the proportion and characteristics of healthcare encounters within 7 days before sepsis hospitalizations. Using the Merative MarketScan administrative claims database, we conducted a retrospective observational cohort study to quantify pre-admission healthcare encounters among children hospitalized with sepsis. The Merative MarketScan database includes inpatient, outpatient, and emergency medical claims from employer-based insurance plans and Medicaid data from approximately 7 million healthcare consumers across multiple states. Included patients were 0-18 years old and hospitalized with sepsis between January 1, 2016, and December 31, 2022. Children were required to have 30 days of continuous insurance enrollment before admission. None. Our primary outcome was the occurrence of any healthcare encounter in the 7 days before sepsis hospitalization, including outpatient, emergency department, or inpatient visits. Of those encounters, we identified the proportion that were related to infection. We compared hospitalization characteristics, including mechanical ventilation, ICU use, and length of stay, among those with vs. without pre-sepsis healthcare utilization. We identified 6928 pediatric sepsis hospitalizations, of whom 64.3% (4452/6928) had a complex chronic condition with a median age of 10 years (interquartile range, 3-15 yr). Overall, 53.5% (3707/928) of sepsis hospitalizations had a healthcare encounter within 7 days of admission, including 33.7% (2338/6928) with an outpatient visit, 28.2% (1956/6928) with an emergency department visit, and 6.2% (431/6928) with an inpatient hospitalization. Among sepsis hospitalizations with any pre-admission encounter, 38.9% (1445/3707) had an infection-related diagnosis documented at the encounter. There was no difference in mechanical ventilation, ICU use, or length of stay between those with vs. without pre-sepsis healthcare encounters. Over half of children hospitalized with sepsis were evaluated in the outpatient or emergency department setting in the week preceding admission, with one in five evaluated for infection. Further understanding of these pre-admission encounters may allow for earlier sepsis identification and possibly intervention in the prehospital setting.
中文摘要:脓毒症是危重患儿发病和死亡的主要原因,但脓毒症入院前的医疗使用模式仍不清楚。我们测量了脓毒症住院前7天内医疗接触的比例和特征。利用Merative MarketScan行政索赔数据库,开展回顾性观察性队列研究,量化因脓毒症住院的儿童在入院前的医疗接触。Merative MarketScan数据库包含基于雇主保险计划的住院、门诊和急诊医疗索赔,以及来自多个州约700万医疗消费者的Medicaid数据。纳入患者为0~18岁,2016年1月1日至2022年12月31日期间因脓毒症住院。患儿需在入院前有连续30天保险参保记录。无。主要结局为脓毒症住院前7天内发生任何医疗接触,包括门诊、急诊或住院就诊。在这些接触中,我们识别与感染相关的比例。比较有和无脓毒症前医疗使用的患儿住院特征,包括机械通气、ICU使用和住院时间。共识别6928例儿童脓毒症住院,其中64.3%(4452/6928)患有复杂慢性病,中位年龄10岁(四分位距3~15岁)。总体上,53.5%(3707/928)的脓毒症住院在入院前7天内有医疗接触,其中33.7%(2338/6928)有门诊就诊,28.2%(1956/6928)有急诊就诊,6.2%(431/6928)有住院。在入院前有任何医疗接触的脓毒症住院中,38.9%(1445/3707)在接触时记录了感染相关诊断。有和无脓毒症前医疗接触者在机械通气、ICU使用或住院时间方面无差异。超过半数因脓毒症住院的儿童在入院前一周在门诊或急诊接受评估,约五分之一因感染接受评估。进一步理解这些入院前接触,可能有助于更早识别脓毒症,并可能在院前环境中进行干预。
To apply Autor's labor economics task framework to classify emergency physician tasks by automation susceptibility and map current artificial intelligence (AI) capabilities to each category. We synthesized 6 published time-motion studies, ACGME Core Entrustable Professional Activities, and the O∗NET emergency physician task inventory into a unified list of 14 task categories. Two board-certified emergency physicians independently classified each task using Autor's 4-category framework. Current AI capabilities were mapped to each task using a 3-tier schema: Replace, Augment, or No Current Application. Nine tasks (64.3%) were classified as nonroutine abstract, 3 (21.4%) as routine cognitive, and 2 (14.3%) as nonroutine manual. No tasks were Routine Manual. AI replacement is concentrated in routine cognitive tasks (documentation, medical records review, emergency department operations management), which consume 20% to 40% of physician shift time. Augmentation dominates in nonroutine abstract domains. Nonroutine manual tasks show minimal AI penetration. Routine cognitive tasks consume a disproportionate share of emergency physician shift time, making them the immediate target for AI-driven workflow restructuring. Beyond this, augmentation of nonroutine abstract tasks is accelerating, warranting ongoing reassessment of automation boundaries across all task categories. As AI capabilities continue to expand, structured task-level analyses of this kind will be essential for anticipating workforce needs and informing AI implementation strategy, residency training design, and physician preparation in emergency medicine.
中文摘要:将 Autor 的劳动经济学任务框架用于按自动化易感性对急诊医师任务进行分类,并把当前人工智能能力映射到各类任务。研究者将 6 项已发表的时间-动作研究、ACGME 核心可信赖专业活动和 O*NET 急诊医师任务清单整合为统一的 14 类任务清单。两名委员会认证的急诊医师使用 Autor 的四类框架独立分类每项任务。当前 AI 能力按三层方案映射到每项任务:替代、增强或当前无应用。9 项任务(64.3%)被归类为非例行抽象任务,3 项(21.4%)为常规认知任务,2 项(14.3%)为非例行操作任务。没有任务属于常规操作。AI 替代集中于常规认知任务(文书工作、病历审查、急诊科运营管理),这些任务占医师班次时间的 20% 至 40%。增强在非例行抽象领域占主导。非例行操作任务的 AI 渗透极少。常规认知任务占用急诊医师班次时间的比例过高,使其成为 AI 驱动工作流程重构的直接目标。除此之外,非例行抽象任务的增强正在加速,需要对所有任务类别的自动化边界持续重新评估。随着 AI 能力继续扩展,此类结构化任务层面分析对于预判人力需求、指导 AI 实施策略、住院医师培训设计以及急诊医学中医师准备将至关重要。
Spine and pelvis diseases impair motor control through pain and neurological dysfunction, resulting in characteristic gait abnormalities. However, existing clinical screening and initial triage rely on static imaging, which overlooks gait patterns and limits efficiency for the primary assessment of these diseases. To enhance efficiency and enable clinically aligned diagnostics, we utilize gait videos and propose a hierarchical diagnostic model for spine and pelvis diseases. Based on gait videos, our method progresses from disease-region localization to pathological characterization, explicitly mimicking the clinical diagnostic process. To capture dynamic gait features, we leverage a Spatiotemporal Transformer that jointly models structural dependencies among body regions and motion rhythms. To ensure diagnostic coherence, we design a clinically inspired Tree Hierarchy Classifier that integrates region localization and pathology assessment, while preventing incompatible cross-level predictions. We collected clinical gait videos from 419 patients to train and validate our proposed model. At the first diagnostic level, the model distinguishes cervical/thoracic from lumbar/pelvis diseases, achieving an accuracy of 76% and an AUC of 85%. The second diagnostic level performs pathological characterization, further classifying cases into tumor and non-tumor subtypes across these regions. We further provide clinical interpretability via spatiotemporal attention visualizations, revealing that the model captures gait patterns consistent with established pathophysiological mechanisms. By aligning gait patterns with the dynamic functional impact of disease, we demonstrate the potential of gait video analysis as an efficient approach for the primary screening of spine and pelvis diseases.
中文摘要:脊柱与骨盆疾病通过疼痛和神经功能障碍损害运动控制,产生特征性步态异常。现有临床筛查和初诊分诊依赖静态影像,忽略步态模式,限制这类疾病初步评估的效率。为提高效率并实现与临床一致的诊断,我们利用步态视频提出脊柱与骨盆疾病的分层诊断模型。该方法基于步态视频,从疾病区域定位推进到病理特征刻画,明确模仿临床诊断流程。为捕捉动态步态特征,我们采用时空 Transformer,联合建模身体区域间的结构依赖和运动节律。为保证诊断一致性,我们设计受临床启发的树状层级分类器,将区域定位与病理评估整合,同时避免不相容的跨层级预测。我们收集419例患者的临床步态视频用于训练和验证所提模型。在第一诊断层级,模型区分颈/胸段疾病与腰/骨盆疾病,准确率为76%,AUC为85%。第二诊断层级进行病理特征刻画,进一步将这些区域的病例分类为肿瘤与非肿瘤亚型。我们通过时空注意力可视化提供临床可解释性,显示模型捕捉到的步态模式与既有病理生理机制一致。通过将步态模式与疾病的动态功能影响对齐,我们展示步态视频分析作为脊柱与骨盆疾病初筛高效方法的潜力。
Emergency department (ED) pediatric readiness and pediatric inpatient services have changed over time in many hospitals, but the impact of these changes on pediatric outcomes is unclear. To evaluate pediatric mortality associated with changes to ED pediatric readiness and pediatric inpatient services over a 10-year period. This cohort study included data from January 1, 2012, through December 31, 2021, for 759 hospitals in 11 states that completed the 2013 and 2021 National Pediatric Readiness Program assessments. Participants were children aged 0 to 17 years who received care in an ED resulting in hospital admission, interhospital transfer, or death. Data analysis was performed from May 2025 to May 2026. Changes in ED pediatric readiness and inpatient pediatric services, as measured through national assessments in 2013 and 2021. ED readiness change groups were characterized based on the weighted Pediatric Readiness Score (wPRS, range 0-100) associated with survival (wPRS ≥88 vs wPRS <88): sustained high readiness, gained, lost, or never had. Changes in pediatric inpatient services were defined as sustained, gained, lost, or never had. In-hospital mortality, including ED and inpatient deaths. There were 2 416 030 children, including 337 167 who were injured (median [IQR] age, 10 [4-15] years; 4642 deaths [1.38%]) and 2 078 863 who were medically ill (median [IQR] age, 6 [1-14] years; 18 576 deaths [0.89%]). Of the 759 hospitals, the median (IQR) wPRS in 2013 vs 2021 was 71 (58-86) and 72 (62-88), respectively. Ninety-nine EDs (13.0%) had sustained high readiness, 85 (11.2%) gained readiness, 78 (10.3%) lost readiness, and 497 (65.5%) never had high readiness. For inpatient services, 225 hospitals (29.6%) sustained inpatient services, 36 (4.7%) gained services, 120 (15.8%) lost services, and 378 (49.8%) never had services. After risk adjustment, EDs that lost or never had high ED readiness were associated with 1727 (95% CI, 751-2646) and 3776 (95% CI, 2327-5143) excess deaths, respectively. Hospitals that lost or never had inpatient services were associated with 1657 (95% CI, 1214-2067) and 3745 (95% CI, 3127-4328) excess deaths, respectively. This study found that the loss or persistent lack of high ED pediatric readiness and pediatric inpatient services were independently associated with excess mortality in children. Increasing ED readiness and adding inpatient services may augment pediatric survival in the US health care system.
中文摘要:急诊科儿科准备度与儿科住院服务在许多医院随时间发生变化,这些变化对儿科结局的影响尚不清楚。评估10年间急诊科儿科准备度和儿科住院服务变化相关的儿科死亡率。这项队列研究纳入2012年1月1日至2021年12月31日期间11个州759所医院的数据,这些医院完成了2013年和2021年全国儿科准备度项目评估。参与者为0至17岁在急诊科接受诊疗并导致住院、院际转运或死亡的儿童。数据分析于2025年5月至2026年5月进行。通过2013年和2021年全国评估衡量急诊科儿科准备度和儿科住院服务的变化。急诊科准备度变化组根据与生存相关的加权儿科准备度评分(wPRS,范围0-100;wPRS≥88与wPRS<88)划分:持续高准备度、获得、失去或从未具备。儿科住院服务变化定义为持续、获得、失去或从未具备。结局为院内死亡,包括急诊科死亡和住院死亡。共有2 416 030名儿童,其中337 167名受伤(年龄中位数[IQR]10[4-15]岁;4642例死亡[1.38%]),2 078 863名内科疾病患儿(年龄中位数[IQR]6[1-14]岁;18 576例死亡[0.89%])。759所医院中,2013年与2021年wPRS中位数(IQR)分别为71(58-86)和72(62-88)。99个急诊科(13.0%)持续高准备度,85个(11.2%)获得准备度,78个(10.3%)失去准备度,497个(65.5%)从未具备高准备度。住院服务方面,225所医院(29.6%)持续具备住院服务,36所(4.7%)获得服务,120所(15.8%)失去服务,378所(49.8%)从未具备服务。风险调整后,失去或从未具备高急诊科准备度的急诊科分别与1727例(95%CI,751-2646)和3776例(95%CI,2327-5143)超额死亡相关。失去或从未具备住院服务的医院分别与1657例(95%CI,1214-2067)和3745例(95%CI,3127-4328)超额死亡相关。该研究发现,失去或持续缺乏高急诊科儿科准备度及儿科住院服务与儿童超额死亡率独立相关。提高急诊科准备度并增加住院服务可能改善美国医疗体系中的儿科生存。
Flat head/neck pigmented macules can be diagnostically challenging. To assess the impact of reflectance confocal microscopy (RCM) integration to dermoscopic triage of equivocal lesions. Prospective multicenter study of equivocal flat macules. Lesions suspicious or discordant were biopsied/excised; double-negative lesions were followed ≥1 year. Histopathology served as reference standard. A total of 2006 lesions from 801 patients (mean age 66.2 years) were evaluated. After dermoscopy-RCM integration, 236/2006 (11.8%) lesions were managed as malignant (226 biopsied/excised; 10 noninvasively treated: 8 basal cell carcinoma [BCC] and 2 lentigo maligna [LM]). Twenty-six lesions changed at follow-up and were removed, with 4 malignancies (0.4%; 3 LM, 1 BCC). Histology (n = 252) confirmed 114 malignancies (62 LM/lentigo maligna melanoma [LMM]; 52 BCC/squamous cell carcinoma [SCC]). Dermoscopy detected 54.8% of LM/LMM and 90.4% of BCC/SCC; RCM correctly diagnosed 91.9% of LM/LMM and 94.2% of BCC/SCC. Verification and selection biases and follow-up losses. Integrating RCM significantly improves LM/LMM sensitivity detection and specificity for benign lesions compared to dermoscopy alone, minimizing overtreatment and missed malignancies. Although a small residual risk of missed malignancy persists, the combined approach offers a highly safe, noninvasive pathway for managing equivocal lesions in cosmetically sensitive areas.
中文摘要:头颈部平坦色素斑的诊断常具挑战性。评估将反射式共聚焦显微镜(RCM)整合入皮肤镜分流对可疑病变的影响。这是一项针对可疑平坦色素斑的前瞻性多中心研究。可疑或不一致的病变接受活检或切除;皮肤镜与RCM双阴性病变随访至少1年。以组织病理学为参考标准。共评估801例患者的2006个病变,平均年龄66.2岁。皮肤镜与RCM整合后,236/2006(11.8%)个病变按恶性管理(226个活检或切除;10个接受无创治疗:8个基底细胞癌[BCC]和2个恶性雀斑样痣[LM])。26个病变在随访中发生变化并被切除,其中4个为恶性(0.4%;3个LM,1个BCC)。组织学检查(n=252)证实114个恶性病变(62个LM/恶性雀斑样痣黑素瘤[LMM];52个BCC/鳞状细胞癌[SCC])。皮肤镜检出54.8%的LM/LMM和90.4%的BCC/SCC;RCM正确诊断91.9%的LM/LMM和94.2%的BCC/SCC。研究局限包括验证偏倚、选择偏倚和随访丢失。与单用皮肤镜相比,整合RCM显著提高LM/LMM的检出敏感性及良性病变的特异性,减少过度治疗和漏诊恶性病变。尽管仍存在少量漏诊恶性病变的残余风险,联合路径为美容敏感部位的可疑病变提供了一种高度安全的无创管理路径。
Patients with psychiatric emergencies experience emergency department (ED) lengths of stay 3 times longer than those with nonpsychiatric complaints, contributing to crowding and inefficiency. We evaluated whether a novel staffing model, the Psychiatric Model of Care, reduced length of stay for these patients. This quality improvement study used an interrupted time series design at a tertiary, urban academic medical center to analyze deidentified ED encounters from January 1, 2023, to December 31, 2024, spanning preimplementation, roll-out, and postimplementation periods. The model embedded psychiatry-specialized nurse practitioners and support staff in the ED 24/7 for assessment, crisis stabilization, and disposition planning. Adults with a psychiatric chief complaint, psychiatry consultation, or an involuntary psychiatric hold were included. The primary outcome was ED length of stay (time from rooming to final disposition) analyzed using segmented quantile regression. Among 5,222 encounters, median ED length of stay decreased from 8.35 hours (IQR 3.76-18.35 hours) to 5.61 hours (IQR 3.00-10.24 hours), with an adjusted median difference of -1.64 hours (95% confidence interval [CI] -3.15 to -0.13). The largest reductions occurred for patients on 72-hour (-9.66 hours; 95% CI -12.92 to -6.40) and 14-day (-18.80 hours; 95% CI -52.76 to -10.67) involuntary holds, and those transferred to psychiatric facilities (-4.80 hours; 95% CI -10.46 to -1.88). Differences were not significant for patients without holds or those discharged or admitted. The Psychiatric Model of Care significantly reduced ED length of stay for patients with psychiatric emergencies, suggesting a promising approach to improve patient flow and care delivery.
中文摘要:精神科急症患者在急诊科的停留时间是非精神科主诉患者的3倍,造成拥挤和效率下降。我们评估了一种新的人员配置模式——精神科照护模式——是否缩短了这些患者的停留时间。这项质量改进研究在三级城市学术医学中心采用中断时间序列设计,分析2023年1月1日至2024年12月31日期间去标识化的急诊就诊记录,覆盖实施前、推广期和实施后阶段。该模式将精神科专科执业护士和支持人员24/7嵌入急诊科,负责评估、危机稳定和去向安排。纳入标准为成年患者,具有精神科主诉、接受精神科会诊或被非自愿精神科留置。主要结局为急诊科停留时间(从进入诊室到最终去向的时间),采用分段分位数回归分析。在5,222次就诊中,急诊科停留时间中位数从8.35小时(四分位距3.76-18.35小时)降至5.61小时(四分位距3.00-10.24小时),调整后中位数差为-1.64小时(95%置信区间-3.15至-0.13)。降幅最大的是72小时非自愿留置患者(-9.66小时;95%置信区间-12.92至-6.40)和14天非自愿留置患者(-18.80小时;95%置信区间-52.76至-10.67),以及转至精神科机构的患者(-4.80小时;95%置信区间-10.46至-1.88)。无留置患者或出院/入院患者的差异不显著。精神科照护模式显著缩短了精神科急症患者的急诊科停留时间,提示这是改善患者流转和照护提供的有前景方法。
To determine the incidence, practice patterns, and outcomes of emergency physician-performed awake tracheal intubations in a tertiary-care emergency department (ED). In this study of the prospective Airway Interventions Registry and Observational database, we screened all intubations performed at an academic, tertiary-care ED between January 1, 2015, and January 1, 2025, for adults undergoing first-attempt awake tracheal intubation by an emergency physician. We excluded patients undergoing sedation-only or dissociation-only intubation. Our primary outcome was overall success without any of the following major adverse events: critical hypoxemia (SpO2<80%), critical hypotension (systolic blood pressure<65 mmHg), or cardiac arrest. Our secondary outcomes were the frequencies of first-pass success, adverse events, and conversion to rapid sequence intubation. Among the 1,213 ED intubations screened during the 10-year study period, 87 (7.2%) were emergency physician-performed awake intubations. Most patients undergoing awake intubation had anatomic (80%) or physiologic (87%) predictors of difficulty, or both (68%). Success without a major adverse event occurred in 80 (92%; 95% confidence interval 86% to 98%) patients. There was first-pass success in 62 (71%) and rapid sequence intubation conversion in 6 (6.9%) patients. Critical hypoxemia, critical hypotension, and cardiac arrest occurred in 3%, 2%, and 2%, respectively. In this preliminary single-center study, emergency physicians performed awake intubation with relatively high incidence, high overall success, and low rates of major adverse events.
中文摘要:为明确三级医疗急诊科中急诊医师实施清醒气管插管的发生率、实践模式与结局,本研究基于前瞻性气道干预登记与观察数据库,筛查2015年1月1日至2025年1月1日期间在一家学术型三级医疗急诊科实施的全部插管,纳入由急诊医师首次尝试进行清醒气管插管的成人患者,排除仅镇静或仅解离麻醉下插管的患者。主要结局为整体成功且未发生以下任一重大不良事件:严重低氧血症(SpO2<80%)、严重低血压(收缩压<65 mmHg)或心脏骤停。次要结局包括首次通过成功率、不良事件发生率以及转为快速序贯插管的比例。10年研究期间共筛查1213例急诊插管,其中87例(7.2%)为急诊医师实施的清醒插管。接受清醒插管的患者多数存在解剖性(80%)或生理性(87%)困难预测因素,或两者兼有(68%)。80例(92%;95%置信区间86%至98%)患者实现无重大不良事件的成功。首次通过成功62例(71%),转为快速序贯插管6例(6.9%)。严重低氧血症、严重低血压和心脏骤停分别发生于3%、2%和2%的患者。在这项初步的单中心研究中,急诊医师实施清醒插管的发生率相对较高,整体成功率较高,重大不良事件发生率较低。
Clinical demands in the emergency department (ED) may contribute to decision and attention fatigue as clinician time-on-shift increases, impacting patient care. Emergency department pharmacists review orders and intervene to correct problems related to safety and appropriateness. This study's objective was to evaluate and characterize the rate of pharmacist interventions on ED medication orders. We hypothesized that pharmacist interventions would increase with clinician time-on-shift. We performed a retrospective study of 2 EDs within a single health system between January 2022 and November 2023. Medication and pharmacy intervention details were extracted and linked to clinician schedules, pharmacist schedules, and ED crowding scores. Mixed-effects logistic regression modeling identified factors associated with pharmacist interventions. Pharmacists intervened on 9,054 (1.5%) of 622,171 medication orders placed by 308 clinicians. Pharmacy intervention rate increased with clinician time-on-shift (odds ratio 1.04 for each hour; 95% confidence interval 1.03 to 1.05), with meaningful variation in this effect between individual clinicians. Stratified by clinician type (attendings, residents, or physician assistants) and shift timing (overnight versus daytime shifts), the association between time-on-shift and pharmacy intervention rate remained positive. Stratified by site (A versus B), the association was positive at site A but not at site B. The likelihood of orders requiring pharmacist interventions increased as ED clinicians' time-on-shift increased. This association was consistently observed across differing clinician types and shift timing, but variable across the 2 sites of the study. Clinical staffing models and quality of care could be improved by addressing stressors and fatigue accumulation informed by this analytical model.
中文摘要:急诊科临床需求可能随临床医生在岗时间增加而促成决策疲劳与注意力疲劳,影响患者照护。急诊科药师审核医嘱并针对安全性和适宜性问题进行干预。本研究旨在评估并描述药师对急诊科用药医嘱干预的发生率,假设药师干预会随临床医生在岗时间增加而增加。研究回顾性纳入单一医疗系统内2个急诊科2022年1月至2023年11月的数据,提取用药与药师干预细节,并与临床医生排班、药师排班及急诊拥挤评分链接。采用混合效应逻辑回归模型识别与药师干预相关的因素。308名临床医生开具的622171条用药医嘱中,药师干预9054条(1.5%)。药师干预率随临床医生在岗时间增加而升高(每增加1小时,比值比1.04,95%置信区间1.03至1.05),该效应在不同临床医生个体间存在有意义的差异。按临床医生类型(主治医师、住院医师或医师助理)和班次时间(夜班与白班)分层后,在岗时间与药师干预率的关联仍为正相关。按院区分层(A与B),A院区该关联为正,B院区未见正关联。随着急诊科临床医生在岗时间增加,医嘱需要药师干预的可能性升高。这一关联在不同临床医生类型和班次时间中一致观察到,但在研究两个院区间存在差异。基于该分析模型识别压力源和疲劳累积,可改进临床人员配置模式和照护质量。
To compare a rule-based computable phenotype designed to identify patients with opioid use disorder in the emergency department (ED) with a large language model, using expert physician review as the reference standard. We conducted a retrospective study of randomly sampled adult ED encounters (January 1, 2023 to October 17, 2024) at a single academic health system. We drew a stratified random sample based on whether encounters met a preexisting rule-based phenotype for identifying opioid use disorder. The phenotype incorporated diagnosis codes, medications for opioid use disorder, urine toxicology results, addiction consultations, and keyword matching. With zero-shot prompting, a large language model (ChatGPT 4.1) classified opioid use disorder using ED notes from the index visit. Two board-certified emergency physicians independently determined the presence of opioid use disorder by full chart review; discrepancies were adjudicated by a third reviewer. Using inverse probability weighting based on the sampling fractions, we estimated sensitivity, specificity, positive predictive value, and negative predictive value. Among 302 encounters, weighted opioid use disorder prevalence was 5.6% (95% confidence interval [CI], 4.0 to 7.0%). The structured phenotype demonstrated sensitivity 0.84 (95% CI, 0.42 to 0.97) and specificity 0.964 (95% CI, 0.96 to 0.97) (positive predictive value 0.58; negative predictive value 0.99). The large language model demonstrated sensitivity 0.81 (95% CI 0.70-0.88) and specificity 0.996 (95% CI, 0.993 to 0.998) (positive predictive value 0.92; negative predictive value 0.99). Specificity was significantly higher for the large language model (P<.0001). Both approaches demonstrated strong diagnostic performance. Although the structured phenotype showed slightly higher sensitivity, the large language model achieved higher specificity and positive predictive value, suggesting potential to reduce false-positive alerts in ED workflows. Prospective validation in other populations is needed.
中文摘要:比较一种用于在急诊科识别阿片类药物使用障碍患者的基于规则的可计算表型与大型语言模型,并以专家医师复核作为参考标准。研究回顾性纳入单一学术医疗系统2023年1月1日至2024年10月17日随机抽样的成人急诊就诊记录。抽样按就诊记录是否符合既有的阿片类药物使用障碍规则表型进行分层随机。该表型纳入诊断编码、阿片类药物使用障碍治疗药物、尿液毒理学结果、成瘾咨询及关键词匹配。采用零样本提示,由大型语言模型ChatGPT 4.1根据索引就诊的急诊记录对阿片类药物使用障碍进行分类。两名委员会认证的急诊医师独立通过完整病历复核判定是否存在阿片类药物使用障碍,分歧由第三名复核者裁定。基于抽样比例的逆概率加权,估计敏感度、特异度、阳性预测值和阴性预测值。302次就诊中,加权阿片类药物使用障碍患病率为5.6%(95%CI 4.0至7.0%)。结构化表型的敏感度为0.84(95%CI 0.42至0.97),特异度为0.964(95%CI 0.96至0.97),阳性预测值为0.58,阴性预测值为0.99。大型语言模型的敏感度为0.81(95%CI 0.70至0.88),特异度为0.996(95%CI 0.993至0.998),阳性预测值为0.92,阴性预测值为0.99。大型语言模型的特异度显著更高(P<.0001)。两种方法均表现出较强的诊断性能。结构化表型敏感度略高,大型语言模型特异度和阳性预测值更高,提示其可能减少急诊工作流程中的假阳性提醒。仍需在其他人群中开展前瞻性验证。
Emergency physicians experience substantial documentation burden, contributing to physician burnout. Human scribes reduce documentation workload but are expensive and pose staffing challenges. Ambient artificial intelligence (AI) scribes offer a potential alternative by automating note generation from clinician-patient conversations using AI. We compared ambient AI and human scribes against encounters with no scribe on emergency physicians' documentation time and clinical productivity. This retrospective cross-sectional observational study evaluated emergency department encounters from January 2025 to September 2025 at 4 hospitals within a large integrated health care system. Encounters were categorized as ambient AI scribe, human scribe, or no scribe. Patient demographics, documentation time, work relative value units (wRVUs), and shift data were extracted. Attending documentation time was modeled using median quantile regression with standard errors clustered at the physician level and controlling for encounter-level variables. Clinical productivity measured as total wRVUs per shift hour was modeled using generalized estimating equations adjusting for physician and shift-level variables. Among 198,178 emergency department encounters, 8,489 (4.3%) used ambient AI scribes, 15,947 (8.0%) used human scribes, and 173,742 (87.7%) had no scribe. Median patient age was 49 years (interquartile range 30 to 68 years), and 53.1% were female. Compared with encounters with no scribe, ambient AI scribes were associated with a 1.6-minute reduction in adjusted median attending documentation time per note (95% confidence interval 0.3 to 2.9), whereas human scribes were associated with a 3.3-minute reduction (95% confidence interval 2.3 to 4.3). Total wRVUs per shift hour did not differ among groups. Ambient AI and human scribes were associated with reduced physician documentation time. Clinical productivity did not differ between study groups.
中文摘要:急诊医师面临显著的病历记录负担,这一负担会促成职业倦怠。人工病历记录员可减轻记录工作量,但成本较高并带来人员配置难题。环境人工智能(AI)记录工具通过AI从医患对话自动生成病历,可能成为替代方案。本研究比较环境AI记录员、人工记录员与无记录员接诊在急诊医师记录时间和临床生产力上的差异。这项回顾性横断面观察研究纳入2025年1月至2025年9月某大型整合医疗系统内4家医院的急诊科接诊记录。接诊按环境AI记录员、人工记录员或无记录员分类。提取患者人口学特征、记录时间、工作相对价值单位(wRVUs)和班次数据。主治医师记录时间采用中位数分位数回归建模,标准误按医师水平聚类,并控制接诊层面变量。临床生产力以每班次小时总wRVUs衡量,采用广义估计方程建模,并校正医师和班次层面变量。198178次急诊接诊中,8489次(4.3%)使用环境AI记录员,15947次(8.0%)使用人工记录员,173742次(87.7%)无记录员。患者年龄中位数49岁(四分位距30至68岁),女性占53.1%。与无记录员接诊相比,环境AI记录员与每份病历调整后主治医师记录时间中位数减少1.6分钟相关(95%置信区间0.3至2.9),人工记录员则减少3.3分钟(95%置信区间2.3至4.3)。每班次小时总wRVUs在各组间无差异。环境AI记录员和人工记录员均与医师记录时间缩短相关。各组临床生产力无差异。
Frequent past-year emergency department (ED) use is a risk factor for suicide but also presents an intervention opportunity. This study aimed to quantify ED visit timing among suicide decedents by past-year ED use and characterize differences between suicide decedents and other ED patient populations. ED records were obtained from the North Carolina Disease Event Tracking and Epidemiological Collection Tool (NC DETECT), and death records were obtained from the NC Violent Death Reporting System (NC-VDRS). ED visits corresponding to the decedent's suicide were probabilistically linked to their corresponding death record. Decedents were classified as frequent (≥4) and infrequent (<4) users based on nonfatal ED visits occurring within one year of their death. Timing from decedents' final nonfatal visit to death was assessed. Decedents' demographics and visit characteristics were compared with all ED patients and mental health patients, stratified by past-year use. From 2019 to 2020, 670 of 2,883 NC-VDRS suicide decedents linked to an ED visit associated with their suicide. One third (n=213) of linked decedents had past-year ED use. Among these individuals, 21.6% (n=46) were frequent users. Within 30 days of their final nonfatal visit, only 28% of frequent users survived, compared with 65% of infrequent users (difference: -36.4% [-51.3% to -21.5%]). Suicide decedents with frequent use were distinct from infrequent users and from both reference groups regarding demographic and visit-level characteristics. Suicide decedents who visited the ED once or who were frequent users were demographically distinct from the overall population of ED patients. Timing from final nonfatal ED visit to death by suicide varied with past-year use.
中文摘要:过去一年频繁使用急诊科(ED)是自杀的风险因素,也提供了干预机会。本研究旨在按过去一年ED使用情况量化自杀死亡者的ED就诊时间,并描述自杀死亡者与其他ED患者人群之间的差异。ED记录来自北卡罗来纳州疾病事件追踪与流行病学收集工具(NC DETECT),死亡记录来自北卡罗来纳州暴力死亡报告系统(NC-VDRS)。与死者自杀对应的ED就诊通过概率方法与相应死亡记录链接。依据死亡前一年内发生的非致命ED就诊,将死者分为频繁使用者(≥4次)和非频繁使用者(<4次)。评估死者最后一次非致命就诊至死亡的时间。将死者的人口学与就诊特征与所有ED患者及精神健康患者比较,并按过去一年使用情况分层。2019至2020年,2,883名NC-VDRS自杀死亡者中有670名链接到与其自杀相关的ED就诊。链接死者中三分之一(n=213)过去一年有ED使用。这些人中21.6%(n=46)为频繁使用者。最后一次非致命就诊后30天内,频繁使用者仅28%存活,非频繁使用者为65%(差异:-36.4% [-51.3%至-21.5%])。频繁使用的自杀死亡者在人口学和就诊层面特征上不同于非频繁使用者,也不同于两个参照组。曾就诊一次ED的自杀死亡者或频繁使用者,其人口学特征不同于ED患者总体。最后一次非致命ED就诊至自杀死亡的时间随过去一年使用情况而变化。
Hurricane Helene struck Western North Carolina in September 2024, leaving an entire region without power, clean water, or internet connectivity for more than a week. A small, rural, community hospital and its emergency department, which normally sees 84 patients per day, suddenly became the sole source of medical care for an estimated 200,000 residents and experienced a 70% surge in patient volume. Although structural damage to the hospital was limited, the complete loss of digital connectivity rendered electronic medical records, laboratory information systems, radiology, pharmacy, and routine communication tools inoperable. Forced back into an analog system of care, clinicians rapidly redesigned workflows: in-person huddles replaced digital messaging, point-of-care testing replaced central laboratory processing, radiologists interpreted imaging in real time at the scanner, and paper charting was used. When patients dependent on powered medical devices such as oxygen concentrators and left ventricular assist devices overwhelmed emergency department space, the hospital created a staffed medical device shelter in a nearby high school. Paper medication administration records and take-home medication packs were developed to allow safe discharge despite pharmacy closures. This experience revealed that, in modern hospital disaster planning, uninterrupted internet access is a critical contingency to plan for. Backup generators cannot compensate for the loss of digital connectivity. Hospitals should prepare for extended digital outages by maintaining point-of-care diagnostics, physical copies of critical order sets, and plans for alternative care locations for medically fragile patients. Here, we share lessons learned from the connectivity outages during Hurricane Helene and its aftermath, and how small, rural hospitals can serve as community anchors during prolonged infrastructure failure.
中文摘要:2024年9月,飓风海伦妮袭击北卡罗来纳州西部,使整个地区超过一周没有电力、清洁用水和互联网连接。一家小型乡村社区医院及其急诊科通常每天接诊84名患者,突然成为约20万居民唯一的医疗照护来源,患者量激增70%。医院建筑结构损坏有限,但数字连接完全中断,使电子病历、实验室信息系统、放射学、药房和常规沟通工具无法使用。临床人员被迫回到模拟式照护系统,迅速重新设计工作流程:面对面晨会交接取代数字消息,床旁检测取代中心实验室处理,放射科医生在扫描仪旁实时判读影像,并采用纸质记录。依赖氧气浓缩器和左心室辅助装置等电动医疗设备的患者挤满急诊科空间时,医院在附近一所高中设立了配备人员的医疗设备庇护点。药房关闭期间,医院制定纸质给药记录和带回家药物包,使患者能够安全出院。这段经历表明,在现代医院灾难规划中,不间断的互联网接入是需要规划的关键应急事项。备用发电机无法弥补数字连接中断。医院应通过维持床旁诊断、关键医嘱集的纸质副本,以及为医学上脆弱患者规划替代照护地点,来为长时间数字中断做准备。此处分享飓风海伦妮期间及之后连接中断的经验教训,以及小型乡村医院如何在长期基础设施故障期间充当社区锚点。
Repeated blood sampling remains the basis of neonatal biochemical assessment, although it is painful and, in extremely preterm infants, removes close to one third of the circulating blood volume. Non-invasive biosensing offers alternatives, but most studies report analytical figures of merit or correlation with blood, which do not show whether a measurement meets the requirements of clinical use. This review maps neonatal biomarkers to saliva, sweat, tears, urine, and exhaled breath and to electrochemical, optical, and chemiresistive platforms, and compares their technical progress with the requirements of clinical use. Adapting established test-evaluation methodology, we define the evidence required for replacement, triage, add-on, monitoring, discovery, and diagnosis with matrix-native thresholds, and we add requirements specific to non-invasive matrices: sampling failure, variable matrix-to-blood ratios, and matrix confounders. Neonatal data show that the same statistic can lead to opposite conclusions, as salivary caffeine and C-reactive protein illustrate. Only sweat chloride and transcutaneous bilirubin are established in routine neonatal practice. Among representative custom-engineered devices, the evidence mostly stops at paired comparison in selected, case-control, or balanced samples, and performance in consecutively enrolled infants is rarely reported. For small molecules and electrolytes, progress now depends more on study design, namely consecutive enrollment and paired sampling at clinically indicated blood draws, than on further gains in analytical sensitivity. Extending the framework to early-life protection, we argue that a measurement protects an infant only when it detects change in time for an effective intervention, and that this chain is so far best supported within established screening pathways.
中文摘要:反复采血仍是新生儿生化评估的基础,尽管其有创疼痛,在极早产儿中几乎移除近三分之一循环血量。无创生物传感提供替代方案,但多数研究报告分析性能指标或与血液的相关性,未能显示测量是否满足临床使用要求。本综述将新生儿生物标志物映射到唾液、汗液、泪液、尿液和呼出气,以及电化学、光学和化学电阻平台,并将其技术进展与临床使用要求比较。借用既有检验评估方法,我们定义替代、分诊、附加、监测、发现和诊断所需的证据,采用基质原生阈值,并加入无创基质特有要求:采样失败、基质-血液比值变异和基质混杂因素。新生儿数据表明同一统计量可导致相反结论,唾液咖啡因和C反应蛋白即为例子。仅汗液氯离子和经皮胆红素在新生儿常规实践中确立。在代表性定制工程设备中,证据多止于选定、病例对照或平衡样本的配对比较,连续入组婴儿中的性能鲜有报告。对于小分子和电解质,进展现在更多取决于研究设计,即连续入组和在临床指征采血时配对采样,而非分析灵敏度进一步提高。将该框架扩展至早期生命保护,我们认为一项测量只有在能及时发现变化并有有效干预时才能保护婴儿,而这一链条迄今在既定筛查路径中得到最好支持。
基础研究 (2篇)
Ageing is a process of continuous decline of cellular health. This decline could be attributed to loss of functions to various crucial protein players regulating the triage of cellular physiology. Systematic decline of cellular proteostasis is one major change that orchestrates alterations in functioning of other biological indicators, including cellular energetics, signal transduction, and metabolic adaptation. Among many molecular players governing physiological changes, E3 ubiquitin ligases emerge as central regulators due to their ability to confer specificity within the ubiquitin-proteasome system (UPS). They operate at crossroads of crucial pathways, like DNA damage response, oxidative stress signaling, mitochondrial homeostasis, autophagy, inflammation, and hormonal regulation. This review discusses data accumulated over decades explaining how a wide spectrum of intrinsic and extrinsic stressors, including but not limited to proteotoxic stress, metabolic imbalance, environmental and lifestyle factors modulate the expression, activity, and substrate selectivity of E3 ligases. We weighed the ubiquity of E3 ligases in various cellular processes with its regulatory importance using available literature and develop an E3 centric framework that explains how, in a context-dependent manner, the E3 ubiquitin ligases respond to changes, restore proteostasis, and stabilize internal milieu. Finally, we examine the emerging pharmacological interventions targeting E3 ubiquitin ligases and exploiting their therapeutic potential in delaying ageing-associated pathways and physiological changes. Overall, the article positions E3 ligases as context-dependent regulators of ageing and underscores several key unanswered questions essential for ageing research.
中文摘要:衰老是细胞健康持续下降的过程。这种下降可归因于调控细胞生理分诊的多种关键蛋白功能丧失。细胞蛋白稳态的系统性下降是统筹其他生物学指标变化的一项主要改变,这些指标包括细胞能量学、信号转导和代谢适应。在调控生理变化的众多分子参与者中,E3泛素连接酶因其能够在泛素-蛋白酶体系统(UPS)内赋予特异性而成为核心调控因子。它们作用于DNA损伤应答、氧化应激信号、线粒体稳态、自噬、炎症和激素调节等关键通路的交叉点。数十年来积累的数据解释了广泛的内源性和外源性应激源如何调节E3连接酶的表达、活性和底物选择性,这些应激源包括但不限于蛋白毒性应激、代谢失衡、环境和生活方式因素。结合现有文献,E3连接酶在多种细胞过程中的普遍性与调控重要性得到权衡,并由此构建以E3为中心的框架,解释E3泛素连接酶如何以情境依赖的方式响应变化、恢复蛋白稳态并稳定内环境。靶向E3泛素连接酶的新兴药理干预及其在延缓衰老相关通路和生理变化方面的治疗潜力亦被审视。总体而言,E3连接酶被定位为衰老的情境依赖性调控因子,衰老研究必不可少的若干关键未解问题也得到强调。
Integrating high-throughput in vitro data into next-generation risk assessment (NGRA) workflows requires screening strategies that yield quantitative potency estimates and mechanistically interpretable biological signals. Transcriptomic and morphological profiling are increasingly adopted for early-stage hazard identification by enabling triage of substances for resource-intensive follow-up and prioritizing candidates most likely to present meaningful risk. In this study, we aimed to characterize biological concordance and uncertainty by quantifying how well high-throughput transcriptomics (HTTr) and Cell Painting PLUS (CPP) bioactivity profiles recover target-relevant biological signals in immortalized human renal proximal tubule epithelial RPTEC/TERT1 cells using 313 reference chemicals with high-confidence target annotations. Through quality control procedures and biological activity filters we yielded 142 reference chemicals spanning 66 different targets, which were systematically evaluated for biological concentration-responses by HTTr and CPP. HTTr was evaluated using TXG-MAPr-based qualitative and quantitative gene network activity analysis. HTTr showed the most prominent activity for targets that were highest expressed in RPTEC/TERT1 cells. Active chemical-pairs showed strong gene network activity correlation albeit with different potencies. Similarly, the highest transcriptomic concordance was observed for reference chemicals acting in the same pathway, such as EGFR/MEK or PI3K/AKT/mTOR. CPP often showed high sensitivity primarily at the organelle level providing limited mechanistic insight for chemical grouping. Collectively, the results support HTTr and CPP as complementary early-tier assays within an in vitro weight-of-evidence safety testing framework. Although CPP is suitable as a cost-effective screening modality, HTTr offers higher mechanistic resolution for mode-of-action inference in high-throughput bioactivity screening and therefore remains necessary for high-confidence mechanistic interpretation.
中文摘要:将高通量体外数据整合到下一代风险评估(NGRA)工作流程,需要能够给出定量效力估计和机制可解释生物信号的筛选策略。转录组学和形态学分析正越来越多用于早期危害识别,可对待测物进行分流以开展资源密集的后续研究,并优先选择最可能具有实际风险的候选物。本研究旨在利用313种具有高置信度靶点注释的参考化学品,在永生化人肾近端小管上皮RPTEC/TERT1细胞中,量化高通量转录组学(HTTr)和Cell Painting PLUS(CPP)生物活性谱对靶点相关生物信号的还原程度,从而刻画生物学一致性和不确定性。通过质量控制流程和生物活性过滤,获得涵盖66个不同靶点的142种参考化学品,并用HTTr和CPP系统评估其生物学浓度反应。HTTr采用基于TXG-MAPr的定性和定量基因网络活性分析进行评估。HTTr对在RPTEC/TERT1细胞中表达最高的靶点显示出最突出的活性。活性化学品对显示出强基因网络活性相关性,但效力不同。转录组一致性最高的情况见于作用于同一通路的参考化学品,如EGFR/MEK或PI3K/AKT/mTOR。CPP常在细胞器水平显示较高敏感性,为化学品分组提供的机制信息有限。这些结果支持HTTr和CPP作为体外证据权重安全测试框架中的互补早期层级试验。CPP适合作为成本有效的筛选方式,而HTTr在高通量生物活性筛选中为作用模式推断提供更高的机制分辨率,因此对于高置信度机制解释仍然必要。
2脓毒症与感染性休克 (16篇)
临床研究 (10篇)
To evaluate long-term mortality among sepsis survivors in Catalonia over a 15-year period and to identify factors associated with increased mortality within 2 years after hospital discharge. Retrospective population-based cohort study. Acute-care hospitals in Catalonia, Spain. Adult and pediatric patients hospitalized with sepsis between 2005 and 2019 identified using the International Classification of Diseases, 9th Revision, Clinical Modification and International Classification of Diseases, 10th Revision, Clinical Modification codes for infection and acute organ dysfunction. Patients who died during hospitalization, were transferred to another facility, or represented readmission episodes were excluded. None. Data were obtained from the Catalan Minimum Basic Dataset of Acute-Care Hospitals, with longitudinal follow-up through the Central Registry of Insured Persons. Comorbidities were assessed using the Charlson comorbidity index. Logistic regression and Cox proportional hazards models were used to identify predictors of long-term mortality. Among 296,554 hospital admissions for sepsis, 237,075 patients (79.9%) survived to hospital discharge. Of these, 42% died (99,571) within 2 years. Long-term mortality increased significantly with age, ranging from 5.8% in patients younger than 15 years to 62% in those older than 84 years (p < 0.0001), and with comorbidity burden (21%, 38%, 51%, and 67% for Charlson index 0, 1-2, 3-4, and ≥ 5, respectively; p < 0.0001). Neoplasia (hazard ratio [HR], 2.011), liver cirrhosis (HR, 1.562), and dementia (HR, 1.304) were the comorbidities most strongly associated with mortality. Longer hospital stays were also associated with increased mortality. A progressive decline in long-term mortality was observed during 2017-2019. Long-term mortality among sepsis survivors remains high, with more than 40% dying within 2 years after hospital discharge. These findings support the need for structured post-sepsis care strategies focused on high-risk patients, improved continuity of care, and prevention of long-term sepsis-related complications.
中文摘要:评估加泰罗尼亚地区15年间脓毒症幸存者的长期死亡率,并识别出院后2年内死亡风险升高的相关因素。研究为基于人群的回顾性队列研究,地点为西班牙加泰罗尼亚的急症医院。纳入2005年至2019年因脓毒症住院的成人和儿童患者,使用国际疾病分类第9版临床修订版和国际疾病分类第10版临床修订版中感染与急性器官功能障碍编码识别。排除住院期间死亡、转至其他机构或重复入院记录的患者。干预:无。数据来自加泰罗尼亚急症医院最低基本数据集,并通过参保人员中央登记系统进行纵向随访。合并症采用Charlson合并症指数评估。使用logistic回归和Cox比例风险模型识别长期死亡率的预测因素。在296,554例脓毒症住院记录中,237,075例患者(79.9%)存活至出院。其中42%(99,571例)在2年内死亡。长期死亡率随年龄显著升高,从15岁以下患者的5.8%升至84岁以上患者的62%(p < 0.0001),也随合并症负担升高(Charlson指数0、1-2、3-4和≥5时分别为21%、38%、51%和67%;p < 0.0001)。肿瘤(风险比2.011)、肝硬化(风险比1.562)和痴呆(风险比1.304)是与死亡率关联最强的合并症。住院时间较长也与死亡率升高相关。2017-2019年期间观察到长期死亡率逐步下降。脓毒症幸存者的长期死亡率仍然很高,出院后2年内超过40%死亡。这些发现支持需要针对高风险患者制定结构化的脓毒症后照护策略、改善照护连续性并预防长期脓毒症相关并发症。
Sepsis remains a major cause of global morbidity and mortality despite advances in recognition, antimicrobial therapy, and organ support, reflecting its biological heterogeneity and the absence of broadly effective host-directed treatments. Here, we synthesize recent evidence across the three domains that define contemporary sepsis: epidemiology, pathophysiology, and management. Global and regional data indicate a persistently high but uneven burden, shaped by differences in case definitions, population structure, healthcare resources, and ascertainment. Mechanistically, sepsis is best viewed as an interconnected systems disorder in which hyperinflammation and immunoparalysis coexist with oxidative stress, endothelial and coagulation injury, immunometabolic dysfunction, gut dysbiosis, mitochondrial damage, and dysregulated programmed cell death, collectively driving organ dysfunction. Current management remains centered on timely antimicrobials, source control, individualized fluid and vasopressor therapy, corticosteroids, and organ support, while biomarker-guided immunotherapy and other host-directed strategies remain investigational. Recent randomized trials have mainly refined how established treatments are delivered rather than identified a universally effective new therapy. We also evaluate preclinical evidence for natural compounds targeting inflammatory and cell-death networks and highlight persistent methodological, pharmacokinetic, and translational barriers. Integrating rigorous phenotyping, mechanistic biomarkers, and guideline-based care may provide a more realistic path toward precision sepsis therapy.
中文摘要:脓毒症仍是全球发病和死亡的主要原因,尽管在识别、抗微生物治疗和器官支持方面已有进展,这反映其生物学异质性以及缺乏广泛有效的宿主导向治疗。本文综合近期在定义当代脓毒症的三个领域——流行病学、病理生理学和管理——的证据。全球和区域数据显示负担持续很高但不均衡,受病例定义、人口结构、医疗资源和病例确认差异影响。机制上,脓毒症最好被视为相互关联的系统性疾病,其中过度炎症和免疫麻痹与氧化应激、内皮和凝血损伤、免疫代谢功能障碍、肠道菌群失调、线粒体损伤及程序性细胞死亡失调并存,共同驱动器官功能障碍。当前管理仍以及时抗微生物治疗、感染源控制、个体化液体和血管升压药治疗、糖皮质激素及器官支持为中心,而生物标志物指导的免疫治疗和其他宿主导向策略仍处于研究阶段。近期随机试验主要细化了既有治疗的实施方式,而非发现普遍有效的新疗法。我们也评估了靶向炎症和细胞死亡网络的天然化合物的临床前证据,并强调持续存在的方法学、药代动力学和转化障碍。整合严格表型分析、机制生物标志物和指南推荐治疗,可能为脓毒症精准治疗提供更现实的路径。
The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating mortality, with over 80,000 opioid-involved overdose deaths in the USA in 2022. Despite the proven effectiveness of opioid agonist therapy, specifically methadone and buprenorphine, treatment coverage remains inadequate, with profound gaps in opioid use disorder (OUD) continuum of care. Injection-related infections, particularly skin and soft tissue infections, bacteremia, osteomyelitis, and infective endocarditis, have increased substantially since the early 2000s and carry a high risk of morbidity and mortality. Risk is further compounded by criminalization, stigma, incarceration, and comorbid psychiatric conditions. Emerging concerns such as xylazine-associated necrotic wounds illustrate the dynamic intersection of substance use and infectious disease. While direct-acting antivirals have made hepatitis C curable, barriers to treatment persist, and uptake of HIV prevention strategies, including pre-exposure prophylaxis, remains low among people who inject drugs. Integration of addiction treatment into infectious disease and hospital care improves outcomes, yet systemic and policy barriers limit access. Innovative models such as syringe service programs, mobile units, and inpatient addiction consult services demonstrate the feasibility of integrated, patient-centered care. Evidence gaps remain regarding optimal antibiotic strategies for serious infections in people with OUD, and research and policy must address exclusionary practices, stigma, and fragmented systems of care. A synergistic approach integrating OUD treatment, infectious disease management, risk reduction, and trauma-informed care is essential to reduce preventable deaths and improve long-term health outcomes.
中文摘要:阿片类药物流行已形成传染病共病流行,注射吸毒推动HIV、病毒性肝炎及严重细菌和真菌感染发病率上升。阿片类药物使用继续造成沉重死亡负担,2022年美国有超过8万例涉及阿片类药物的过量死亡。阿片受体激动剂治疗,尤其是美沙酮和丁丙诺啡,已被证明有效,治疗覆盖仍不足,阿片使用障碍照护连续体存在明显缺口。注射相关感染,特别是皮肤软组织感染、菌血症、骨髓炎和感染性心内膜炎,自2000年代初以来显著增加,并带来高致病和死亡风险。犯罪化、污名、监禁和共病精神疾病进一步叠加风险。赛拉嗪相关坏死性伤口等新问题显示物质使用与传染病的动态交叉。直接抗病毒药物使丙型肝炎可治愈,治疗障碍持续存在,注射吸毒人群对HIV预防策略包括暴露前预防的使用率仍低。将成瘾治疗整合进传染病和医院照护可改善结局,系统性和政策障碍限制可及性。针具服务项目、移动单元和住院成瘾会诊服务等创新模式显示以患者为中心整合照护可行。关于阿片使用障碍患者严重感染的最佳抗生素策略仍存在证据缺口,研究和政策必须处理排斥性做法、污名和碎片化照护系统。将阿片使用障碍治疗、传染病管理、风险降低和创伤知情照护整合的协同方法,对减少可预防死亡和改善长期健康结局至关重要。
Create systematic evidence maps of novel biomarkers of kidney injury from a mapping review to guide future implementation in patient care. PubMed/MEDLINE and Embase. Systematic evidence maps included clinical trials and observational studies in critically ill patients, investigating novel kidney biomarkers for acute kidney injury (AKI). Six thousand eight hundred five records were screened, and 1116 studies were included that related to one or more novel biomarkers and AKI. Adult populations accounted for 78.6% of the studies, and 93.3% used a cohort design to investigate AKI biomarkers. Mixed critically ill populations, cardiac surgery, and sepsis were identified as the most frequently studied clinical contexts in 69.5% of the studies. Systematic evidence maps were synthesized for biomarker studies to predict AKI ( n = 944), prognosticate clinical outcomes ( n = 647), diagnose AKI etiology ( n = 109), enrich clinical trials ( n = 6), and manage AKI ( n = 12). Implementation strategies for patient care included surveilling patients at risk of AKI, including patients undergoing surgery and those exposed to multiple nephrotoxic drugs. Substantial clinical evidence assessing the accuracy of biomarkers compared with diagnosis of AKI exists, with fewer practical trials in clinical use. Still, guidance on implementation approaches can be gleaned from evaluations using biomarkers for the management of critically ill patients, particularly in surgical and nephrotoxin-exposed populations where evidence is available. This review identifies the landscape of current evidence and highlights priorities for future management and enrichment trials needed to bridge the gap between predictive accuracy and clinical decision-making.
中文摘要:通过映射综述构建肾损伤新型生物标志物的系统证据图,为未来患者照护中的实施提供指引。检索PubMed/MEDLINE和Embase。系统证据图纳入在重症患者中开展、研究新型肾脏生物标志物用于急性肾损伤(AKI)的临床试验和观察性研究。共筛选6805条记录,纳入1116项涉及一种或多种新型生物标志物与AKI的研究。成人人群占78.6%,93.3%的研究采用队列设计考察AKI生物标志物。混合重症人群、心脏手术和脓毒症是最常研究的临床情境,占69.5%。系统证据图按用途综合:预测AKI(n=944)、预后判断临床结局(n=647)、诊断AKI病因(n=109)、富集临床试验(n=6)和管理AKI(n=12)。患者照护的实施策略包括监测有AKI风险的患者,涵盖接受手术者和暴露于多种肾毒性药物者。已有大量临床证据评估生物标志物相较AKI诊断的准确性,但临床实际应用中的实用性试验较少。不过,从将生物标志物用于重症患者管理的评估中仍可获得实施路径的指导,尤其是在有证据可用的手术人群和肾毒性药物暴露人群中。该综述梳理了当前证据格局,并强调未来管理与富集试验的优先事项,以弥合预测准确性与临床决策之间的差距。
To determine the effect of peripheral perfusion-guided resuscitation on 28-day mortality in adults with vasodilatory shock. We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Scopus from inception to November 2025. We included randomized controlled trials (RCTs) comparing peripheral perfusion-guided resuscitation with standard care or lactate-guided resuscitation; all eligible trials enrolled patients with septic shock. Trial characteristics, intervention and comparator protocols, and outcomes were extracted. Risk of bias was assessed with the Cochrane Risk of Bias tool for randomized trials 2.0 tool and certainty of evidence with the Grading of Recommendations, Assessment, Development, and Evaluation approach. We conducted a prespecified dual-framework meta-analysis comprising a primary frequentist random-effects model and a Bayesian hierarchical model with alternative prior assumptions. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and was preregistered with PROSPERO (CRD420251229564). Seven RCTs ( n = 2408) were included. In the primary frequentist analysis, the pooled risk ratio (RR) for 28-day mortality with peripheral perfusion-guided resuscitation was 0.87 (95% CI, 0.76-1.01; p = 0.06; moderate-certainty evidence), with the CI crossing the line of no effect. No heterogeneity was detected ( I2 = 0%). The two largest and lowest-risk trials were individually nonsignificant. The prespecified Bayesian analysis estimated a 97.2% posterior probability that RR is less than 1 (P [RR < 1]), broadly consistent across alternative prior assumptions. Among adults with septic shock, peripheral perfusion-guided resuscitation yielded a lower 28-day mortality estimate that did not meet statistical significance in the frequentist analysis. The Bayesian component of the dual framework was directionally concordant, estimating a high posterior probability that RR is less than 1, although the magnitude of any effect remains uncertain. Adequately powered trials are needed to confirm whether this signal reflects a clinically meaningful benefit.
中文摘要:评估外周灌注导向复苏对成人血管扩张性休克患者28天死亡率的影响。检索PubMed、Embase、Cochrane对照试验中心注册库和Scopus,时间自建库至2025年11月。纳入比较外周灌注导向复苏与标准治疗或乳酸导向复苏的随机对照试验;所有符合条件试验均纳入脓毒症休克患者。提取试验特征、干预与对照方案及结局。使用Cochrane随机试验偏倚风险工具2.0评估偏倚风险,采用GRADE方法评估证据确定性。按预设开展双重框架荟萃分析,包括主要频率学派随机效应模型和采用替代先验假设的贝叶斯分层模型。综述遵循PRISMA,并在PROSPERO预注册(CRD420251229564)。共纳入7项随机对照试验(n=2408)。主要频率学派分析中,外周灌注导向复苏的28天死亡率合并风险比(RR)为0.87(95% CI 0.76-1.01;p=0.06;中等确定性证据),置信区间跨越无效线。未检测到异质性(I2=0%)。两项规模最大且风险最低的试验单独分析均无统计学意义。预设贝叶斯分析估计RR小于1的后验概率为97.2%(P[RR<1]),在不同替代先验假设下大致一致。在脓毒症休克成人中,外周灌注导向复苏得到较低的28天死亡率估计,但频率学派分析未达统计学显著性。双重框架中的贝叶斯部分方向一致,估计RR小于1的后验概率较高,但效应幅度仍不确定。需要样本量充足的试验确认该信号是否反映具有临床意义的获益。
One in four surgical patients carries a drug allergy label, of which an estimated 90% are incorrect. Avoidance of first-choice drug therapies can lead to worse postoperative outcomes. We sought to determine the nature and extent of any association between drug allergy labels and postoperative complications. A multicentre observational study was performed in 21 UK National Health Service hospitals. Eligible patients were ≥18 yr of age and undergoing common surgical procedures: primary hip or knee replacement, internal fixation of closed long bone fracture, colorectal resection, transurethral resection of prostate or bladder tumour, Caesarean delivery, or hysterectomy. Exclusion criteria were the use of antibiotics in the two weeks before surgery or previous participation in the study. The primary outcome was postoperative complications within 30 days after surgery, a composite outcome comprising all postoperative infections, anastomotic leak, acute respiratory distress syndrome, myocardial infarction, postoperative bleeding, pulmonary embolism, stroke, antimicrobial side-effects, and death. Among 13 646 patients, 3924 (29%) carried ≥1 drug allergy label. Labelled patients were more likely to develop postoperative complications (989/3924 [25%] vs 1926/9722 [20%]; odds ratio [OR] 1.21 [1.10-1.34]; P<0.001). They were more likely to develop surgical site infections (337/3924 [9%] vs 760/9722 [8%]; OR 1.19 [1.03-1.38]; P<0.018), and any postoperative infection (750/3924 [19%] vs 1472/9722 [15%]; OR 1.24 [1.11-1.38]; P<0.001). Labelled patients experienced an increased risk of allergic drug reactions (31/3924 [0.01%] vs 29/9722 [<0.01%]; OR 3.00 [1.77-5.09]; P<0.001), but no increase in mortality. Drug allergy labels are common, but often incorrect. Patients with drug allergy labels experience worse postoperative outcomes, including infective and noninfective complications and an increased risk of allergic drug reactions. ISRCTN Registry (ISRCTN15775657).
中文摘要:每4名手术患者中约有1人带有药物过敏标签,其中估计90%并不正确。回避首选药物治疗可能导致术后结局更差。本研究旨在确定药物过敏标签与术后并发症之间关联的性质和程度。研究在英國国家医疗服务体系的21家医院开展多中心观察性研究。纳入标准为年龄≥18岁并接受常见外科手术者:初次髋或膝关节置换、闭合性长骨骨折内固定、结直肠切除、经尿道前列腺或膀胱肿瘤切除、剖宫产或子宫切除。排除标准为术前两周使用抗生素或既往参加过本研究。主要结局为术后30天内并发症,这一复合结局包括所有术后感染、吻合口漏、急性呼吸窘迫综合征、心肌梗死、术后出血、肺栓塞、卒中、抗菌药物副作用和死亡。在13646名患者中,3924名(29%)带有至少1个药物过敏标签。带标签患者更可能发生术后并发症(989/3924[25%]对1926/9722[20%];比值比[OR]1.21[1.10-1.34];P<0.001)。他们更可能发生手术部位感染(337/3924[9%]对760/9722[8%];OR1.19[1.03-1.38];P<0.018),以及任何术后感染(750/3924[19%]对1472/9722[15%];OR1.24[1.11-1.38];P<0.001)。带标签患者发生过敏性药物反应的风险增加(31/3924[0.01%]对29/9722[<0.01%];OR3.00[1.77-5.09];P<0.001),但死亡率未增加。药物过敏标签常见,但常不正确。带有药物过敏标签的患者术后结局更差,包括感染性和非感染性并发症,并且发生过敏性药物反应的风险增加。ISRCTN注册库(ISRCTN15775657)。
To examine contemporary nationwide trends in sepsis incidence and mortality in South Korea and the associated clinical and socioeconomic factors. Retrospective, population-based cohort study. Korea's healthcare system from 2011 to 2022, utilizing the National Health Insurance Service database. Adult patients 18 years old or older hospitalized for sepsis and identified using the International Classification of Diseases , 10th Revision codes. None. Incidence and mortality were analyzed annually over the study period. Poisson and linear regression models were used to analyze temporal trends in sepsis incidence and mortality. Multivariable logistic regression was performed to evaluate risk factors for in-hospital mortality. In all, 1,149,379 sepsis cases were identified. The crude incidence of sepsis increased from 141.8 to 337.3 per 100,000 person-years from 2011 to 2022, whereas the age-standardized incidence increased by 53.1%. In-hospital mortality decreased from 27.0% to 17.0%. Poisson regression analysis showed significant increases in crude and age-standardized incidence (incidence rate ratio [IRR], 1.09; 95% CI, 1.08-1.09; p < 0.001 and IRR, 1.04; 95% CI, 1.04-1.04; p < 0.001, respectively). In-hospital mortality consistently declined from 27.0% in 2011 to 17.0% in 2022 (β = -1.1%; p < 0.001; R2 = 0.91). However, the total number of deaths increased from 15,605 in 2011 to 25,326 in 2022 (β = 779; p < 0.001; R2 = 0.98). Multivariable analysis identified that older age, male sex, higher comorbidity burden, and greater disease severity were independent risk factors for mortality. Socioeconomic disparities were evident: medical aid beneficiaries and rural residents had higher mortality, whereas treatment at tertiary hospitals was associated with improved outcomes. In this nationwide claims-based study, recorded sepsis incidence increased and in-hospital mortality declined over time, although these trends warrant cautious interpretation given potential shifts in case identification practices. Socioeconomic disparities in mortality persisted throughout the study period.
中文摘要:考察韩国脓毒症发病率和死亡率的当代全国趋势及相关临床和社会经济因素。研究为回顾性、基于人群的队列研究,依托韩国医疗体系2011至2022年的数据,使用国民健康保险服务数据库。纳入18岁及以上因脓毒症住院的患者,采用国际疾病分类第十版(ICD-10)编码识别。无干预措施。按年度分析研究期间的发病率和死亡率。采用泊松回归和线性回归分析脓毒症发病率与死亡率的时间趋势,采用多变量logistic回归评估院内死亡的危险因素。共识别1,149,379例脓毒症病例。2011至2022年,粗发病率由141.8/10万人年升至337.3/10万人年,年龄标化发病率上升53.1%。院内死亡率由27.0%降至17.0%。泊松回归分析显示粗发病率和年龄标化发病率均显著上升(粗发病率IRR=1.09,95%置信区间1.08-1.09,p<0.001;年龄标化发病率IRR=1.04,95%置信区间1.04-1.04,p<0.001)。院内死亡率从2011年的27.0%持续降至2022年的17.0%(β=-1.1%;p<0.001;R²=0.91)。死亡总人数由2011年的15,605例增至2022年的25,326例(β=779;p<0.001;R²=0.98)。多变量分析显示,年龄较大、男性、合并症负担较高和疾病严重程度较高是死亡的独立危险因素。社会经济差异明显:医疗救助受益者和农村居民死亡率更高,三级医院治疗与结局改善相关。这项基于全国理赔数据的研究显示,记录的脓毒症发病率随时间上升,院内死亡率下降;鉴于病例识别实践可能发生变化,这些趋势需要谨慎解释。研究期间死亡的社会经济差异持续存在。
Large-volume hospitals for critically ill patients are generally associated with improved outcomes. However, the effect of ICU volume together with patient severity remains insufficiently evaluated. Therefore, the present study aimed to determine the impact of ICU patient volume stratified by Sequential Organ Failure Assessment (SOFA) scores (0-24) on mortality and clarify the possible effect of volume within a specific severity range. Retrospective observational study using a nationwide Japanese database. Japanese Diagnosis Procedure Combination inpatient database. A total of 568,340 adult patients were admitted to the ICU in 430 hospitals between October 1, 2020, and March 31, 2023. None. The primary outcome was in-hospital mortality. We calculated the facility-level annual patient volume above a SOFA score threshold of X (range: 0-24) and examined its association with mortality using multilevel mixed-effects logistic regression models. Although total ICU volume was not significantly associated with mortality (adjusted odds ratio [OR] per 10-patient increase: 0.999; 95% CI, 0.999-1.000; p = 0.147), the volume of ICU patients above a SOFA score threshold of 5 was significantly associated with decreased in-hospital mortality (OR, 0.997; 95% CI, 0.995-0.998; p < 0.001). Overall, the adjusted ORs progressively decreased as the SOFA score threshold increased, indicating an enhanced inverse association at increased severity levels. Increased volumes of patients with severe illnesses were associated with decreased in-hospital mortality rates; this inverse volume-outcome relationship became more pronounced as the severity threshold increased.
中文摘要:收治危重患者量大的医院通常与结局改善相关。但ICU收治量与患者病情严重程度的共同作用仍未得到充分评价。本研究旨在确定按序贯器官衰竭评估(SOFA)评分(0-24)分层后的ICU患者收治量对死亡率的影响,并阐明特定严重程度范围内收治量的可能作用。研究为回顾性观察性研究,使用日本全国数据库,即日本诊断程序组合住院数据库。纳入2020年10月1日至2023年3月31日期间430家医院ICU收治的568340例成年患者。无干预。主要结局为院内死亡。我们计算了SOFA评分阈值X(范围0-24)以上的机构层面年患者收治量,并使用多水平混合效应logistic回归模型检验其与死亡率的关联。尽管ICU总收治量与死亡率无显著关联(每增加10例患者的校正比值比[OR]为0.999;95%CI 0.999-1.000;p=0.147),SOFA评分阈值5以上的ICU患者收治量与院内死亡率降低显著相关(OR 0.997;95%CI 0.995-0.998;p<0.001)。总体而言,随着SOFA评分阈值升高,校正OR逐步降低,表明在严重程度较高时负向关联增强。重症患者收治量增加与院内死亡率降低相关;随着严重程度阈值提高,这种负向收治量-结局关系更为明显。
Hyperinflammatory and hypoinflammatory phenotypes previously identified in sepsis and acute respiratory distress syndrome may enable precision therapies, but their clinical relevance and translational modeling in severe pneumonia remain incompletely characterized. To examine biomarker-defined hyperinflammatory and hypoinflammatory phenotypes in critically ill patients with pneumonia (pulmonary sepsis), test whether the biomarkers that define these phenotypes identify subgroups and outcomes in a mouse model of bacterial pneumonia, and determine whether the mouse phenotypes respond differently to therapeutic interventions. We performed latent class analysis (LCA) in a cohort of 548 ICU patients with pulmonary sepsis to identify inflammatory phenotypes and test the association of these phenotypes with clinical outcomes using validated classifier models. We developed a mouse model of pneumococcal pneumonia that recapitulated key aspects of these phenotypes and tested responses to dexamethasone and IL-6 receptor blockade. Two phenotypes were identified in patients with pulmonary sepsis: a hyperinflammatory phenotype with more lung injury and increased mortality, and a hypoinflammatory phenotype with more favorable outcomes. Despite uniform pathogen exposure and baseline conditions, LCA identified 2 phenotypes in the mice with divergent trajectories (lung injury and mortality). Therapeutic benefit from anti-inflammatory interventions was observed exclusively in the more inflamed mice. By integrating clinical data from human studies and experimental findings in a clinically relevant mouse model, this study provides a translational framework for developing phenotype-targeted therapies for critical illness, with the goal of improving patient outcomes.
中文摘要:脓毒症和急性呼吸窘迫综合征中既往识别出的高炎症型与低炎症型可能为精准治疗提供依据,但其在重症肺炎中的临床相关性和转化建模仍未充分明确。研究旨在考察肺炎(肺源性脓毒症)危重患者中由生物标志物定义的高炎症型和低炎症型,检验定义这些表型的生物标志物能否在细菌性肺炎小鼠模型中识别亚组和结局,并判断小鼠表型对治疗干预的反应是否不同。我们对548例肺源性脓毒症ICU患者队列进行潜伏类别分析,以识别炎症表型,并使用经验证的分类模型检验这些表型与临床结局的关联。我们建立了肺炎链球菌肺炎小鼠模型,该模型再现了这些表型的关键特征,并检测了其对地塞米松和IL-6受体阻断的反应。肺源性脓毒症患者中识别出两种表型:高炎症型伴更重肺损伤和更高死亡率,低炎症型结局更有利。尽管病原暴露和基线条件一致,潜伏类别分析仍在小鼠中识别出两种表型,其肺损伤和死亡率轨迹不同。抗炎干预的治疗获益仅见于炎症更重的小鼠。通过整合人类研究的临床数据与临床相关小鼠模型的实验发现,本研究为开发面向表型的重症疾病治疗提供了转化框架,目标是改善患者结局。
Sepsis assessment relies largely on organ-dysfunction scores and systemic biomarkers, which provide limited information on immune-effector function. We developed NeutroDrop, an integrated droplet microfluidic platform for single-cell profiling of neutrophil reactive oxygen species (ROS)-related oxidative activity and neutrophil elastase (NE)-associated proteolytic activity. Under standardized fMLP stimulation, individual neutrophils were co-encapsulated with fluorescent probes in monodisperse droplets, while membrane-integrity screening and software-assisted image analysis excluded multicell and membrane-compromised droplets. The study included 1012 neutrophils from 10 healthy controls and 2353 neutrophils from 20 patients with sepsis. Analysis of patient-level median signals showed reduced NE activity in sepsis (group means, 28.91 vs. 72.32), whereas ROS showed a nonsignificant decrease (72.14 vs. 92.26). Healthy-reference single-cell analysis revealed marked depletion of high ROS/high NE neutrophils in sepsis (2.89% vs. 16.86%), leading to the PerHighHigh index for healthy/sepsis classification. Local abundance analysis identified a data-derived low-amplitude ROS-NE region associated with non-survival; its patient-level abundance, Pi(R), stratified 12-day outcome with 83.33% sensitivity and 92.85% specificity in the discovery cohort. These locked rules were implemented in NeutroDrop-Plus, which correctly classified all 10 operator-blinded samples and matched 12-day outcomes in 5 of 6 sepsis cases. NeutroDrop converts neutrophil single-cell functional heterogeneity into quantitative biosensing indicators for adjunctive sepsis classification and exploratory short-term outcome stratification.
中文摘要:脓毒症评估主要依赖器官功能障碍评分和系统性生物标志物,这些指标对免疫效应功能提供的信息有限。我们开发了NeutroDrop,一种集成液滴微流控平台,用于单细胞分析中性粒细胞活性氧(ROS)相关氧化活性和中性粒细胞弹性蛋白酶(NE)相关蛋白水解活性。在标准化fMLP刺激下,单个中性粒细胞与荧光探针共包封于单分散液滴中,膜完整性筛查和软件辅助图像分析排除多细胞和膜受损液滴。研究纳入10名健康对照的1012个中性粒细胞和20例脓毒症患者的2353个中性粒细胞。患者水平中位信号分析显示脓毒症中NE活性降低(组均值28.91 vs. 72.32),ROS呈非显著性下降(72.14 vs. 92.26)。以健康对照为参考的单细胞分析显示脓毒症中高ROS/高NE中性粒细胞明显减少(2.89% vs. 16.86%),由此形成用于健康/脓毒症分类的PerHighHigh指数。局部丰度分析识别出一个由数据衍生的低振幅ROS-NE区域,与未存活相关;其患者水平丰度Pi(R)在发现队列中以83.33%敏感性和92.85%特异性分层12天结局。这些锁定规则在NeutroDrop-Plus中实现,正确分类全部10份操作者盲法样本,并在6例脓毒症病例中匹配5例的12天结局。NeutroDrop将中性粒细胞单细胞功能异质性转化为定量生物传感指标,用于脓毒症辅助分类和探索性短期结局分层。
基础研究 (6篇)
Covering: up to 2025Toll-like receptor 2 (TLR2) is a versatile pattern recognition receptor whose activity can be tuned in either direction-agonism or antagonism-to produce distinct therapeutic outcomes, ranging from vaccine adjuvants and cancer immunotherapeutics to anti-inflammatory agents for sepsis, neuroinflammation, and autoimmune disease. Natural products from bacteria, fungi, plants, and marine organisms have emerged as a structurally rich source of TLR2 modulators, encompassing acylated lipopeptides, glycolipids, polysaccharides, flavonoids, non-flavonoid polyphenols, an aromatic aldehyde, an aporphine alkaloid, and even large bacterial antagonist proteins. This review surveys these natural TLR2 agonists and inhibitors, highlighting how the effective allocation of hydrophobic chains between the TLR2 pocket and its partner receptor, rather than total acyl-chain number alone, combines with chain branching, stereochemical presentation and polar head-group interactions to govern TLR1/TLR6 heterodimer selectivity among bacterial and gut-commensal lipids, and how mechanistically distinct inhibitory strategies-direct receptor competition, transcriptional downregulation, and TIR-domain interference-converge on a shared druggable interface exploited independently by plant polyphenols and staphylococcal virulence factors alike. Persistent experimental challenges are also discussed, including microbial contamination of natural extracts and structural heterogeneity of isolated lipids, along with how total synthesis and chemically defined oligomers have resolved these ambiguities, underscoring natural products as a promising yet still underexploited chemical space for developing selective TLR2-targeted therapeutics.
中文摘要:涵盖至2025年。Toll样受体2(TLR2)是一种功能多样的模式识别受体,其活性可被双向调节,即激动或拮抗,从而产生不同的治疗效应,涵盖疫苗佐剂、肿瘤免疫治疗药物,以及用于脓毒症、神经炎症和自身免疫病的抗炎药物。源自细菌、真菌、植物与海洋生物的天然产物已成为结构类型丰富的TLR2调节剂来源,包括酰化脂肽、糖脂、多糖、黄酮类、非黄酮多酚、一种芳香醛、一种阿朴啡生物碱,甚至大型细菌拮抗蛋白。本综述梳理这些天然TLR2激动剂与抑制剂,重点说明疏水链在TLR2口袋与其配对受体之间的有效分配,而非仅看酰基链总数,如何与链分支、立体化学呈现及极性头基相互作用共同决定细菌脂质与肠道共生菌脂质对TLR1/TLR6异二聚体的选择性;并说明机制各异的抑制策略,即直接受体竞争、转录下调与TIR结构域干扰,如何汇聚于同一可成药界面,而植物多酚与葡萄球菌毒力因子各自独立地利用了该界面。文中亦讨论长期存在的实验难题,包括天然提取物的微生物污染与分离脂质的结构异质性,以及全合成与化学限定寡聚体如何化解这些不确定性,表明天然产物仍是开发选择性TLR2靶向治疗药物中具前景却尚未充分利用的化学空间。
Sepsis-induced cardiomyopathy (SICM) is an acute, often reversible myocardial depression driven by the host response to infection. Cardiac macrophages are central signaling hubs that integrate systemic danger signals and orchestrate myocardial dysfunction. We introduce a "Macrophage Functional Continuum" model, conceptualizing macrophages as dynamic signal integrators undergoing three interconnected phases: sensing and initiation, intrinsic reprogramming and fate determination, and multicellular network execution. Conceptually, these phases represent functional modules that may overlap in time and vary across organs, rather than a rigid chronological sequence. Stage-matched strategies-including immunometabolic modulation, checkpoint control, nanomedicine, and macrophage-based therapies-may provide a more context-sensitive therapeutic framework than conventional anti-inflammatory approaches. This review aims to reframe macrophage biology in SICM and provide a roadmap for translational research.
中文摘要:脓毒症诱导的心肌病(SICM)是一种由宿主对感染的反应驱动的急性、常可逆的心肌抑制。心脏巨噬细胞是核心信号枢纽,整合全身危险信号并协调心肌功能障碍。我们提出「巨噬细胞功能连续体」模型,将巨噬细胞视为动态信号整合者,经历三个相互关联的阶段:感知与启动、内在重编程与命运决定、多细胞网络执行。概念上,这些阶段代表可随时间重叠、并因器官不同而变化的功能模块,而非严格的时间顺序。与阶段匹配的策略,包括免疫代谢调节、检查点控制、纳米医学和基于巨噬细胞的治疗,可能提供比传统抗炎方法更贴合情境的治疗框架。本综述旨在重新构建SICM中的巨噬细胞生物学,并为转化研究提供路线图。
Sepsis often leads to severe liver damage, and currently few effective therapies are available for it. Nicotinamide mononucleotide (NMN), a well-known anti-aging agent, exerts organ-protective effects, yet its detailed mechanisms against acute liver injury remain poorly understood. Here, we established LPS-induced liver injury mouse models, along with in vitro models using primary hepatocytes, primary macrophages and THP-1 cells. We found that LPS triggers ferroptosis and inflammation in both macrophages and hepatocytes, and paracrine inflammatory signals from macrophages further aggravate hepatocyte ferroptosis. NMN effectively reverses these pathological changes. Mechanistically, NMN suppressed mtDNA-mediated cGAS-STING activation and weakened the interaction between STING and ACSL4. Domain mapping, molecular simulations, surface plasmon resonance (SPR) analysis, co-immunoprecipitation and hepatic proximity ligation assay (PLA) collectively demonstrated that NMN destabilized the STING-ACSL4 complex, thereby restraining ferroptosis. In conclusion, NMN protects against LPS-induced acute liver injury by concurrently suppressing cGAS-STING-mediated inflammation and weakening the pro-ferroptotic STING-ACSL4 interaction.
中文摘要:脓毒症常导致严重肝损伤,目前缺乏有效治疗手段。烟酰胺单核苷酸(NMN)是已知的抗衰老剂,具有器官保护作用,但其缓解急性肝损伤的具体机制仍不清楚。本研究建立LPS诱导的小鼠肝损伤模型,并使用原代肝细胞、原代巨噬细胞和THP-1细胞建立体外模型。发现LPS可触发巨噬细胞和肝细胞中的铁死亡与炎症,巨噬细胞分泌的旁分泌炎症信号进一步加重肝细胞铁死亡,NMN能有效逆转这些病理改变。机制上,NMN抑制mtDNA介导的cGAS-STING激活,并削弱STING与ACSL4之间的相互作用。结构域定位、分子模拟、表面等离子共振分析、免疫共沉淀和肝脏邻近连接实验共同表明,NMN使STING-ACSL4复合物不稳定,从而抑制铁死亡。结论是,NMN通过同时抑制cGAS-STING介导的炎症并削弱促铁死亡的STING-ACSL4相互作用,对LPS诱导的急性肝损伤发挥保护作用。
Sepsis-associated encephalopathy (SAE) is a severe neurological complication of sepsis, for which current therapeutic options remain limited. There is an urgent need for innovative strategies that simultaneously target both central and peripheral pathophysiological mechanisms. In this study, we developed a microalgae-nanoparticle multistage biosystem, CV@MT-NPs, by electrostatically assembling melatonin-loaded, quaternary chitosan-modified liposomes (MT-NPs) onto Chlorella vulgaris (CV) microalgae. The resulting CV@MT-NPs enabled sustained melatonin release and significantly prolonged systemic circulation and brain retention of melatonin. In an LPS-induced murine SAE model, CV@MT-NPs markedly improved survival, attenuated cognitive deficits and anxiety-like behaviors, reduced clinical severity, and mitigated body weight loss. Mechanistically, MT-NPs released from CV@MT-NPs entered the brain, where they preserved blood-brain barrier integrity by restoring tight junction proteins and re-establishing astrocyte-endothelial coupling. Furthermore, they suppressed neuroinflammation by inhibiting microglial hyperactivation, promoting microglial homeostasis, attenuating astrogliosis, and protecting mitochondrial structure and function. Beyond the central nervous system, MT-NPs also ameliorated systemic inflammation, restored intestinal barrier integrity, and enhanced M2 macrophage polarization through inhibition of the NF-κB signaling pathway. Notably, the CV component played a complementary role by rebalancing the gut microbiota, specifically enriching beneficial short-chain fatty acid-producing bacteria, and elevating levels of acetic, propionic, and butyric acids in both the gut and the brain. Critically, comprehensive biocompatibility assessments revealed no evidence of acute or chronic toxicity. Collectively, CV@MT-NPs represent a multifunctional, gut-brain axis-modulating therapeutic platform that, when administered prophylactically, demonstrates significant potential to concurrently ameliorate central neuropathology and peripheral immune-metabolic dysfunction, offering a promising preventive strategy for SAE.
中文摘要:脓毒症相关脑病(SAE)是脓毒症严重的神经系统并发症,现有治疗选择仍有限。迫切需要同时靶向中枢与外周病理生理机制的创新策略。通过静电组装将负载褪黑素的季铵化壳聚糖修饰脂质体(MT-NPs)固定于小球藻(CV)上,构建了微藻-纳米颗粒多级生物系统 CV@MT-NPs。所得 CV@MT-NPs 能持续释放褪黑素,并显著延长褪黑素的全身循环和脑内滞留。在 LPS 诱导的小鼠 SAE 模型中,CV@MT-NPs 明显提高生存率,减轻认知缺陷和焦虑样行为,降低临床严重程度,并缓解体重下降。机制上,CV@MT-NPs 释放的 MT-NPs 进入脑内,通过恢复紧密连接蛋白、重建星形胶质细胞-内皮细胞耦联来维持血脑屏障完整性。它们还通过抑制小胶质细胞过度活化、促进小胶质细胞稳态、减轻星形胶质细胞增生、保护线粒体结构与功能来抑制神经炎症。在中枢神经系统之外,MT-NPs 也改善全身炎症,恢复肠道屏障完整性,并通过抑制 NF-κB 信号通路增强 M2 巨噬细胞极化。CV 组分发挥互补作用,重新平衡肠道菌群,特异性富集有益的产生短链脂肪酸的细菌,并提高肠道和脑内乙酸、丙酸和丁酸水平。全面的生物相容性评估未发现急性或慢性毒性证据。总体而言,CV@MT-NPs 是一种多功能、调节肠-脑轴的治疗平台,预防性给药时,在同时改善中枢神经病理和外周免疫代谢功能障碍方面显示出显著潜力,为 SAE 提供有前景的预防策略。
Endothelial dysfunction is a critical determinant of sepsis-associated organ injury, often driven by its interaction with overactivated immune cells. Neutrophils, the dominant early responders in sepsis, contribute to endothelial barrier disruption, yet the underlying metabolic and epigenetic mechanisms remain poorly understood. Here, we observed elevated intracellular lactate levels in neutrophils from septic patients which correlated with organ dysfunction and systemic inflammatory markers. Mechanistically, lactate-induced histone H3K18 lactylation (H3K18la) enhanced ATG7/GSA7 (autophagy related 7) transcription, initiating a non-degradative, secretory autophagy program. This facilitated the extracellular release of IL1B/IL-1B (interleukin 1 beta), a key driver of endothelial dysfunction. Interference of lactate production, ATG7 expression or IL1B signaling alleviated endothelial dysfunction in vitro. In vivo, myeloid-specific deletion of the lactylation writer EP300/p300 (EP300 lysine acetyltransferase) mitigated pulmonary endothelial dysfunction and lung injury. Additionally, the stress-responsive transcription factor ATF4/CREB-2 (activating transcription factor 4) was found to directly interact with both EP300 and H3K18la, amplifying H3K18la-driven ATG7 transcription. Our findings uncover a metabolically driven, epigenetically regulated secretory autophagy pathway in neutrophils that mediates endothelial dysfunction. Our study provides mechanistic insights into neutrophil-endothelial crosstalk in sepsis and identifies EP300, ATG7, and IL1B as potential therapeutic targets for sepsis.Abbreviations: ALI: acute lung injury; ANOVA: analysis of variance; ATF4/CREB-2: activating transcription factor 4; ATG7/GSA7: autophagy related 7; ATP: adenosine triphosphate; BafA1: bafilomycin A1; BMDN: bone marrow-derived neutrophil; C-CASP1: cleaved-caspase 1; CDH5/CD144: cadherin 5; CRP/PTX1: C-reactive protein; CST3: cystatin C; CXCL8/IL-8: C-X-C motif chemokine ligand 8; DAPI: 4',6-diamidino-2-phenylindole; DEG: differentially expressed gene; dHL-60: dimethyl sulfoxide-differentiated HL-60 cell; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent assay; EP300/p300: EP300 lysine acetyltransferase; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic - pyruvic transaminase; GSDMD-N: gasdermin D N-terminal; H&E: hematoxylin and eosin; H3K18la: histone H3K18 lactylation; HRP: horseradish peroxidase; ICU: intensive care unit; IHC: immunohistochemistry; IL1B/IL-1B: interleukin 1 beta; IL1R1/CD121A: interleukin 1 receptor type 1; IL6/IL-6: interleukin 6; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAMP1/CD107a: lysosome associated membrane protein 1; LDHA: lactate dehydrogenase A; LPS: lipopolysaccharide; 3-MA: 3-methyladenine; NLRP3/NALP3: NLR family pyrin domain containing 3; PBS: phosphate-buffered saline; PCT: procalcitonin; PMN: peripheral neutrophils; Rapa: rapamycin; RNA-seq: RNA-sequencing; SERPINE1/PAI1: serpin family E member 1; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; SOFA: Sequential Organ Failure Assessment; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TNF/TNF-alpha: tumor necrosis factor; panKla: pan-histone lactylation; VCAM1/CD106: vascular cell adhesion molecule 1.
中文摘要:内皮功能障碍是脓毒症相关器官损伤的关键决定因素,常由内皮与过度活化免疫细胞的相互作用所驱动。中性粒细胞是脓毒症早期占优势的应答细胞,参与内皮屏障破坏,但其代谢与表观遗传机制仍不清楚。本研究观察到脓毒症患者中性粒细胞内乳酸水平升高,并与器官功能障碍及全身炎症标志物相关。机制上,乳酸诱导的组蛋白H3K18乳酰化(H3K18la)增强ATG7/GSA7转录,启动非降解性的分泌性自噬程序。该程序促进IL1B/IL-1B的细胞外释放,而IL1B是内皮功能障碍的重要驱动因子。干扰乳酸生成、ATG7表达或IL1B信号均可在体外减轻内皮功能障碍。在体内,髓系特异性敲除乳酰化写入酶EP300/p300可减轻肺内皮功能障碍与肺损伤。应激反应性转录因子ATF4/CREB-2可直接与EP300及H3K18la相互作用,放大H3K18la驱动的ATG7转录。研究揭示了一条由代谢驱动、受表观遗传调控的中性粒细胞分泌性自噬通路,该通路介导内皮功能障碍,为脓毒症中中性粒细胞与内皮细胞串扰提供了机制认识,并将EP300、ATG7和IL1B识别为潜在治疗靶点。
Sepsis-induced cardiomyopathy (SIC) markedly increases the overall mortality among patients with sepsis. The pathogenesis of SIC remains incompletely elucidated; specifically, the role of protein lactylation in the onset and progression of SIC awaits further investigation. Using lactylome profilinganalysis, bioinformatics and molecular biology methods, the key proteins and lactylation sites involved in the development of SIC were identified. Amino acid point mutations, molecular dynamic simulation, and biochemical experiments were performed to investigate their biological roles and underlying mechanisms. The lactylome analysis revealed 439 differentially lactylated sites in the myocardium of septic mice compared with control group.Through integrated bioinformatic analysis and molecular validation, we demonstrated that lactylation of ubiquinol-cytochrome c reductase core protein 2 (Uqcrc2) plays a pivotal role in SIC, andidentified K109 as the critical lactylation site. Mechanistically,Uqcrc2 K109 lactylation disrupts mitochondrial respiratory chain function and exacerbates cardiomyocyte apoptosis. Importantly,inhibition of Uqcrc2 K109 lactylation attenuates this apoptotic process. Furthermore, we identifiedlysine acetyltransferase 6A (KAT6A) as a novel lactyltransferase, mediating Uqcrc2 lactylation. Our study reveals that the lactate-KAT6A-Uqcrc2 lactylation-mitochondrial apoptosis axis plays a pivotal role in SIC.
中文摘要:脓毒症诱导的心肌病(SIC)显著增加脓毒症患者总体死亡率。SIC发病机制尚未完全阐明;蛋白乳酰化在SIC发生发展中的作用有待进一步研究。采用乳酰化组学分析、生物信息学和分子生物学方法,鉴定参与SIC发展的关键蛋白及乳酰化位点。通过氨基酸点突变、分子动力学模拟和生化实验研究其生物学作用及潜在机制。乳酰化组学分析显示,与对照组相比,脓毒症小鼠心肌中有439个差异乳酰化位点。通过整合生物信息学分析和分子验证,我们证明泛醇-细胞色素c还原酶核心蛋白2(Uqcrc2)的乳酰化在SIC中起关键作用,并确定K109为关键乳酰化位点。机制上,Uqcrc2 K109乳酰化破坏线粒体呼吸链功能并加重心肌细胞凋亡。抑制Uqcrc2 K109乳酰化可减轻该凋亡过程。研究还鉴定出赖氨酸乙酰转移酶6A(KAT6A)为一种新的乳酰转移酶,介导Uqcrc2乳酰化。我们的研究揭示乳酸-KAT6A-Uqcrc2乳酰化-线粒体凋亡轴在SIC中起关键作用。
3循环支持与休克 (10篇)
临床研究 (8篇)
Fulminant myocarditis (FM) is a complex clinical syndrome characterized by acute myocardial inflammation and cardiogenic shock. Evidence on long-term outcomes, mortality risk factors, and targeted treatment options remains limited. This retrospective analysis included consecutive adult patients admitted for FM between January 2012 and November 2022 at 26 European tertiary centres. According to endomyocardial biopsy (EMB) findings, patients were categorized as lymphocytic (LM), eosinophilic (EM), necrotizing eosinophilic (NEM), and giant-cell myocarditis (GCM) for the main analyses. Patients with inconclusive histopathology and those who did not undergo EMB were analysed separately. Primary outcomes were in-hospital and 1-year mortality. Multivariable logistic regression models were employed as generalized linear models to analyse the association of prespecified risk factors with mortality. Estimated associations are reported as odds ratios, generalized marginal effects, and adjusted prediction plots. A total of 271 patients [median age 43 years (interquartile range: 33-55 years), 58% male] were included in the analysis, of whom 146 fulfilled histopathologic criteria of LM (n = 99), EM (n = 18), NEM (n = 3), or GCM (n = 26). In the remaining 125 cases, EMB was inconclusive (n = 48) or not performed (n = 77). While there were no significant differences in cardiac arrest rate, admission Simplified Acute Physiology Score (SAPS) II, ventricular function, initial pH, and liver and kidney function parameters between histopathologic subgroups, the use of immunosuppressive medications and need for organ replacement varied. In the overall population, in-hospital and 1-year mortality were 31% and 34%, respectively. The highest 1-year mortality rate was observed among patients with GCM (LM: 25%, EM: 28%, NEM: 33%, GCM: 54%, P = .04). Patients who survived to discharge had an excellent functional outcome and long-term recovery of ventricular function. In total, 17 patients (6%) received a heart transplant during follow-up. Older age, lower pH, and histopathologic diagnosis of GCM were independently associated with in-hospital and 1-year mortality. In-hospital mortality among patients with FM remains high. Age, pH, and histopathological findings may serve as prognostic markers to identify high-risk patients and to guide treatment strategies. Long-term outcomes are excellent among those who survive to discharge.
中文摘要:暴发性心肌炎(FM)是一种以急性心肌炎症和心源性休克为特征的复杂临床综合征。关于长期结局、死亡危险因素和靶向治疗选择的证据仍然有限。这项回顾性分析纳入2012年1月至2022年11月期间在26家欧洲三级中心连续收治的成人FM患者。根据心内膜心肌活检(EMB)结果,患者被分为淋巴细胞性(LM)、嗜酸性(EM)、坏死性嗜酸性(NEM)和巨细胞性心肌炎(GCM)进行主要分析。组织病理学结果不确定及未接受EMB的患者单独分析。主要结局为院内死亡率和1年死亡率。采用多变量logistic回归模型作为广义线性模型分析预设危险因素与死亡率的关联。估计关联以比值比、广义边际效应和校正预测图报告。共271例患者[中位年龄43岁(四分位距33-55岁),58%为男性]纳入分析,其中146例符合LM(n=99)、EM(n=18)、NEM(n=3)或GCM(n=26)的组织病理学标准。其余125例中,EMB结果不确定(n=48)或未进行(n=77)。组织病理学亚组间心脏骤停发生率、入院简化急性生理学评分(SAPS)II、心室功能、初始pH及肝肾功能指标无显著差异,但免疫抑制药物使用和器官替代治疗需求存在差异。总体人群中,院内死亡率和1年死亡率分别为31%和34%。1年死亡率最高见于GCM患者(LM:25%,EM:28%,NEM:33%,GCM:54%,P=.04)。存活出院者功能结局良好,心室功能长期恢复。随访期间共有17例患者(6%)接受心脏移植。年龄较大、较低pH及GCM组织病理学诊断与院内死亡率和1年死亡率独立相关。FM患者院内死亡率仍然较高。年龄、pH和组织病理学发现可作为预后标志物,用于识别高危患者并指导治疗策略。存活出院者的长期结局良好。
To evaluate the effects of sodium bicarbonate therapy on mortality and renal outcomes in critically ill adults with metabolic acidosis. We performed a systematic review and Bayesian random-effects meta-analysis of randomised controlled trials (RCTs) comparing intravenous sodium bicarbonate with placebo or usual care in adult intensive care unit patients with metabolic acidosis. MEDLINE, Embase and CENTRAL were searched from inception to December 2025, with an updated search on 2 April 2026. The primary outcome was short-term all-cause mortality. Secondary outcomes included renal replacement therapy (RRT) initiation, 90-day mortality, RRT-free days, vasopressor-free days, intensive care unit and hospital length of stay and adverse events. Four RCTs including 1544 patients were analysed. Sodium bicarbonate did not show a clear short-term mortality benefit (RR 0.94, 95% CrI 0.73-1.22), with a posterior probability of benefit of 72.1%. For RRT initiation, sodium bicarbonate was associated with a lower risk (RR 0.74, 95% CrI 0.59-0.98), with a posterior probability of benefit of 97.2%. Effects on other outcomes were small or imprecise, and no consistent safety signal was identified. Current randomised evidence does not demonstrate a clear survival benefit from sodium bicarbonate therapy in critically ill adults with metabolic acidosis, but suggests a high probability of reducing RRT initiation. Further trials should define the patients most likely to benefit. PROSPERO registration: CRD420251246519.
中文摘要:评估碳酸氢钠治疗对危重成人代谢性酸中毒患者死亡率和肾脏结局的影响。我们开展了系统评价和贝叶斯随机效应荟萃分析,纳入比较静脉碳酸氢钠与安慰剂或常规治疗的随机对照试验,对象为成人重症监护病房代谢性酸中毒患者。检索MEDLINE、Embase和CENTRAL,自建库至2025年12月,并于2026年4月2日更新检索。主要结局为短期全因死亡率。次要结局包括启动肾脏替代治疗(RRT)、90天死亡率、无RRT天数、无升压药天数、重症监护病房和住院时间及不良事件。共分析4项随机对照试验、1544例患者。碳酸氢钠未显示明确的短期死亡获益(RR 0.94,95% CrI 0.73-1.22),获益的后验概率为72.1%。对于启动RRT,碳酸氢钠与较低风险相关(RR 0.74,95% CrI 0.59-0.98),获益后验概率为97.2%。对其他结局的影响较小或不精确,未发现一致的安全性信号。现有随机证据未显示碳酸氢钠治疗对危重成人代谢性酸中毒患者有明确生存获益,但提示降低RRT启动的概率较高。后续试验应明确最可能获益的患者。PROSPERO注册号:CRD420251246519。
During venoarterial extracorporeal membrane oxygenation (VA ECMO), organ perfusion no longer entirely depends on native cardiac output, which may reduce the therapeutic advantage of inotropic drugs relative to their risks. We hypothesized that, in this setting, higher cumulative inotropic exposure would be associated with impaired cardiac recovery. Observational cohort study on the effects of longitudinal inotropic exposure during VA ECMO support. Temporal changes in inotropic support during VA ECMO support were evaluated. Cumulative inotropic exposure per day during VA ECMO support was calculated using the area under the curve of a standardized inotropic score. These cumulative inotropic scores were associated with the risk of ECMO weaning failure up to 30 days (a composite of death, ongoing need for ECMO support, or the need for heart replacement therapy), mortality, and complications, using joint modeling techniques. Six hospitals in the Netherlands. Adult patients with severe cardiogenic shock (CS) receiving VA ECMO support between 2018 and 2024. None. Out of 440 patients with various causes of CS, 235 patients (53.4%) developed ECMO weaning failure. Inotropic support remained largely unchanged in the days following VA ECMO initiation. Adjusted joint models showed that a higher cumulative inotropic exposure during VA ECMO support was associated with an increased risk for ECMO weaning failure (hazard ratio [HR], 1.04; 95% CI, 1.00-1.07), 30-day mortality (HR, 1.04; 95% CI, 1.01-1.08), arrhythmias (HR, 1.05; 95% CI, 1.01-1.08), and protracted lactate clearance (HR, 0.96; 95% CI, 0.92-0.99). In patients requiring VA ECMO support for refractory CS, inotropic support is often maintained at similar levels after ECMO initiation. Higher cumulative inotropic exposure was associated with an increased risk for ECMO weaning failure. Prospective studies are needed to investigate whether inotropes can be tapered or even stopped and whether such a strategy could improve cardiac recovery.
中文摘要:在静脉-动脉体外膜氧合(VA ECMO)期间,器官灌注不再完全依赖自身心输出量,这可能降低正性肌力药物相对于其风险的治疗获益。研究假设在此背景下,较高的累积正性肌力药物暴露与心脏恢复受损相关。对VA ECMO支持期间纵向正性肌力药物暴露的影响进行观察性队列研究。评估VA ECMO支持期间正性肌力支持的时间变化。使用标准化正性肌力评分的曲线下面积计算VA ECMO支持期间每日累积正性肌力药物暴露。采用联合模型技术,将这些累积正性肌力评分与至30天ECMO撤机失败风险(死亡、仍需ECMO支持或需要心脏替代治疗的复合终点)、死亡率和并发症相关联。荷兰六家医院。2018年至2024年接受VA ECMO支持的成人严重心源性休克患者。无干预。440例不同原因心源性休克患者中,235例(53.4%)发生ECMO撤机失败。VA ECMO启动后数日内正性肌力支持基本未变。校正联合模型显示,VA ECMO支持期间较高的累积正性肌力药物暴露与ECMO撤机失败风险增加(风险比[HR],1.04;95% CI,1.00-1.07)、30天死亡率(HR,1.04;95% CI,1.01-1.08)、心律失常(HR,1.05;95% CI,1.01-1.08)和乳酸清除延迟(HR,0.96;95% CI,0.92-0.99)相关。对于因难治性心源性休克需要VA ECMO支持的患者,ECMO启动后正性肌力支持常维持在相似水平。较高的累积正性肌力药物暴露与ECMO撤机失败风险增加相关。需要前瞻性研究探讨正性肌力药物能否减量甚至停用,以及该策略能否改善心脏恢复。
To describe the utilization, feasibility, and operator-reported diagnostic and management impact of transesophageal lung ultrasound (TELUS) integrated into resuscitative transesophageal echocardiography (TEE) for the assessment of mechanically ventilated adults with shock. Multicenter observational cohort study using prospectively collected data. Twenty-three hospitals from the Resuscitative Transesophageal Echocardiography Collaborative Registry (rTEECoRe) network. From 1213 registry TEE examinations, 379 met the inclusion criteria for shock evaluation or hemodynamic monitoring in mechanically ventilated adults; 96 (25.3%) of these included TELUS. None. TELUS integration was associated with significantly higher operator-reported identification of shock etiology compared with resuscitative TEE alone (86.5% vs. 75.3%; odds ratio [OR], 1.95; 95% CI, 1.02-3.72; p = 0.04). Although overall clinical management changes were more frequently reported in the TELUS group, this difference did not reach statistical significance (78.1% vs. 71.7%; OR, 1.40; 95% CI, 0.82-2.41; p = 0.22). TELUS examinations were associated with longer procedure duration (median 21.5 vs.19.0 min; p = 0.01) and were predominantly performed by intensivists. Pulmonary findings, including B-lines, pleural effusions, consolidations, and A-line patterns, varied in frequency and were occasionally associated with specific respiratory or antimicrobial interventions. Procedure-related complications were rare and similar between groups. In this multicenter cohort of mechanically ventilated adults with shock, adding TELUS to resuscitative TEE was associated with a higher rate of operator-reported identification of shock etiology and was feasible with minimal additional procedure time. Prospective studies with standardized TELUS acquisition and interpretation, independent adjudication, and evaluation of patient-centered outcomes are needed to define clinical scenarios of incremental value.
中文摘要:描述将经食管肺超声(TELUS)整合入复苏性经食管超声心动图(TEE)用于机械通气成人休克评估时的使用情况、可行性以及操作者报告的诊断与管理影响。研究为多中心观察性队列,采用前瞻性收集的数据,纳入复苏性经食管超声心动图协作登记网络(rTEECoRe)中23家医院。1213例登记TEE检查中,379例符合机械通气成人休克评估或血流动力学监测的纳入标准;其中96例(25.3%)包含TELUS。与单独复苏性TEE相比,整合TELUS与操作者报告的休克病因识别率显著更高相关(86.5%对75.3%;比值比[OR]1.95;95%置信区间1.02-3.72;p=0.04)。TELUS组报告总体临床管理改变更常见,但差异未达统计学意义(78.1%对71.7%;OR1.40;95%置信区间0.82-2.41;p=0.22)。TELUS检查与更长的操作时间相关(中位数21.5对19.0分钟;p=0.01),且主要由重症医学科医师实施。肺部表现包括B线、胸腔积液、实变和A线模式,出现频率不一,偶尔与特定呼吸或抗微生物干预相关。操作相关并发症少见,两组相似。在这一机械通气成人休克多中心队列中,将TELUS加入复苏性TEE与更高的操作者报告休克病因识别率相关,并且可行,仅增加少量操作时间。仍需采用标准化TELUS采集与判读、独立裁定并评估以患者为中心结局的前瞻性研究,以明确其具有增量价值的临床场景。
In addition to medical considerations, economic factors are increasingly influencing hospital planning. While guidelines suggest ICU room design and layout likely affect outcomes, data supporting current recommendations are scarce. The aim of this study was to investigate the association of shared rooms vs. single rooms, high vs. low visibility, and distances of nurses' and doctors' charting areas to patients' rooms with mortality and length of stay in a large, mixed-discipline cohort. Retrospective observational cohort study. Four ICUs at the University Medical Center Mannheim, Germany. Critically ill adults with ICU admission between January 2019 and May 2022 for at least 24 hours. None. Associations of the index variables with in-hospital mortality and ICU length of stay were assessed by multivariate regression, adjusting for biological sex, Simplified Acute Physiology Score II, need for vasopressors, need for ventilation, and medical vs. surgical admission. Five thousand two hundred ninety-three patient stays with a mortality rate of 18% and a mean length of stay of 6.3 ± 9.2 days in survivors were eligible for this analysis. In the overall cohort, none of the index variables showed associations with mortality. Patients admitted to single rooms showed a mean length of stay increase by 0.81 days (95% CI, 0.04-1.57 d; p = 0.039) compared with shared rooms with up to three beds. In this mixed cohort of medical and surgical ICUs, neither single rooms compared with shared rooms, high-visibility rooms compared with low-visibility rooms, nor distances to nurses' or doctors' charting areas were associated with mortality. The observed increase in length of stay associated with single room admission highlights the need to balance privacy and infection control benefits with potential implications for ICU capacity and operational efficiency.
中文摘要:除医疗因素外,经济因素对医院规划的影响日益增加。指南提出ICU房间设计与布局可能影响结局,支持现行推荐的数据仍少。本研究在大样本混合学科队列中考察共用房间与单人房间、高可见度与低可见度、护士和医生记录区到患者房间的距离与死亡率和住院时长的关系。研究为回顾性观察性队列研究,地点为德国曼海姆大学医学中心四个ICU,纳入2019年1月至2022年5月入住ICU且停留至少24小时的危重成人,无干预。采用多变量回归评估索引变量与院内死亡率和ICU住院时长的关联,校正生物性别、简化急性生理评分II、血管升压药需求、通气需求以及内科与外科入院。5293例患者住院纳入分析,死亡率为18%,存活者平均住院时长为6.3±9.2天。总体队列中,各索引变量均未显示与死亡率相关。与最多三床的共用房间相比,入住单人房间患者的平均住院时长增加0.81天(95% CI,0.04-1.57天;p=0.039)。在这个内科和外科ICU混合队列中,单人房间与共用房间、高可见度房间与低可见度房间、到护士或医生记录区的距离,均与死亡率无关。单人房间入院相关的住院时长增加提示,需要权衡隐私和感染控制获益与对ICU容量和运行效率的潜在影响。
To investigate the effect of a 1-hour resuscitation bundle, including early antibiotics, hemodynamic optimization with fluids and vasopressors as needed, and hydrocortisone therapy as needed, implemented in a prehospital setting by a mobile ICU (MICU) team, on 28-day mortality in adults with septic shock. A multicenter, open-label, cluster-randomized study from May 09, 2016, to November 2, 2018. Prehospital emergency ambulance in France. Adults with suspected septic shock at the time of management by the prehospital MICU team. The 1-hour resuscitation bundle included antibiotics, up to 35 mL/kg of ideal body weight of isotonic saline administered within the first 60 minutes, norepinephrine if mean blood pressure (MBP) remained less than 65 mm Hg or if diastolic blood pressure remained less than 40 mm Hg, and 100 mg of IV hydrocortisone when MBP remained less than 65 mm Hg while the patient was receiving greater than or equal to 1.5 mg/hr of norepinephrine. The primary outcome was 28-day all-cause mortality. Secondary outcomes included mortality rates in the ICU, at hospital discharge, and at 90 days, time alive free of vasopressor drugs, invasive mechanical ventilation, renal replacement therapy, and ICU and hospital lengths of stay. Of 398 participants, 17 did not consent; therefore, 381 participants (96%; mean age, 67 ± 15 yr) were analyzed. In total, 23 of 103 deaths (22%) occurred by 28 days in the 1-hour bundle arm and 76 of 278 deaths (27%) in the usual care arm (risk ratio, 0.81; 95% CI [0.61-1.08]; p = 0.16). The intracluster correlation coefficient was estimated at 0.005 ± 0.002. Secondary outcomes were similar between groups. The prehospital initiation of a 1-hour resuscitation bundle did not reduce 28-day all-cause mortality in adults with septic shock. Imbalances in patient enrollment between centers and a small difference in care provided between the groups may explain these results. NCT02473263 ( http://clinicaltrials.gov/ ).
中文摘要:探讨由移动ICU团队在院前环境中实施的1小时复苏集束化治疗对成人脓毒症休克28天死亡率的影响;该集束包括早期抗生素、按需使用液体和血管加压药进行血流动力学优化,以及按需氢化可的松治疗。研究为多中心、开放标签、整群随机研究,时间自2016年5月9日至2018年11月2日,地点为法国院前急救救护车。研究对象为院前移动ICU团队管理时疑似脓毒症休克的成人。1小时复苏集束包括抗生素、首60分钟内按理想体重给予最多35 mL/kg等渗盐水、若平均血压仍低于65 mmHg或舒张压仍低于40 mmHg则使用去甲肾上腺素,以及当患者接受大于或等于1.5 mg/hr去甲肾上腺素时平均血压仍低于65 mmHg则静脉给予100 mg氢化可的松。主要结局为28天全因死亡率。次要结局包括ICU、出院时和90天死亡率,无血管加压药、无有创机械通气、无肾脏替代治疗的存活时间,以及ICU和住院时间。398名参与者中17人未同意,因此分析381名参与者(96%;平均年龄67±15岁)。1小时集束组103例中23例死亡(22%)发生在28天内,常规治疗组278例中76例死亡(27%)(风险比0.81;95% CI [0.61-1.08];p=0.16)。整群内相关系数估计为0.005±0.002。次要结局在组间相似。院前启动1小时复苏集束未降低成人脓毒症休克28天全因死亡率。中心间患者入组不平衡以及组间所提供治疗的小差异可能解释这些结果。NCT02473263(http://clinicaltrials.gov/)。
Tissue autoregulation to match local blood flow to metabolic demands requires both a high enough upstream mean arterial pressure (MAP) and a perfusion pressure difference between this MAP and the downstream arteriolar critical closing pressure to drive blood flow into the capillaries whose downstream capillary pressure is approximated as mean systemic filling pressure. The closing pressure to mean systemic pressure difference represents a vascular waterfall such that increases or decreases in mean systemic filling pressure below closing pressure do not alter tissue flow. Tissues autoregulate their blood flow by altering upstream local vasomotor tone to increase or decrease closing pressure. In vasoplegia, like septic shock, vascular tone is decreased, often decreasing closing pressure to approximating mean systemic filling pressure. Such conditions abolish autoregulation even if MAP and cardiac output are not decreased. Effective resuscitation from septic shock requires restoration of local vascular waterfalls. Often initial fluid resuscitation and vasopressor infusion restore vascular waterfalls and tissue blood flow. But often it does not. There are few readily available real-time quantitative estimates of tissue perfusion. Presently, only capillary refill time (CRT) monitors tissue blood flow changes. If initial resuscitation to target MAP values does not restore tissue perfusion and CRT is >3 seconds, then potentially a vasopressor test to increase MAP to >75 mmHg may be studied. If vasopressor-induced increases in MAP decrease CRT to <3 seconds, then it can be continued. If not, then return to prior levels to minimize iatrogenic vasopressor risk. This article addresses unanswered questions that need further study.
中文摘要:组织通过自身调节使局部血流匹配代谢需求,既需要足够高的上游平均动脉压(MAP),也需要MAP与下游小动脉临界闭合压之间的灌注压差,以驱动血液进入毛细血管;毛细血管下游压力可近似为平均体循环充盈压。临界闭合压与平均体循环充盈压之间的差值构成血管瀑布,因此当平均体循环充盈压低于临界闭合压时,其升高或降低不会改变组织血流。组织通过改变上游局部血管舒缩张力来升高或降低临界闭合压,从而自身调节血流。在脓毒症休克等血管麻痹状态下,血管张力下降,常使临界闭合压降至接近平均体循环充盈压。即使MAP和心输出量未下降,这种状态也会消除自身调节。脓毒症休克的有效复苏需要恢复局部血管瀑布。初始液体复苏和血管升压药输注常能恢复血管瀑布和组织血流,但也常不能恢复。目前缺少 readily available 的实时组织灌注定量估计,只有毛细血管再充盈时间(CRT)可监测组织血流变化。若以目标MAP进行的初始复苏未恢复组织灌注且CRT大于3秒,则可研究通过血管升压药试验将MAP升至75 mmHg以上。若血管升压药升高MAP后CRT降至3秒以下,可继续使用;若未降至3秒以下,则回到先前水平,以减少医源性血管升压药风险。本文讨论尚需进一步研究的问题。
To evaluate the effect of early administration of Shenfu injection (SFI) on hemodynamics and clinical outcomes in ICU patients with sepsis. Prospective, multicenter randomized controlled trial. Four tertiary care hospitals located in central China. ICU patients 18-75 years old who met the Sepsis-3 diagnostic criteria. Eligible septic patients were randomized to the SFI group or the control group, receiving either SFI or normal saline at a rate of 20 mL/hr in 5 hours from the time of sepsis diagnosis, bid for 3 consecutive days. The primary outcome was the amount of vasopressors administration (calculated as the norepinephrine equivalents [NEEs]). A total of 172 patients were enrolled, with 86 assigned to the SFI group and 86 to the control group. Compared with the control group, the SFI group had no significant improvement in total NEE doses (22.00 [16.00-29.50] vs. 20.00 [12.50-28.50]; p = 0.16). However, compared with the control group, the SFI group showed significantly lower mortality both during ICU stay (3.5% vs. 11.6%; p = 0.04) and 28 days after treatment (15.1% vs. 27.9%; p = 0.04). The SFI group also exhibited a significant improvement in sublingual microcirculation indicators compared with control group. No significant drug-related adverse events were noted in either group. The early administration of SFI did not decrease the dosage of vasopressors. The secondary outcomes suggested a potential decrease in mortality and possible improvement in microcirculation, findings that require further validation.
中文摘要:评价早期给予参附注射液(SFI)对脓毒症ICU患者血流动力学及临床结局的影响。采用前瞻性、多中心随机对照试验。研究纳入华中地区4家三级医院收治的18~75岁、符合Sepsis-3诊断标准的ICU患者。符合条件的脓毒症患者随机分为参附注射液组和对照组,自脓毒症诊断时起分别以20 mL/h速率给予参附注射液或生理盐水,持续5小时,每日2次,连续3天。主要结局为血管升压药使用量(以去甲肾上腺素等效剂量[NEEs]计算)。共纳入172例患者,参附注射液组86例,对照组86例。与对照组相比,参附注射液组总NEE剂量无明显改善(22.00[16.00-29.50] vs. 20.00[12.50-28.50];p=0.16)。但与对照组相比,参附注射液组ICU住院期间死亡率(3.5% vs. 11.6%;p=0.04)和治疗后28天死亡率(15.1% vs. 27.9%;p=0.04)均显著降低。参附注射液组舌下微循环指标较对照组显著改善。两组均未观察到明显的药物相关不良事件。早期给予参附注射液未降低血管升压药用量。次要结局提示死亡风险可能下降及微循环可能改善,这些发现仍需进一步验证。
基础研究 (2篇)
Cardiogenic shock (CS) is a state of acute circulatory failure resulting from impaired myocardial function and reduced cardiac output, leading to inadequate tissue perfusion and subsequent organ dysfunction. In its early phase, CS is typically accompanied by systemic vasoconstriction as a compensatory response aimed at preserving mean arterial pressure and organ perfusion. However, an increasing body of evidence suggests that a subset of patients develop a mixed shock phenotype, characterized by superimposed vasodilation without evidence of concurrent sepsis, which portends a worse prognosis. Failure of the renin-angiotensin-aldosterone system (RAAS) may be a key driver of pathological vasodilation in CS, analogous to recent observations in septic shock. Specifically, RAAS dysfunction could lead to impaired angiotensin II signalling at the angiotensin II type 1 receptor level due to defective angiotensin II generation, enhanced peptide degradation, and/or receptor unavailability. Recognition of RAAS failure in CS could inform novel therapeutic strategies to restore vascular tone and improve outcomes in patients with mixed cardiogenic-vasodilatory shock.
中文摘要:心源性休克(CS)是急性循环衰竭状态,由心肌功能受损和心输出量下降引起,导致组织灌注不足及随后的器官功能障碍。CS早期通常伴随全身性血管收缩,作为维持平均动脉压和器官灌注的代偿反应。然而,越来越多证据提示,一部分患者出现混合性休克表型,表现为在无合并脓毒症证据的情况下叠加血管扩张,且预后更差。肾素-血管紧张素-醛固酮系统(RAAS)衰竭可能是CS中病理性血管扩张的关键驱动因素,类似于近期在脓毒性休克中的观察。具体而言,RAAS功能障碍可因血管紧张素II生成缺陷、肽降解增强和/或受体不可用,导致血管紧张素II在血管紧张素II 1型受体水平的信号受损。识别CS中的RAAS衰竭可为恢复血管张力、改善混合性心源性-血管扩张性休克患者结局提供新的治疗策略。
Fulminant myocarditis (FM) is an acute inflammatory cardiomyopathy with high risk of cardiogenic shock. Current management relies largely on circulatory support, while mechanism-based pharmacological targets remain poorly defined. Cardiac CD45+ single-cell RNA sequencing, whole-heart single-nucleus RNA sequencing, ligand-target inference, spatial validation, and human plasma/myocardial analyses were integrated to define disease-associated cellular interactions. CCR2+ macrophage sorting, macrophage depletion, CVB3-stimulated BMDMs, transcription-factor perturbation, ChIP-qPCR, and promoter assays defined the source and regulation of OSM. OSM signaling was examined using recombinant OSM, OSM-neutralizing antibody, macrophage Osm knockdown, cardiomyocyte Osmr silencing, and STAT3/ERK1/2 inhibition, followed by transcriptomic, mitochondrial, contractile, and in vivo analyses. FM featured expansion of CCR2+ inflammatory macrophages, cardiomyocyte inflammatory/stress remodeling, and enhanced macrophage-to-cardiomyocyte OSM-OSMR signaling. Circulating OSM was increased in patients with FM and correlated with higher NT-proBNP and cTnI and lower LVEF. OSM was produced predominantly by CCR2+ macrophages and transcriptionally induced by IRF1 after CVB3 stimulation. Recombinant OSM aggravated mortality, systolic dysfunction, myocardial inflammation, and cardiac injury. In cardiomyocytes, OSM activated OSMR-dependent STAT3/ERK1/2 signaling and impaired mitochondrial bioenergetics, contractility, and Ca²+ handling. OSM neutralization and macrophage Osm knockdown improved cardiomyocyte respiration and sarcomere shortening after exposure to CVB3-activated macrophage conditioned medium. In vivo, OSM neutralization improved survival, cardiac function, myocardial inflammation, mitochondrial integrity, and ATP content. Macrophage OSM links inflammatory myeloid activation to cardiomyocyte mitochondrial and contractile failure in experimental FM. OSM-OSMR signaling is a candidate mechanism-based pharmacological target for acute inflammatory cardiac dysfunction.
中文摘要:暴发性心肌炎(FM)是一种急性炎症性心肌病,心源性休克风险高。当前处理主要依赖循环支持,基于机制的药物靶点仍不明确。研究整合了心脏CD45+单细胞RNA测序、全心脏单核RNA测序、配体-靶点推断、空间验证以及人血浆和心肌分析,以界定疾病相关细胞互作。通过CCR2+巨噬细胞分选、巨噬细胞清除、CVB3刺激的BMDM、转录因子扰动、ChIP-qPCR和启动子实验,明确OSM的来源与调控。OSM信号通过重组OSM、OSM中和抗体、巨噬细胞Osm敲低、心肌细胞Osmr沉默以及STAT3/ERK1/2抑制进行评估,随后进行转录组、线粒体、收缩功能和体内分析。FM表现为CCR2+炎症性巨噬细胞扩增、心肌细胞炎症/应激重塑以及巨噬细胞向心肌细胞的OSM-OSMR信号增强。FM患者循环OSM升高,并与较高的NT-proBNP和cTnI以及较低的LVEF相关。OSM主要由CCR2+巨噬细胞产生,并在CVB3刺激后由IRF1在转录水平诱导。重组OSM加重死亡、收缩功能障碍、心肌炎症和心脏损伤。在心肌细胞中,OSM激活OSMR依赖的STAT3/ERK1/2信号,并损害线粒体生物能量学、收缩力和Ca²⁺处理。OSM中和与巨噬细胞Osm敲低可改善暴露于CVB3激活巨噬细胞条件培养基后的心肌细胞呼吸和肌节缩短。体内OSM中和改善生存、心脏功能、心肌炎症、线粒体完整性和ATP含量。巨噬细胞OSM将炎症性髓系激活与实验性FM中心肌细胞线粒体和收缩衰竭联系起来。OSM-OSMR信号是急性炎症性心脏功能障碍的候选机制型药物靶点。
4ARDS与呼吸支持 (10篇)
临床研究 (9篇)
Clinical research evaluating mechanical ventilation liberation in patients with acute brain injury (ABI) shows substantial outcome heterogeneity, limiting evidence synthesis. We aimed to develop an internationally endorsed core outcome set (COS) and a hierarchical composite endpoint for ventilation trials in neurocritical care. Following COS-STAD/COS-STAP standards, we conducted a 4-round international Delphi study. Candidate outcomes were identified via a scoping review. A multidisciplinary panel from 31 countries scored outcomes using a 9-point GRADE scale. Inclusion required >70% rating as "critical" (score 7-9) and ≤15% as "not important" (1-3). Two consensus meetings were held to categorize outcomes, select representative measures, and ratify a hierarchical composite endpoint. 78 stakeholders participated in Round 1; 60 completed all rounds (23.1% attrition). Fifty-four outcomes achieved Delphi consensus. At Consensus Meeting 1, these were organized into 16 categories; the highest-scoring outcome per category was selected. Three outcomes were not ratified due to disease-specificity (NIH Stroke Scale) or lack of universal applicability (brain death, coma-free days). The final COS comprised 13 outcomes across 5 domains: respiratory function, survival, complications, functional status, and quality of life. A 3-level hierarchical composite endpoint was ratified at Consensus Meeting 2: (1) intensive care unit survival, (2) no reintubation within 72 hours, and (3) days alive without mechanical ventilation. This study establishes the first COS for ventilation weaning trials in ABI patients. Widespread adoption of these 13 outcomes and the hierarchical composite endpoint will standardize reporting, enable meaningful evidence synthesis, and facilitate clinical translation in neurocritical care. Core Outcome Measures in Effectiveness Trials (COMET) Initiative, registration number 2320.
中文摘要:急性脑损伤(ABI)患者机械通气撤机相关的临床研究结局指标高度异质,限制证据整合。本研究旨在制定国际认可的核心结局集(COS)及神经重症通气试验的分层复合终点。遵循COS-STAD/COS-STAP标准,开展4轮国际德尔菲研究。通过范围综述识别候选结局。来自31个国家的多学科专家组采用9分GRADE量表对结局评分。纳入需满足:评为「critical」(7—9分)的比例>70%,且评为「not important」(1—3分)的比例≤15%。举行两次共识会议以对结局分类、选择代表性测量指标并批准分层复合终点。第1轮有78名利益相关者参与;60名完成全部轮次(失访率23.1%)。54个结局达成德尔菲共识。在第1次共识会议上,这些结局被归入16个类别;每个类别中评分最高的结局被选中。3个结局未获批准,原因分别为疾病特异性(NIH卒中量表)或缺乏普遍适用性(脑死亡、无昏迷天数)。最终COS包含5个域下的13个结局:呼吸功能、生存、并发症、功能状态和生活质量。第2次共识会议批准了3级分层复合终点:(1)重症监护病房生存;(2)72小时内无再插管;(3)无机械通气存活天数。本研究建立了首个用于ABI患者通气撤机试验的COS。广泛采用这13个结局和分层复合终点将规范报告、支持有意义的证据整合,并促进神经重症的临床转化。Core Outcome Measures in Effectiveness Trials(COMET)倡议注册号2320。
High flow nasal oxygen (HFNO) has become a common first-line practice for acute hypoxemic respiratory failure (ARF). In immunocompromised patients, ARF is the leading cause of ICU admission, yet a randomized trial found no overall benefit of HFNO in this population. To assess whether baseline characteristics influence HFNO's effectiveness in preventing invasive mechanical ventilation (IMV) in immunocompromised patients with ARF. A causal forest machine-learning algorithm was derived in the HIGH trial (776 patients randomized to HFNO or conventional oxygen) to predict the HFNO effects on day-28 IMV incidence. Patients with a "do-not-intubate" order (n = 72) were excluded. Model performance was validated through 500 bootstrap iterations and patients were categorized into terciles based on predicted HFNO benefit. Transportability of the model was assessed in an independent observational cohort (818 patients). Among the 704 participants, HFNO's average effect on day-28 IMV was not significant. However, substantial heterogeneity in treatment responses was identified (predicted benefit: from 20.2% [IQR 15.5%-23.9%] absolute IMV risk reduction with HFNO to 7.4% risk reduction [2.9%-11.2%] with conventional oxygen). Patients with the highest predicted benefit were older, more frequently solid organ transplant recipients, less neutropenic, more severely hypoxemic/tachycardic, but with lower non-respiratory sequential organ failure assessment (SOFA) scores. In this subgroup, HFNO was associated with a significant lower incidence of IMV. In the observational cohort, the benefit-ranking performance was preserved, although absolute effect estimates were less calibrated. These results suggest HFNO might benefit specific immunocompromised patients with ARF. Further prospective studies are needed to validate these findings.
中文摘要:高流量鼻导管氧疗(HFNO)已成为急性低氧性呼吸衰竭(ARF)常用的一线处理方式。在免疫功能受损患者中,ARF是收入ICU的首要原因,但一项随机试验未发现HFNO在该人群中具有总体获益。为评估基线特征是否影响HFNO在免疫功能受损ARF患者中预防有创机械通气(IMV)的效果,研究在HIGH试验(776例随机接受HFNO或常规氧疗)中构建因果森林机器学习算法,预测HFNO对第28天IMV发生率的影响。排除有不插管医嘱者72例。通过500次Bootstrap迭代验证模型性能,并按预测HFNO获益将患者分为三分位组。在独立观察性队列(818例)中评估模型的可迁移性。704例参与者中,HFNO对第28天IMV的平均效应不显著。治疗反应存在明显异质性,预测获益从HFNO带来的20.2%(IQR 15.5%-23.9%)绝对IMV风险降低,到常规氧疗带来的7.4%(2.9%-11.2%)风险降低。预测获益最高者年龄更大、实体器官移植受者更多、中性粒细胞减少程度较轻、低氧血症和心动过速更严重,但非呼吸序贯器官衰竭评估(SOFA)评分较低。在该亚组中,HFNO与IMV发生率显著降低相关。在观察性队列中,获益排序性能得以保留,但绝对效应估计校准较差。结果提示HFNO可能使特定免疫功能受损ARF患者获益,仍需进一步前瞻性研究验证。
Coronary microvascular dysfunction (CMD) is highly prevalent in patients with angina and nonobstructive coronary arteries (ANOCA). Microvascular resistance reserve (MRR) is a novel index to assess CMD independently of epicardial disease and driving pressures, but the long-term prognostic value of continuous thermodilution-derived MRR in patients with ANOCA is unknown. To assess the prognostic value of continuous thermodilution-derived MRR and its association with clinical outcomes and symptom burden in patients with ANOCA. This prospective, multicenter cohort study within the Netherlands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) included patients between July 2020 and June 2025 in 4 clinical centers in the Netherlands. Follow-up for clinical events and patient-reported symptoms was completed for up to 3 years. Clinical events were adjudicated by investigators blinded to CFT results. Consecutive patients with ANOCA who underwent continuous thermodilution were included. Abnormal MRR (CMD) was defined as less than 2.1, gray zone as 2.1 to 2.7, and normal microvascular function as 2.7 or greater. The primary clinical outcome was a composite of all-cause death, acute coronary syndrome, stroke, clinically indicated revascularization, repeat angiography without intervention, and unplanned hospital admittance or emergency department visit due to angina or heart failure. Secondary outcomes included angina at baseline and follow-up. Symptoms were assessed using the patient-reported Seattle Angina Questionnaire (SAQ) scores. Among 553 included patients (mean [SD] age, 59.1 [9.6] years; 459 female [83.0%]) with a mean (SD) follow-up of 27.5 (16.1) months, CMD was observed in 94 patients (17.0%). The main composite outcome did not differ across the 3 MRR categories (18 of 94 patients with abnormal [19.1%] vs 21 of 98 patients with gray zone [21.4%] vs 76 of 361 patients with normal [21.1%] MRR; log-rank P = .85). Individual outcomes did not differ between groups. There was no overall longitudinal interaction between MRR and SAQ summary scores. While low MRR (abnormal vs normal groups) was not associated with an increased symptom burden at baseline, it was associated with worse angina at follow-up (mean [SD] SAQ summary score, 53.0 [16.7] vs 60.1 [16.6]; P = .04) and less clinically relevant improvement (9 of 30 patients [30.0%] vs 52 of 88 patients [59.1%]; P = .02). In this study, CMD assessed by continuous thermodilution-derived MRR was not associated with clinical outcomes.
中文摘要:冠状动脉微血管功能障碍(CMD)在有心绞痛且冠状动脉无阻塞性病变(ANOCA)的患者中很常见。微血管阻力储备(MRR)是评估CMD的新指标,不受心外膜病变和驱动压力影响,但连续热稀释法测得的MRR在ANOCA患者中的长期预后价值尚不清楚。评估连续热稀释法测得的MRR的预后价值及其与临床结局和症状负担的关系。这项前瞻性多中心队列研究纳入荷兰侵入性冠状动脉血管运动功能检测注册研究(NL-CFT)中2020年7月至2025年6月期间4家荷兰临床中心的患者,随访临床事件和患者报告症状最长3年。临床事件由对冠状动脉功能检测结果设盲的研究者判定。连续纳入接受连续热稀释法检查的ANOCA患者。MRR低于2.1定义为异常(CMD),2.1至2.7为灰区,2.7及以上为微血管功能正常。主要临床结局为全因死亡、急性冠脉综合征、卒中、有临床指征的血运重建、未干预的重复造影,以及因心绞痛或心力衰竭导致的非计划住院或急诊就诊的复合终点。次要结局包括基线和随访时的心绞痛。症状采用患者报告的西雅图心绞痛问卷(SAQ)评分评估。共纳入553例患者(平均[SD]年龄59.1[9.6]岁;459例女性[83.0%]),平均(SD)随访27.5(16.1)个月,94例(17.0%)存在CMD。主要复合结局在3个MRR类别间无差异(异常组18/94例[19.1%]对比灰区组21/98例[21.4%]对比正常组76/361例[21.1%];log-rank P=.85)。各单项结局在组间无差异。MRR与SAQ汇总评分之间总体无纵向交互作用。低MRR(异常组对正常组)与基线症状负担增加无关,但与随访时更差的心绞痛相关(SAQ汇总评分平均[SD]53.0[16.7]对60.1[16.6];P=.04),且临床相关改善更少(9/30例[30.0%]对52/88例[59.1%];P=.02)。本研究中,连续热稀释法测得的MRR所评估的CMD与临床结局无关。
Alström syndrome (AS) is a rare multisystemic disorder frequently associated with respiratory complications, which are a major cause of premature death. While fibrosis in multiple organs has been historically suggested as a hallmark of AS, including the lungs, definitive evidence in adult patients remains limited. We conducted a retrospective study of adult patients diagnosed as AS seen in our National Multidisciplianry AS clinic from 2010 to 2024. Lung function test and high-resolution computed tomography (HRCT) of the thorax was performed in a subset of patients. Postmortem lung tissue analysis was available from four patients. A total of 25/41 (61%) of the patients were unable to complete full lung function testing. Among those who did, 67% exhibited reduced lung volumes, with 47% showing decreased diffusing capacity of the lung for carbon monoxide but normal or elevated transfer coefficient for carbon monoxide, indicating extrapulmonary restrictive physiology. HRCT scans in 39 patients showed no evidence of diffuse interstitial lung fibrosis; however, breathing artefacts were common. Historical infantile cardiomyopathy was identified as a risk factor for adult pulmonary dysfunction. Post-mortem pathology reports were obtained from four patients and no diffuse fibrosis in the lung tissue was identified in any of the patients. Pulmonary hypertension and Acute Respiratory Distress Syndrome were identified as potential causes of respiratory morbidity and mortality, despite the absence of intrinsic interstitial lung disease. This is the first large cohort study to depict the lung in adult patients with AS. This study provides no evidence for diffuse interstitial lung fibrosis in adult patients with AS, challenging prior assumptions. Pulmonary dysfunction appears mainly due to extrapulmonary restrictive physiology, with infantile cardiomyopathy as a possible risk factor. Pulmonary hypertension and acute respiratory distress syndrome, rather than intrinsic lung disease, likely underlie respiratory morbidity and mortality, highlighting the need for focused cardiopulmonary care. Although this study represents one of the largest single-centre cohorts of patients with AS reported to date, the overall sample size remains limited due to the ultra-rare nature of the disease and findings should be interpreted with caution. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
中文摘要:Alström 综合征(AS)是一种罕见的多系统疾病,常伴呼吸系统并发症,后者是患者早逝的主要原因之一。历史上多认为多器官纤维化(包括肺)是 AS 的标志性特征,但成人患者中的确凿证据仍然有限。本研究对 2010 至 2024 年在本国 AS 多学科专病门诊确诊的成人患者进行回顾性分析,部分患者接受了肺功能检查与胸部高分辨率 CT(HRCT),另有 4 例患者可获取尸检肺组织资料。41 例患者中有 25 例(61%)无法完成全套肺功能检查;在完成者中,67% 存在肺容积下降,47% 一氧化碳弥散量降低但一氧化碳转运系数正常或升高,提示肺外限制性通气生理。39 例的 HRCT 未见弥漫性间质性肺纤维化证据,但呼吸伪影较常见。既往婴儿期心肌病被识别为成年期肺功能异常的危险因素。4 例患者的尸检病理报告均未发现肺组织弥漫性纤维化。尽管不存在肺内间质性病变,肺动脉高压与急性呼吸窘迫综合征仍是呼吸系统并发症与死亡的潜在原因。这是首个描述成人 AS 患者肺部情况的大队列研究,未发现成人 AS 存在弥漫性间质性肺纤维化的证据,对既往假设提出质疑。肺功能异常主要源于肺外限制性生理,婴儿期心肌病可能是危险因素;呼吸系统并发症与死亡更可能由肺动脉高压和急性呼吸窘迫综合征引起,而非肺本身疾病,提示需要针对性的心肺管理。该研究是迄今报道的最大单中心 AS 队列之一,但受疾病超罕见性所限,总体样本量仍偏小,结果应谨慎解读。本研究未获得公共、商业或非营利部门任何资助机构的专项经费。
Postoperative pulmonary complications (PPCs) remain common and are exacerbated by perioperative systemic inflammation. Dexamethasone, administered to millions of patients each year for prophylaxis against postoperative nausea and vomiting, effectively attenuates systemic inflammatory responses, rendering it a plausible adjunct for PPC prevention. In a recent issue of the British Journal of Anaesthesia, Zorrilla-Vaca and colleagues present a well-designed secondary analysis of the individualised, perioperative open-lung ventilation strategy trials showing that antiemetic doses of dexamethasone (4-8 mg i.v.) did not reduce patients' risk of PPCs. In the underlying iPROVE (Individualised, Perioperative Open-Lung Ventilation Strategy) studies, other landmark trials, and clinical routine practice across general patient populations, the key driver and major contributor to PPCs is perioperative atelectasis, which is predominantly determined by surgery, induction of general anaesthesia, and ventilatory management rather than systemic inflammation. The findings by Zorrilla-Vaca and colleagues emphasise the importance of differentiating the pathophysiological pathway of composite clinical outcomes including PPCs when designing preventive strategies, while reaffirming the established safety of dexamethasone at standard doses.
中文摘要:术后肺部并发症(PPCs)仍较常见,并会被围术期全身性炎症加重。地塞米松每年用于数百万患者预防术后恶心呕吐,能有效减轻全身炎症反应,因此被视为预防PPCs的潜在辅助用药。在近期《英国麻醉学杂志》中,Zorrilla-Vaca及其同事对个体化围术期开放肺通气策略试验做了设计良好的二次分析,显示止吐剂量的地塞米松(静脉4~8 mg)并未降低患者发生PPCs的风险。在 underlying iPROVE 研究、其他里程碑式试验以及普通人群的临床常规实践中,PPCs的关键驱动因素和主要contributor是围术期肺不张,而肺不张主要由手术、全身麻醉诱导和通气管理决定,而非全身性炎症。Zorrilla-Vaca及其同事的结果强调,在设计预防策略时需区分包括PPCs在内的复合临床结局的病理生理通路,同时再次确认地塞米松在标准剂量下的既定安全性。
Primary objective: To determine the driving ability of adult ICU survivors 2 months after hospital discharge. Secondary objectives: Evaluate driving resumption at 3, 6, and 12 months; factors associated with driving resumption; and acceptability of a comprehensive driving assessment. Observational cohort study. Certified driving assessment center in the United Kingdom. Adult ICU survivors who received mechanical ventilation (minimum 72 hr) and/or extracorporeal membrane oxygenation. A Driver Vehicle Licensing Agency-approved, driving ability assessment comprising physical and cognitive evaluation, and practical driving skills using a driving simulator, private track in-car assessment, and on-road in-car assessment. We recruited 40 participants (median age, 53 yr [interquartile range (IQR), 46-64 yr]; 13 [32%] female) from six hospitals. Of these, 33 completed the driving assessment at a median of 12.5 weeks following hospital discharge. Twenty-six participants (79%) were assessed as capable of driving a standard vehicle; however, only 15 (45%) had resumed driving. Seven participants (7/33, 21%) were deemed unable to drive a standard vehicle due to either physical ( n = 4/7, 57%), psychological ( n = 2/7, 29%), or cognitive impairment ( n = 1/7, 14%). Driving resumption following adaptations, retraining, or refresher lessons occurred in four participants ( n = 4/7, 57%) in the 12-month study period. Self-reported driving resumption at 3, 6, and 12 months was observed in 21 (62%), 28 (82%), and 30 (91%) participants, respectively. Time to driving resumption ranged from 7 to 274 days following hospital discharge. Median (IQR) driving confidence (10-point Likert scale) increased from 7 (5-8) pre-assessment to 9 (7-10) post assessment ( p < 0.05). Driving assessment acceptability was rated very good or excellent by 32 participants (97%). Using a comprehensive driving assessment 3 months following hospital discharge, approximately three quarters of this cohort were deemed able to drive a standard vehicle, yet less than half had resumed driving. Of those with a driving-related impairment, most could resume driving following intervention.
中文摘要:主要目的:确定成年ICU幸存者出院2个月后的驾驶能力。次要目的:评估出院后3、6、12个月恢复驾驶的情况、与恢复驾驶相关的因素,以及全面驾驶评估的可接受性。研究为观察性队列研究,地点为英国一家认证驾驶评估中心。研究对象为接受机械通气至少72小时和/或体外膜肺氧合的成年ICU幸存者。评估采用经驾驶车辆牌照局批准的驾驶能力评估,包括身体与认知评估,以及使用驾驶模拟器、私人场地车内评估和道路车内评估的实际驾驶技能测试。共从6家医院招募40名参与者,中位年龄53岁(四分位距46-64岁),女性13名(32%)。其中33人在出院后中位12.5周完成驾驶评估。26名参与者(79%)被评估为能够驾驶标准车辆,但仅15人(45%)已恢复驾驶。7名参与者(7/33,21%)因身体损害(4/7,57%)、心理损害(2/7,29%)或认知损害(1/7,14%)被判定不能驾驶标准车辆。在12个月研究期内,这7人中有4人(57%)在车辆改装、再训练或 refresher 课程后恢复驾驶。出院后3、6、12个月自我报告的恢复驾驶分别为21人(62%)、28人(82%)和30人(91%)。恢复驾驶时间距出院为7至274天。驾驶信心中位数(四分位距,10分制Likert量表)从评估前7(5-8)升至评估后9(7-10)(p<0.05)。32名参与者(97%)对驾驶评估的可接受性评价为很好或极好。出院后约3个月采用全面驾驶评估时,该队列约四分之三被判定能够驾驶标准车辆,但不足一半已恢复驾驶。存在驾驶相关损害者中,多数可在干预后恢复驾驶。
Daily witnessed ingestion in community-based pharmacies is standard practice for methadone maintenance treatment for opioid use disorder in British Columbia, Canada. Whether this practice, compared with take-home methadone, may pose a barrier to sustained retention in treatment and its lifesaving benefits is not known. To assess the different initiation times of methadone take-home doses in terms of time to all-cause mortality and methadone discontinuation, defined as a gap in prescribed doses lasting 5 or more days. This cohort study using principles of target trial emulation used observational data from British Columbia, Canada, 2010-2022. Both incident (no history of opioid agonist treatment [OAT]) and prevalent new-user (no OAT within the past month) designs were used. The study included individuals aged 18 years or older who completed OAT induction, were not pregnant or incarcerated, and had no history of cancer treatment or palliative care. Data analyses were conducted from March 5, 2025, to May 29, 2026. Exposure strategies were (1) no take-home dosing, (2) take-home dose initiation within 0 to 4 weeks after completing induction, (3) take-home dose initiation within 5 to 12 weeks after completing induction, (4) take-home dose initiation within 13 to 24 weeks after completing induction, and (5) take-home dose initiation within 25 to 52 weeks after completing induction. Outcomes were time to all-cause mortality and methadone discontinuation. A clone-censor-weight approach was used to estimate the 78-week adjusted risk difference (ARD). A total of 9788 incident users (median age, 34.1 [IQR, 27.2-44.1] years; 32.8% female) and 31 658 prevalent new users (median age, 36.9 [IQR, 29.7-46.2] years; 33.3% female) were included. Compared with no take-home dosing in prevalent new-user analysis, ARDs for the mortality outcome were -0.87 (95% CI, -1.51 to -0.23) for take-home dose initiation within 0 to 4 weeks after completing induction, -0.98 (95% CI, -1.62 to -0.33) for take-home dose initiation within 5 to 12 weeks after completing induction, -0.82 (95% CI, -1.59 to -0.06) for take-home dose initiation within 13 to 24 weeks after completing induction, and -0.31 (95% CI, -1.05 to 0.44) for take-home dose initiation within 25 to 52 weeks after completing induction. Compared with no take-home dosing in prevalent new-user analysis, the discontinuation outcome ARDs were -2.04 (95% CI, -3.99 to -0.10) for take-home dose initiation within 0 to 4 weeks after completing induction, -5.29 (95% CI, -6.82 to -3.76) for take-home dose initiation within 5 to 12 weeks after completing induction, -5.97 (95% CI, -7.16 to -4.78) for take-home dose initiation within 13 to 24 weeks after completing induction, and -4.39 (95% CI, -5.37 to -3.42) for take-home dose initiation within 25 to 52 weeks after completing induction. Similar patterns were observed among incident users. Multiple sensitivity analyses with sample restrictions, time-0 classifications, timeline restrictions, and addressing residual confounding bias supported the primary results. Results of this study suggest that initiating take-home methadone within 5 to 12 weeks and 13 to 24 weeks after completing induction resulted in the greatest benefits in reducing mortality and treatment discontinuation, although any take-home dosing was consistently better than no take-home dosing. These client-level benefits warrant consideration when refining clinical guidelines on take-home dosing.
中文摘要:在加拿大不列颠哥伦比亚省,社区药房每日目睹服药是阿片使用障碍美沙酮维持治疗的标准做法。与带回家美沙酮相比,这种做法是否可能阻碍患者持续留治及其挽救生命获益尚不清楚。研究评估美沙酮带回家剂量的不同启动时间对全因死亡时间和美沙酮停药的影响,停药定义为处方剂量中断持续5天及以上。这项采用目标试验模拟原则的队列研究使用加拿大不列颠哥伦比亚省2010年至2022年的观察数据,采用新发用户(无阿片类激动剂治疗史)和现患新用户(过去1个月内无阿片类激动剂治疗)两种设计。纳入18岁及以上、完成阿片类激动剂治疗诱导、未妊娠或监禁、无癌症治疗或姑息治疗史者。数据分析时间为2025年3月5日至2026年5月29日。暴露策略为:1)无带回家给药;2)完成诱导后0至4周内启动带回家剂量;3)完成诱导后5至12周内启动;4)完成诱导后13至24周内启动;5)完成诱导后25至52周内启动。结局为全因死亡时间和美沙酮停药时间。使用克隆-删失-加权方法估计78周调整风险差。共纳入9788名新发用户(中位年龄34.1岁,IQR 27.2至44.1岁;女性32.8%)和31658名现患新用户(中位年龄36.9岁,IQR 29.7至46.2岁;女性33.3%)。在现患新用户分析中,与无带回家给药相比,死亡结局的调整风险差分别为:完成诱导后0至4周内启动带回家剂量为-0.87(95% CI,-1.51至-0.23),5至12周内启动为-0.98(95% CI,-1.62至-0.33),13至24周内启动为-0.82(95% CI,-1.59至-0.06),25至52周内启动为-0.31(95% CI,-1.05至0.44)。在现患新用户分析中,与无带回家给药相比,停药结局的调整风险差分别为:0至4周内启动为-2.04(95% CI,-3.99至-0.10),5至12周内启动为-5.29(95% CI,-6.82至-3.76),13至24周内启动为-5.97(95% CI,-7.16至-4.78),25至52周内启动为-4.39(95% CI,-5.37至-3.42)。新发用户中观察到相似模式。多项敏感性分析通过样本限制、时间0分类、时间线限制和处理残余混杂偏倚支持主要结果。研究结果提示,完成诱导后5至12周和13至24周内启动带回家美沙酮,在降低死亡和治疗停药方面获益最大,尽管任何带回家给药均持续优于无带回家给药。这些患者层面的获益值得在完善带回家给药临床指南时予以考虑。
Molecular subphenotypes, identified through latent class analysis (LCA) of biomarker profiles, have the potential to guide targeted therapeutics in critical care. We have previously published that intensive insulin management has subphenotype-specific beneficial effects among children with hyperglycemia accompanying cardiorespiratory failure. However, the real-time application of subphenotype-based strategies in clinical settings remains challenging due to the operational aspects of biomarker assays. Our study had three objectives: 1) to compare biomarker measurements from rapid immunoassay and conventional multiplex platforms; 2) to evaluate the cross-platform transportability of a conventional assay-based parsimonious classifier for LCA-derived subphenotypes and compare it with a classifier trained directly on rapid immunoassay data; and 3) to assess the prognostic and predictive significance of rapid immunoassay-based subphenotypes. Retrospective cohort study. Multicenter PICUs. Two hundred sixty-nine critically ill children with acute cardiorespiratory failure and hyperglycemia (2012-2016). None. LCA was previously used to derive hyperinflammatory and hypoinflammatory classes using a conventional multiplex assay of 13 plasma biomarkers. After feature selection, a parsimonious classifier using interleukin (IL)-6, IL-8, and soluble tumor necrosis factor receptor 1 (sTNFR-1) was developed to predict LCA-derived subphenotypes. We applied this classifier to rapid immunoassay biomarker measurements, yielding an area under the receiver operating characteristic curve (AUROC) of 0.90 (95% CI, 0.85-0.95). However, calibration was poor due to systematic underestimation of sTNFR-1 concentrations by the rapid platform. We then derived and internally validated via bootstrapping a de novo classifier using rapid immunoassay data, achieving an AUROC of 0.90 (95% CI, 0.86-0.95) and excellent calibration. Using a probability threshold of ≥ 0.5, the de novo classifier matched LCA-derived classifications in 241 of 269 cases (accuracy 89.6%). Rapid immunoassay-based subphenotypes demonstrated differences in mortality (33.3% in hyperinflammatory vs. 11.8% in hypoinflammatory; p = 0.009) and differential response to intensive insulin management (interaction p = 0.024). A parsimonious, rapid immunoassay-based classifier can approximate LCA-derived molecular subphenotypes while preserving their prognostic and predictive significance, with the potential to inform future subphenotype-based precision trials.
中文摘要:通过生物标志物谱的潜在类别分析(LCA)识别出的分子亚表型,有望在重症监护中指导靶向治疗。我们此前发表的研究显示,在伴高血糖的急性心肺衰竭儿童中,强化胰岛素管理具有亚表型特异性获益。然而,由于生物标志物检测在操作层面的限制,基于亚表型的策略在临床环境中实时应用仍具挑战。本研究有三个目标:1)比较快速免疫分析与传统多重检测平台的生物标志物测量结果;2)评估基于传统检测的简约分类器对LCA衍生亚表型的跨平台可迁移性,并与直接在快速免疫分析数据上训练的分类器进行比较;3)评估基于快速免疫分析的亚表型的预后意义和预测意义。回顾性队列研究。多中心PICU。269例急性心肺衰竭伴高血糖的危重儿童(2012—2016年)。无干预。此前使用13种血浆生物标志物的传统多重检测,通过LCA得出高炎症型和低炎症型类别。特征选择后,开发了使用白细胞介素(IL)-6、IL-8和可溶性肿瘤坏死因子受体1(sTNFR-1)的简约分类器,用于预测LCA衍生亚表型。我们将该分类器应用于快速免疫分析生物标志物测量,得到的受试者工作特征曲线下面积(AUROC)为0.90(95% CI,0.85—0.95)。然而,由于快速平台系统性低估sTNFR-1浓度,校准较差。随后,我们利用快速免疫分析数据开发并通过自助法进行内部验证了一个新分类器,AUROC为0.90(95% CI,0.86—0.95),校准优秀。采用概率阈值≥0.5时,新分类器在269例中有241例与LCA衍生分类一致(准确率89.6%)。基于快速免疫分析的亚表型显示死亡率存在差异(高炎症型33.3% vs. 低炎症型11.8%;p=0.009),且对强化胰岛素管理的反应不同(交互作用p=0.024)。一个基于快速免疫分析的简约分类器可近似LCA衍生分子亚表型,同时保留其预后和预测意义,并有可能为未来基于亚表型的精准试验提供信息。
Vaccine effectiveness (VE) estimates are needed to determine the effectiveness of respiratory syncytial virus (RSV) vaccinations during their first season of availability among populations at high risk for severe RSV. To assess RSV VE against RSV-associated outcomes for nursing home residents. This retrospective cohort study of Medicare fee-for-service beneficiaries used electronic medical claims data from September 10, 2023, to March 30, 2024. A cohort was created for each outcome: an RSV-associated hospitalization cohort; an RSV-associated death cohort; a severe RSV-associated outcome cohort; and an RSV-associated thromboembolic event cohort. To be eligible for inclusion in a cohort, a Medicare fee-for-service beneficiary must be aged 65 years or older, reside in a US nursing home during the study period for at least 1 day, have continuous enrollment in Medicare Parts A and B (365 days prior to the index date), and have continuous enrollment in Part D (beginning on June 21, 2023). RSV vaccination. Outcomes were RSV-associated hospitalization, RSV-associated death, severe RSV-associated outcomes (intensive care unit or critical care unit admission, medical ventilator use, or RSV-associated death), and RSV-associated thromboembolic event. RSV diagnoses and outcome definitions were based on claims with relevant International Classification of Diseases and Related Health Problems, Tenth Revision codes. RSV vaccine doses were determined from Medicare Part D claims using the National Drug Code Directory. Hazard ratios (HRs) from multivariable Cox proportional hazards models compared the times to first outcomes among RSV vaccinated beneficiaries and unvaccinated beneficiaries. VE was calculated as (1-HR) × 100%. Of 597 430 included Medicare beneficiaries (66% female; median age, 82 [IQR, 75-88] years), RSV VE against RSV-associated hospitalizations was 73% (95% CI, 65%-79%). Among beneficiaries aged 65 to 74 years VE was 60% (95% CI, 35%-76%), 75% (95% CI, 67%-82%) among beneficiaries 75 years or older, 67% (95% CI, 55%-76%) among short-stay residents (<100 cumulative days), and 80% (95% CI, 68%-87%) among long-stay residents (≥100 cumulative days). VE against RSV-associated death was 56% (95% CI, 39%-69%), VE against severe RSV-associated outcomes was 59% (95% CI, 44%-70%), and VE against RSV-associated thromboembolic events was 66% (95% CI, 44%-79%). In this study, in the first season of availability, RSV vaccines were associated with improved RSV-associated outcomes among US Medicare beneficiaries residing in nursing homes.
中文摘要:需要评估疫苗有效性(VE),以确定呼吸道合胞病毒(RSV)疫苗在首次可及季节中对重症RSV高风险人群的有效性。评估RSV疫苗对养老院居民RSV相关结局的有效性。这项针对Medicare按服务收费受益人的回顾性队列研究使用2023年9月10日至2024年3月30日的电子医疗索赔数据。每个结局分别建立队列:RSV相关住院队列、RSV相关死亡队列、重症RSV相关结局队列和RSV相关血栓栓塞事件队列。纳入队列需为65岁及以上Medicare按服务收费受益人,研究期间在美国养老院居住至少1天,持续参加Medicare A和B部分(指数日期前365天),并持续参加D部分(自2023年6月21日起)。暴露为RSV疫苗接种。结局为RSV相关住院、RSV相关死亡、重症RSV相关结局(重症监护室或危重症监护室入住、使用医用呼吸机或RSV相关死亡)以及RSV相关血栓栓塞事件。RSV诊断和结局定义基于含有相关国际疾病分类第十版代码的索赔。RSV疫苗剂量通过国家药品代码目录从Medicare D部分索赔确定。采用多变量Cox比例风险模型的风险比(HR)比较RSV接种和未接种受益人首次结局的时间。VE计算为(1-HR)×100%。在597430名纳入的Medicare受益人中(66%女性;中位年龄82岁[IQR, 75-88]岁),RSV疫苗对RSV相关住院的VE为73%(95% CI, 65%-79%)。65至74岁受益人VE为60%(95% CI, 35%-76%),75岁及以上为75%(95% CI, 67%-82%),短期入住居民(累计<100天)为67%(95% CI, 55%-76%),长期入住居民(累计≥100天)为80%(95% CI, 68%-87%)。对RSV相关死亡的VE为56%(95% CI, 39%-69%),对重症RSV相关结局的VE为59%(95% CI, 44%-70%),对RSV相关血栓栓塞事件的VE为66%(95% CI, 44%-79%)。在这项研究中,在首次可及季节,RSV疫苗与美国养老院Medicare受益人中RSV相关结局改善相关。
基础研究 (1篇)
The purpose of this study was to assess the feasibility of color K-edge imaging enabled by spectral photon-counting CT (SPCCT) for simultaneous ventilation-perfusion evaluation using xenon and a gadolinium-based agent within healthy rabbit lungs. In this animal study, a clinical SPCCT prototype was used to perform lung imaging in five New Zealand white rabbits. A phantom study was performed to assess gadolinium quantification accuracy and cross-contamination. Animals underwent controlled mechanical ventilation with xenon gas wash-in and received an intravenous injection of a gadolinium-based ultrasmall rigid platform (USRP) (dose, 2.3 mL·kg-1; injection rate, 3 mL·s-1; concentration, 0.29 mmol Gd.mL-1). Material decomposition yielded specific xenon and gadolinium K-edge images. Xenon maps were validated against dynamic specific ventilation maps using Pearson correlation test and linear regression analysis. Regional lung distribution was analyzed using Kruskal-Wallis test. Five rabbits (mean weight, 2.9 ± 0.06 [standard deviation] kg) were evaluated. In phantoms, measured gadolinium concentrations showed a perfect linear correlation with prepared concentrations (R2 = 1). In vivo, normalized steady-state xenon maps demonstrated a strong correlation with specific ventilation maps, with a pooled Pearson correlation coefficient of 0.88 and a pooled R2 of 0.78. Simultaneous imaging revealed a homogeneous xenon distribution with a median value across rabbits of 60.2% (first quartile [Q1], 59.3%; third quartile [Q3], 67.9%), with no significant regional differences. The median gadolinium perfusion across rabbits was 6.1% (Q1, 3.0%; Q3, 7.1%), with a significant dorsal-ventral gradient (P < 0.05) where the median value increased from 0.2% (Q1, -0.2%; Q3, 1.3%) in ventral regions to 6.9% (Q1, 3.8%; Q3, 10.6%) in dorsal regions. Color K-edge xenon/gadolinium-enhanced lung imaging using SPCCT is feasible in healthy animals, enabling the simultaneous specific and quantitative imaging of lung gas and blood volume.
中文摘要:本研究旨在评估利用光谱光子计数CT(SPCCT)实现彩色K边缘成像,在健康兔肺内联合使用氙气和钆基制剂同步评价通气与灌注的可行性。这项动物研究使用临床SPCCT原型机对五只新西兰白兔进行肺部成像。通过体模研究评估钆定量准确性和交叉污染。动物接受控制性机械通气并吸入氙气,同时静脉注射钆基超小刚性平台(USRP)(剂量2.3 mL·kg-1;注射速率3 mL·s-1;浓度0.29 mmol Gd·mL-1)。物质分解获得特异性氙和钆K边缘图像。氙图与动态特异性通气图通过Pearson相关检验和线性回归分析进行验证。区域肺分布采用Kruskal-Wallis检验分析。共评估五只兔(平均体重2.9 ± 0.06(标准差)kg)。在体模中,测得的钆浓度与配制浓度呈完全线性相关(R2 = 1)。在体内,归一化稳态氙图与特异性通气图呈强相关,合并Pearson相关系数为0.88,合并R2为0.78。同步成像显示氙分布均匀,各兔中位值为60.2%(第一四分位数[Q1]59.3%;第三四分位数[Q3]67.9%),无显著区域差异。各兔钆灌注中位值为6.1%(Q1 3.0%;Q3 7.1%),存在显著背腹梯度(P < 0.05),中位值从腹侧的0.2%(Q1 -0.2%;Q3 1.3%)升高至背侧的6.9%(Q1 3.8%;Q3 10.6%)。使用SPCCT进行彩色K边缘氙/钆增强肺成像在健康动物中可行,能够同步实现肺气体和血容量的特异性定量成像。
5重症营养与其他 (9篇)
临床研究 (8篇)
Delirium is a common yet underrecognized neuropsychiatric syndrome in cardiovascular medicine associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures-such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions-may be particularly vulnerable to its development. Delirium incidence varies widely across cardiovascular procedures, influenced by patient characteristics, procedural invasiveness, and diagnostic methodology. Risk factors include advanced age, baseline cognitive impairment, cerebrovascular disease, extended operative times, perioperative complications, and systemic inflammation. Diagnostic tools such as the Confusion Assessment Method (CAM) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score are established but underutilized in the diagnosis of delirium. While preventive strategies emphasizing non-pharmacological, multicomponent approaches-such as early mobilization, cognitive stimulation, and sleep hygiene-are supported by strong evidence, preventive use of pharmacologic agents remains controversial. Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. Overall, delirium poses a significant clinical challenge in cardiovascular medicine and requires a proactive, interdisciplinary approach. Systematic risk assessment and multimodal preventive strategies should be the standard of care, while pharmacologic treatment should be symptom- and context-specific. Further high-quality studies are needed to inform evidence-based guidelines tailored to cardiovascular populations. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies.
中文摘要:谵妄是心血管医学中常见但未被充分认识的神经精神综合征,与住院时间延长、死亡率增加和长期认知功能下降相关。接受介入或外科心血管操作的患者,例如经导管主动脉瓣置换、外科主动脉瓣置换、冠状动脉旁路移植或经皮冠状动脉介入治疗,可能尤其容易发生谵妄。不同心血管操作之间谵妄发生率差异很大,受患者特征、操作侵入性和诊断方法影响。危险因素包括高龄、基线认知障碍、脑血管病、手术时间延长、围术期并发症和全身性炎症。混淆评估法(CAM)和重症监护室混淆评估法(CAM-ICU)评分等诊断工具已经确立,但在谵妄诊断中应用不足。强调非药物、多组分干预的预防策略,如早期活动、认知刺激和睡眠卫生,有较强证据支持;药物预防仍存在争议。药物治疗仅用于特定病例;右美托咪定在重症监护室环境中显示获益,喹硫平和利培酮等抗精神病药可谨慎使用。总体而言,谵妄是心血管医学中的重大临床挑战,需要积极主动的多学科处理。系统风险评估和多模式预防策略应成为标准诊疗,药物治疗应针对症状和具体情境。仍需进一步高质量研究,以制定适合心血管人群的循证指南。这篇最新综述总结当前关于心血管医学中谵妄的流行病学、机制、临床表现、诊断、预防和治疗的文献。通过整合介入心脏病学、心脏外科和精神科的研究结果及跨学科专家讨论,该综述旨在界定这一患者群体的独特易感性,突出关键知识空白,并为制定有针对性的循证管理策略奠定基础。
To develop and validate a shorter Family Satisfaction in the ICU (FS-ICU) questionnaire that reduces survey length while preserving content and psychometric performance for quality improvement and benchmarking. The FS-ICU survey assesses family perceptions of care, communication, and decision-making and has been translated into multiple languages with implementation across diverse health care systems internationally. In a province-wide electronic implementation in Ontario, more than 40% of initiated surveys were incomplete, suggesting that survey length may limit practicality for large-scale quality improvement and benchmarking. Multistage study using provincial FS-ICU survey data and an independent multicenter validation dataset for item reduction, psychometric evaluation, agreement testing, and external validation of a shortened questionnaire. A 12-member expert working group, convened for a Critical Care Services Ontario initiative, used provincial web-based data from adult ICUs across Ontario to develop a shorter version, FS-ICUshort. External validation was applied to FS-ICUshort using a separate multicenter Canadian revised FS-ICU dataset. A 12-member expert working group led by Dr. Daren K. Heyland, including administrative staff, ICU clinical staff, patient experience specialists, and quality improvement specialists from Ontario, used provincial FS-ICU rollout data. None. Using empirical criteria and expert ratings, the FS-ICU was reduced from 29 to 12 items: seven in the satisfaction-with-care domain (FS-Care) and five in the communication and decision-making domain (FS-DM). FS-ICUshort showed high internal consistency (Cronbach's α = 0.93 for FS-Care, 0.86 for FS-DM, and 0.94 for total). Confirmatory factor analysis supported a two-factor structure with better fit than a single-factor model. Scores from FS-ICUshort closely matched full FS-ICU, with mean differences less than or equal to 1.1 points on a 0-100 scale and intraclass correlations of 0.97-0.99. External validation replicated these results. The 12-item FS-ICUshort maintains the core content and psychometric quality of the original FS-ICU while significantly reducing length, supporting routine use in ICU family experience measurement and benchmarking.
中文摘要:开发并验证简版ICU家庭满意度问卷(FS-ICU),在保留内容与心理测量性能的前提下缩短问卷长度,以用于质量改进和基准比较。FS-ICU评估家庭对照护、沟通和决策的感受,已被翻译成多种语言并在国际不同卫生系统中实施。在安大略省全省电子化实施中,已启动问卷超过40%未完成,提示问卷长度可能限制其在大规模质量改进和基准比较中的实用性。采用多阶段研究,利用省级FS-ICU调查数据和一个独立的多中心验证数据集进行条目缩减、心理测量评价、一致性检验以及简版问卷的外部验证。由Critical Care Services Ontario倡议召集的12人专家工作组,使用安大略省成人ICU的省级网络数据开发简版FS-ICUshort。使用另一套加拿大多中心修订版FS-ICU数据对FS-ICUshort进行外部验证。由Daren K. Heyland博士领导的12人专家工作组包括安大略省行政人员、ICU临床人员、患者体验专家和质量改进专家,使用省级FS-ICU推广数据。无干预。采用经验标准和专家评分,将FS-ICU从29个条目缩减至12个:照护满意度领域(FS-Care)7个,沟通与决策领域(FS-DM)5个。FS-ICUshort显示高内部一致性(Cronbach's α:FS-Care为0.93,FS-DM为0.86,总问卷为0.94)。验证性因子分析支持双因子结构,拟合优于单因子模型。FS-ICUshort得分与完整FS-ICU接近,在0-100量表上平均差异小于或等于1.1分,组内相关系数为0.97-0.99。外部验证重复了这些结果。12条目的FS-ICUshort保留了原FS-ICU的核心内容和心理测量质量,同时显著缩短长度,支持其用于ICU家庭体验测量和基准比较的常规使用。
Midostaurin and quizartinib are approved with intensive chemotherapy (IC) in patients with newly diagnosed FLT3 internal tandem duplication (ITD)-positive acute myeloid leukemia (AML), but no randomized clinical trials have directly compared them. To compare 1-year overall survival (OS) among patients with FLT3-ITD variant AML initiating IC with midostaurin or quizartinib. This multicenter, retrospective cohort study included patients with newly diagnosed FLT3-ITD variant AML treated at 12 US referral centers between January 1, 2018, and May 31, 2025. Data analysis was performed from January 2026 to August 2026. Induction therapy with IC plus midostaurin or quizartinib. The primary outcome was 1-year overall survival (OS). Secondary outcomes included 1-year event-free survival (EFS), induction response, and hematopoietic cell transplant (HCT) rates at first remission; FLT3 clearance after induction was exploratory. Safety outcomes included rates of febrile neutropenia, infections, intensive care unit use, total parenteral nutrition and granulocyte colony-stimulating factor use, discharge to a rehabilitation facility after index hospitalization, and early mortality. Cox proportional hazards regression models were adjusted for baseline covariates and HCT as time dependent. Among 215 patients (median [IQR] age, 56.0 [45.0-65.0] years; 119 [55.3%] female), 127 (59.1%) received midostaurin and 88 (40.9%) received quizartinib. Median (IQR) follow-up was 667.0 (289.0-1368.0) days for midostaurin and 324.0 (168.0-546.5) days for quizartinib, reflecting the latter's more recent approval. One-year OS was 78.0% for midostaurin and 93.0% for quizartinib (hazard ratio [HR], 0.22; 95% CI, 0.08-0.58; P = .002). The 1-year EFS was 56.0% for midostaurin and 77.0% for quizartinib (HR, 0.43; 95% CI, 0.25-0.74; P = .003). Patients receiving quizartinib had higher rates of composite complete remission (75 [85.2%] vs 93 [73.2%]; P = .03), whereas rates of FLT3 clearance after induction (20 [38.5%] for quizartinib vs 27 [40.3%] for midostaurin; P = .84) and HCT in first remission (47 [53.4%] for quizartinib vs 83 [65.4%] for midostaurin; P = .08) were comparable. Midostaurin was associated with higher intensive care unit use (19 [15.0%] vs 4 [4.5%]; P = .02), discharge to a rehabilitation facility (9 [7.1%] vs 1 [1.1%]; P = .04), and treatment interruptions (32 [25.2%] vs 10 [11.4%]; P = .01). A sensitivity analysis limited to patients treated in 2023 or later (more balanced follow-up) showed directionally consistent but nonsignificant OS and EFS differences. In this cohort study of adults with FLT3-ITD variant AML, IC plus quizartinib was associated with improved 1-year survival, induction response, and safety compared with IC plus midostaurin.
中文摘要:米哚妥林与奎扎替尼均获批与强化化疗联合用于新诊断FLT3内部串联重复阳性急性髓系白血病,但尚无随机临床试验直接比较两者。本研究比较以米哚妥林或奎扎替尼联合强化化疗起始治疗的FLT3-ITD变异型急性髓系白血病患者1年总生存。该多中心回顾性队列研究纳入2018年1月1日至2025年5月31日在美国12家转诊中心治疗的新诊断FLT3-ITD变异型急性髓系白血病患者,数据分析时间为2026年1月至2026年8月。暴露为诱导治疗采用强化化疗联合米哚妥林或奎扎替尼。主要结局为1年总生存,次要结局包括1年无事件生存、诱导反应、首次缓解时造血细胞移植率,诱导后FLT3清除为探索性指标。安全性结局包括发热性中性粒细胞减少、感染、重症监护病房使用、全肠外营养和粒细胞集落刺激因子使用、指数住院后转至康复机构以及早期死亡率。Cox比例风险回归模型校正基线协变量并将造血细胞移植作为时间依赖变量。215例患者中位年龄56.0岁,女性119例,127例接受米哚妥林,88例接受奎扎替尼。米哚妥林中位随访667.0天,奎扎替尼324.0天,反映后者获批较晚。1年总生存米哚妥林为78.0%,奎扎替尼为93.0%,风险比0.22,95%置信区间0.08至0.58,P=0.002。1年无事件生存米哚妥林为56.0%,奎扎替尼为77.0%,风险比0.43,95%置信区间0.25至0.74,P=0.003。奎扎替尼组复合完全缓解率更高,为85.2%对73.2%,P=0.03;诱导后FLT3清除率分别为38.5%和40.3%,P=0.84,首次缓解时造血细胞移植率分别为53.4%和65.4%,P=0.08。米哚妥林组重症监护病房使用率更高,为15.0%对4.5%,P=0.02;转至康复机构比例更高,为7.1%对1.1%,P=0.04;治疗中断率更高,为25.2%对11.4%,P=0.01。限定于2023年及以后治疗患者的敏感性分析随访更均衡,总生存和无事件生存差异方向一致但无统计学意义。在这项FLT3-ITD变异型急性髓系白血病成人队列研究中,强化化疗联合奎扎替尼与改善1年生存、诱导反应和安全性相关。
Although external validation of machine learning (ML)-based delirium risk models is a key stage in the model development pipeline, few published reports exist. Moreover, ML-based delirium risk models commonly degrade in performance during external validation. To examine the performance of a fusion multimodal with natural language processing (NLP) delirium risk stratification model in live clinical practice with cross-hospital external validation. This quality improvement study evaluated live clinical deployment of the model among patients 60 years or older who were admitted to non-intensive care units at Mount Sinai Hospital (MSH), with external validation performed at Mount Sinai Morningside Hospital (MSM), from December 1, 2024, to December 31, 2025. Primary outcomes were performance of the risk stratification model, assessed by area under the receiver operating characteristic curve (AUROC), and monthly delirium detection rates. A 2 × 2 confusion matrix was created, and the 4 cells were used to calculate model performance metrics and compare associated diagnostic yield between premodel deployment and active model deployment periods. The overall sample included 33 095 admissions to non-intensive care units at MSM and MSH (mean [SD] age, 74.86 (9.22) years; 15 601 women [47.1%], 17 271 men [52.2%]). A total of 9020 MSM inpatient admissions were assigned a delirium risk score by the risk stratification model during live clinical operations and were compared to 21 186 MSH inpatient admissions that were assigned a risk score by the same model. Age at admission significantly differed between patients at MSM and MSH (MSM: median [IQR] age, 75.79 [68.25-83.88] years vs MSH: 72.62 [66.64-79.65] years; P < .001). Patients from MSM and MSH also significantly differed by sex, race and ethnicity, surgical vs medical primary diagnosis, length of stay, and dementia prevalence rate. Among 11 909 MSM patients, patients in the pre-ML cohort (median [IQR] age, 78.00 [71.00-85.00] years) were significantly older than those in the post-ML cohort (median [IQR] age, 75.79 [68.25-83.88] years) (P < .001). The AUROC of the model was 0.91 (95% CI, 0.90-0.92) for MSM and 0.94 (95% CI, 0.93-0.94) for MSH. The positive predictive value of the model was 25.9% for MSM and 19.4% for MSH. For MSM, the mean monthly delirium detection rate significantly increased from 9.23% (95% CI, 8.07%-10.38%) to 19.59% (95% CI, 17.32%-21.85%) after model deployment (P < .001). In this quality improvement study, an ML-based delirium risk stratification model maintained acceptable discriminative performance during external deployment without retraining and was similar to its performance at the development site without retraining. Model deployment was also associated with increased diagnostic yield but a high false positive rate. These findings provide further evidence of the potential generalizability of the model.
中文摘要:尽管基于机器学习(ML)的谵妄风险模型的外部验证是模型开发流程中的关键阶段,已发表报告仍很少。基于ML的谵妄风险模型在外部队列验证中常出现性能下降。为考察融合多模态与自然语言处理(NLP)的谵妄风险分层模型在真实临床实践中的表现并进行跨医院外部验证,这项质量改进研究于2024年12月1日至2025年12月31日在Mount Sinai Hospital(MSH)非重症监护病房60岁及以上住院患者中开展模型实时临床部署,并在Mount Sinai Morningside Hospital(MSM)进行外部验证。主要结局为风险分层模型性能,采用受试者工作特征曲线下面积(AUROC)评估,并观察每月谵妄检出率。研究构建2×2混淆矩阵,用4个单元格计算模型性能指标,并比较模型部署前与模型主动部署期间的诊断产出。总样本包括MSM和MSH非重症监护病房的33 095次住院(平均[SD]年龄74.86[9.22]岁;15 601名女性[47.1%],17 271名男性[52.2%])。在实时临床运行中,风险分层模型为9020次MSM住院分配了谵妄风险评分,并与同一模型评分的21 186次MSH住院进行比较。MSM与MSH患者入院年龄存在显著差异(MSM:中位[IQR]年龄75.79[68.25-83.88]岁 vs MSH:72.62[66.64-79.65]岁;P < .001)。MSM与MSH患者在性别、种族和民族、外科与内科主要诊断、住院时长及痴呆患病率方面也存在显著差异。在11 909例MSM患者中,ML应用前队列(中位[IQR]年龄78.00[71.00-85.00]岁)显著年长于ML应用后队列(中位[IQR]年龄75.79[68.25-83.88]岁)(P < .001)。模型在MSM的AUROC为0.91(95% CI,0.90-0.92),在MSH为0.94(95% CI,0.93-0.94)。模型阳性预测值在MSM为25.9%,在MSH为19.4%。MSM模型部署后平均每月谵妄检出率从9.23%(95% CI,8.07%-10.38%)显著升至19.59%(95% CI,17.32%-21.85%)(P < .001)。在这项质量改进研究中,基于ML的谵妄风险分层模型在未重新训练的情况下进行外部部署时保持了可接受的区分性能,并与开发站点未重新训练时的表现相近。模型部署还与诊断产出增加相关,但假阳性率较高。这些发现进一步提示该模型具有潜在可推广性。
To effectively support recovery, intensive care unit (ICU) clinicians require training to identify patients at risk of post-intensive care syndrome and implement interventions during and after ICU admission. This study aimed to identify and prioritise curriculum topics for educating interprofessional ICU clinicians on evidence-based ICU recovery care across the continuum of critical illness. A two-round e-Delphi study followed by a structured consensus meeting endorsed by the European Society of Intensive Care Medicine (ESICM) was conducted. A steering committee generated an initial list of curriculum topics. In round 1, participants rated topic importance (9-point Likert scale) and suggested additional topics. In round 2, they rated newly identified topics and ranked priorities. Topics reaching consensus (≥70% rating as critical [7-9]; ≤15% rating as not important [1-3]) were discussed during the final consensus meeting. Participants' mean age was 43.5 (±10.5) years and they were predominantly female (n = 90, 66.7%). Priority topics included early mobilisation during ICU admission, post-intensive care syndrome, delirium prevention and management, implementation of the ABCDEF bundle, and cognitive support and rehabilitation. The final set of learning modules for a future curriculum was established. Priority topics and learning modules for an expert-developed curriculum framework for ICU recovery were established with interprofessional ICU clinicians through a structured international consensus process with moderate levels of participant retention between the two Delphi rounds and full consensus agreement among experts. This framework may support in delivering recovery-focused care across the continuum of critical illness.
中文摘要:为有效支持康复,ICU临床医生需要接受培训,以识别有重症后综合征风险的患者,并在ICU入住期间及之后实施干预。研究旨在确定并优先排序课程主题,用于教育跨专业ICU临床医生,使其在重症疾病全过程中提供循证ICU康复照护。研究开展了两轮电子德尔菲研究,随后举行由欧洲重症医学会(ESICM)支持的结构化共识会议。指导委员会生成了初始课程主题清单。第一轮中,参与者对主题重要性评分(9点李克特量表)并提出新增主题。第二轮中,他们对新识别的主题评分并排序优先级。达到共识的主题(≥70%评为关键[7-9分];≤15%评为不重要[1-3分])在最终共识会议上讨论。参与者平均年龄43.5(±10.5)岁,以女性为主(n=90,66.7%)。优先主题包括ICU入住期间早期活动、重症后综合征、谵妄预防与管理、ABCDEF集束化策略的实施、认知支持与康复。未来课程的最终学习模块集已确定。通过结构化国际共识程序,与跨专业ICU临床医生确立了ICU康复专家课程框架的优先主题和学习模块,两轮德尔菲之间参与者保留率为中等,专家间达成完全共识。该框架可支持在重症疾病全过程中提供以康复为重点的照护。
Post-COVID-19 syndrome is burdensome and not yet adequately treatable, with persistent symptoms including fatigue, dyspnoea, and cognitive impairment. The Pan American Health Organisation recommends rigorous evaluation of potentially beneficial interventions. We investigated the efficacy and safety of prednisolone and vitamins B1, B6, and B12 in patients with post-COVID-19. This randomised, double-blind, placebo-controlled phase 3 trial (2 × 2 factorial design) was conducted in adults with post-COVID-19 at three university sites in Germany. Adult patients with persistent symptoms after a documented SARS-CoV-2 infection ≥12 weeks ago and without acute COVID-19, major comorbidities, pregnancy or breastfeeding, prior intensive care treatment for COVID-19, recent use of trial drugs, or potentially interacting concomitant medications were included. From January 13, 2023 until July 25, 2024 participants were randomly assigned to 28 days of once-daily oral treatment with prednisolone (20 mg on days 1-5, 5 mg on days 6-28), B vitamins (thiamine nitrate [B1], 100 mg, pyridoxine hydrochloride [B6] 50 mg, and cyanocobalamin [B12] 500 μg), prednisolone and B vitamins, or placebo. The primary outcome was change in overall symptom severity from baseline to day 28, assessed in the intention-to-treat population (participants who received at least one dose of study drug) at the first follow-up visit after randomisation with a customised Patient-Reported Outcomes Measurement Information System (PROMIS) total T-score. A change of ≥3 points was considered clinically meaningful. Efficacy was assessed using a pre-specified factorial analysis of the main effects of prednisolone and B vitamins. Safety was assessed by analysing frequency and severity of adverse events in all randomised patients (safety population). This completed trial is registered with ClinicalTrials.gov (NCT05638633). Of 2498 patients assessed for eligibility, 323 were randomised and 310 patients had evaluable data for the outcomes. The mean age was 44 (standard deviation (SD) 13) years, 200 participants were women. The mean change in PROMIS T-score was -4·3 (SD 5·1) with prednisolone, -3·2 (SD 5·0) with B vitamins, -4·5 (SD 4·5) with prednisolone plus B vitamins, and -2·9 (SD 4·6) with placebo. The adjusted mean difference between participants treated with prednisolone and those not treated was -1·4 points (95% confidence interval (CI), -2·5 to -0·4; p = 0·008), driven primarily by the change in the fatigue subscore (-6·4 points, p < 0·001). B vitamins showed no statistically significant or clinically meaningful difference compared with no B vitamins (adjusted mean difference (MD), -0·1 points; 95% CI, -1·2 to +1·0; p = 0·85). Adverse events were equally distributed between groups, with no study-drug-related serious adverse events. This trial showed a statistically significant short-term reduction in symptom severity in the five dimensions of the PROMIS score in patients with post-COVID with low-dose prednisolone. However, the effect did not reach the prespecified threshold for clinical relevance. Further research is needed to confirm the efficacy of prednisolone and to determine the optimal dose and treatment duration while balancing benefits against longer-term adverse effects. German Federal Ministry of Research, Technology and Space, Vogel Stiftung Dr. Eckernkamp, Hevert-Arzneimittel GmbH & Co. KG.
中文摘要:Post-COVID-19综合征负担较重,目前尚缺乏充分有效的治疗,持续症状包括疲劳、呼吸困难与认知障碍。泛美卫生组织建议对可能有益的干预措施进行严格评估。本研究考察泼尼松龙及维生素B1、B6、B12在Post-COVID-19患者中的疗效与安全性。这项随机、双盲、安慰剂对照3期试验采用2×2析因设计,在德国3个大学站点纳入成人Post-COVID-19患者。纳入标准为有记录的SARS-CoV-2感染至少12周后仍存在持续症状,且无急性COVID-19、重大合并症、妊娠或哺乳、因COVID-19接受过重症治疗、近期使用试验药物或可能发生相互作用的合并用药。2023年1月13日至2024年7月25日,参与者被随机分配接受28天每日一次口服治疗:泼尼松龙(第1至5天20 mg,第6至28天5 mg)、B族维生素(硝酸硫胺素B1 100 mg、盐酸吡哆醇B6 50 mg、氰钴胺B12 500 μg)、泼尼松龙联合B族维生素或安慰剂。主要结局为基线至第28天总体症状严重度变化,在意向治疗人群(至少接受一剂研究药物)中于随机化后首次随访时采用定制患者报告结局测量信息系统(PROMIS)总T评分评估。变化≥3分被视为具有临床意义。疗效采用预设析因分析评估泼尼松龙与B族维生素的主效应。安全性通过分析所有随机化患者(安全性人群)的不良事件频率与严重程度评估。该已完成试验注册于ClinicalTrials.gov(NCT05638633)。2498例患者接受资格评估,323例被随机化,310例具有可评估结局数据。平均年龄44岁(标准差13),200例为女性。PROMIS T评分平均变化为泼尼松龙组-4·3(标准差5·1)、B族维生素组-3·2(标准差5·0)、泼尼松龙联合B族维生素组-4·5(标准差4·5)、安慰剂组-2·9(标准差4·6)。接受泼尼松龙者与未接受者之间的校正平均差为-1·4分(95%置信区间-2·5至-0·4;p=0·008),主要由疲劳子评分变化驱动(-6·4分,p<0·001)。B族维生素与未使用B族维生素相比无统计学显著或临床意义差异(校正平均差-0·1分;95%置信区间-1·2至+1·0;p=0·85)。不良事件在各组间分布均衡,未发生与研究药物相关的严重不良事件。该试验显示,低剂量泼尼松龙使Post-COVID-19患者PROMIS评分五个维度的症状严重度在短期内有统计学显著下降。但该效应未达到预设的临床相关性阈值。仍需进一步研究确认泼尼松龙的疗效,并在获益与长期不良效应之间权衡,确定最佳剂量与疗程。资助方为德国联邦研究、技术与空间部、Vogel Stiftung Dr. Eckernkamp、Hevert-Arzneimittel GmbH & Co. KG。
Pre-admission functional status might be associated with mortality in critically ill patients admitted to the ICU. With this systematic review, we aimed to investigate the association of pre-admission functional domains with mortality after ICU admission and which functional measures were used. We searched PubMed, Embase, and the Cochrane Register of Controlled Trials for studies of acutely admitted adult ICU patients reporting pre-admission functional status and mortality. Exploratory outcomes were mechanical ventilation, renal replacement therapy, delirium, ICU and hospital length of stay, discharge destination, and health-related quality of life. Screening, data extraction, and risk-of-bias evaluation were performed in duplicate. Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Of the 55 observational studies included, 21 contributed to the meta-analyses. Overall, 26.7% of the participants were deceased at variable follow-up (ICU to 1 yr). Frailty prevalence ranged from 3.6% to 76.8%, and functional dependency from 10.6% to 68.7%. Meta-analysis showed a risk ratio (RR) of 0.62 (95% confidence interval [CI] 0.58-0.67, P<0.01) for all-cause mortality between non-frail and frail participants and an RR of 0.47 (95% CI 0.40-0.54, P<0.01) between independent and dependent participants. No statistically significant association was found in the subgroup analysis of exploratory outcomes. Statistical and clinical heterogeneity were substantial, and overall certainty of evidence was very low. Pre-admission frailty and functional dependency were associated with higher mortality after ICU admission. Overall, the evidence is very uncertain, and the true effect could differ substantially from our estimates.
中文摘要:入住ICU前功能状态可能与危重患者死亡相关。本系统评价旨在探讨入住ICU前功能域与ICU入住后死亡之间的关联,以及使用了哪些功能评估指标。检索PubMed、Embase和Cochrane对照试验注册库,纳入报告入住ICU前功能状态和死亡的急性入住成人ICU患者研究。探索性结局为机械通气、肾脏替代治疗、谵妄、ICU住院时间和医院住院时间、出院去向及健康相关生活质量。筛查、数据提取和偏倚风险评估均由两人独立完成。证据确定性采用推荐分级的评估、制定与评价(GRADE)方法评估。共纳入55项观察性研究,其中21项进入荟萃分析。总体而言,26.7%的参与者在不同随访时间点(从ICU到1年)死亡。衰弱患病率为3.6%至76.8%,功能依赖为10.6%至68.7%。荟萃分析显示,非衰弱与衰弱参与者全因死亡的风险比为0.62(95%置信区间0.58-0.67,P<0.01),独立与依赖参与者的风险比为0.47(95%置信区间0.40-0.54,P<0.01)。探索性结局的亚组分析未发现统计学显著关联。统计异质性和临床异质性均较大,总体证据确定性极低。入住ICU前衰弱和功能依赖与ICU入住后更高死亡相关。总体证据很不确定,真实效应可能与估计值存在较大差异。
Research examining informed consent in critical care studies is limited. The objective of this study was to describe the patterns and predictors of consent. Research coordinators prospectively documented each consent encounter including consent model (a priori or deferred, also known as consent to continue), who requested consent (research coordinator, site investigator, and ICU physician), who provided or declined consent (patient, substitute decision-maker [SDM], and other), the method to obtain consent (in-person or via telephone), and reasons for consent decline, if applicable. Research coordinators retrospectively reported center characteristics. Using multilevel logistic regression, we evaluated the association of consent provision with characteristics of the consent encounter and participating center. International randomized trial of stress ulcer prophylaxis for invasively ventilated patients. None. Among 5024 patients or SDMs approached for consent, the consent rate was 85.0% (ranging from 27.3% to 100%). In 2638 patients (52.5%), an a priori approach was used, and of these, 696 patients (26.4%) declined. The remaining 2386 participants (47.5%) were enrolled by deferred consent, of whom 58 participants (2.4%) ultimately declined. Among first consent encounters, 80.2% were with SDMs, 19.6% with patients, and 0.2% with others. Higher consent rates were independently associated with the deferred consent model (odds ratio [OR], 16.56; 95% CI, 11.50-23.84), consent encounters involving patients (OR, 2.67; 95% CI, 1.63-4.37), and consent encounters during the COVID-19 pandemic (OR, 2.01; 95% CI, 1.30-3.11) or postpandemic period (OR, 2.26; 95% CI, 1.34-3.80) compared with prepandemic. Consent rates were not associated with center characteristics including ICU size, ICU research experience, or research coordinator experience. Deferred consent was used as often as a priori consent in this trial. The informed consent rate was associated with the deferred model, consent from patients, and consent encounters during or after the pandemic.
中文摘要:危重症研究中关于知情同意的研究有限。本研究旨在描述同意的模式与预测因素。研究协调员前瞻性记录每次知情同意过程,包括同意模式(预先同意或延迟同意,也称继续同意)、由谁请求同意(研究协调员、站点研究者或ICU医生)、由谁提供或拒绝同意(患者、替代决策者或其他)、获取同意的方式(面对面或电话)以及拒绝同意原因(如适用)。研究协调员回顾性报告中心特征。采用多水平logistic回归评估是否获得同意与知情同意过程特征及参与中心特征的关系。研究背景为一项针对有创通气患者的应激性溃疡预防国际随机试验。干预为无。在5024名被接洽的患者或替代决策者中,同意率为85.0%(范围27.3%至100%)。2638名患者(52.5%)采用预先同意方式,其中696名(26.4%)拒绝。其余2386名参与者(47.5%)通过延迟同意入组,其中58名(2.4%)最终拒绝。首次知情同意过程中,80.2%与替代决策者进行,19.6%与患者进行,0.2%与其他人员进行。较高的同意率独立关联于延迟同意模式(比值比[OR] 16.56;95% CI 11.50-23.84)、涉及患者的知情同意过程(OR 2.67;95% CI 1.63-4.37),以及与疫情前相比,在COVID-19疫情期间(OR 2.01;95% CI 1.30-3.11)或疫情后时期(OR 2.26;95% CI 1.34-3.80)进行的知情同意过程。同意率与中心特征无关,包括ICU规模、ICU研究经验或研究协调员经验。本试验中延迟同意与预先同意使用频率相当。知情同意率与延迟同意模式、患者本人同意以及疫情期间或疫情后进行的知情同意过程相关。
基础研究 (1篇)
In premature infants, successful ex utero maturation depends on endogenous and exogenous stimuli. Chemical insults during this period may impact long-term development. Given immature hepatic biotransformation, parenteral xenobiotic exposure may be of particular toxicological relevance. We conducted a single-center case study to characterize the xenobiotic burden of neonatal parenteral nutrition (PN). A standardized PN regimen for a 28-week, 1000 g reference infant was passed through infusion lines and the flow-through analyzed via a multianalyte exposome LC-MS/MS assay. Eighteen of 221 targeted xenobiotics were detected. Diisononyl phthalate (DINP, 780 ng/mL), bisphenol A (BPA, 250 ng/mL), methylparaben (MP, 74 ng/mL), and 5-hydroxymethyl-2-furanoic acid (HMFA, 43 ng/mL) showed the highest mean concentrations. The estimated daily intake of BPA (9.5 μg/kg bw/d) exceeded calculated and official Health-Based Guidance Values. Consistent with immature detoxification, pharmacokinetic modeling suggested accumulation of DINP, MINP, and free BPA in premature infants. The higher predicted exposure of premature infants to free BPA warrants investigation into 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP) formation under potentially saturated Phase II metabolism. An exploratory analysis of plasma data from extremely premature infants indicated PN as a contributory rather than predominant source of intervention-related exposure. These findings represent a relevant clinical reference scenario rather than a population-wide exposure estimate.
中文摘要:早产儿出生后能否顺利成熟,取决于内源性与外源性刺激。这一时期的化学暴露可能影响远期发育。由于肝脏生物转化功能尚不成熟,经肠外途径进入体内的外源化学物在毒理学上可能尤其值得关注。我们开展了一项单中心病例研究,以刻画新生儿肠外营养(PN)所携带的外源化学物负荷。将适用于28周、1000 g参考婴儿的标准化PN方案经输液管路输注,并对流出的液体用多分析物暴露组LC-MS/MS方法检测。在221种目标外源化学物中检出18种。邻苯二甲酸二异壬酯(DINP,780 ng/mL)、双酚A(BPA,250 ng/mL)、对羟基苯甲酸甲酯(MP,74 ng/mL)和5-羟甲基-2-呋喃甲酸(HMFA,43 ng/mL)的平均浓度最高。BPA估算日摄入量(9.5 μg/kg体重/日)超过计算所得及官方健康指导值。与解毒功能不成熟相一致,药代动力学建模提示DINP、MINP和游离BPA可在早产儿体内蓄积。早产儿游离BPA预测暴露更高,提示在Ⅱ相代谢可能饱和的情况下需研究4-甲基-2,4-双(4-羟基苯基)戊-1-烯(MBP)的生成。对极早产儿血浆数据的探索性分析提示,PN是干预相关暴露的促成来源之一,而非主要来源。这些结果反映的是一个有临床参考意义的情境,而不是人群层面的暴露估计。
6中毒与环境急症 (7篇)
临床研究 (3篇)
Nerve agent poisoning is often linked with mass-casualty events. Typical examples are battlefield use or large terrorist attacks. However, documented incidents from the last decades show a broader and more complex picture. The perspective follows a line of documented cases. It starts with the 1978 ricin "umbrella" murder of Georgi Markov in London (non-nerve agent attack, but historically important). It then moves to the sarin attacks in Matsumoto (1994) and the Tokyo subway (1995), the VX assassinations by the Aum Shinrikyo cult (1994-1995), the 2013 sarin attack in Ghouta and the recent targeted poisonings of Kim Jong-nam (2017), Sergei and Yulia Skripal (2018), Dawn Sturgess and Charlie Rowley (2018) and Alexei Navalny (2020). We use these cases to show how route of exposure, dose, formulation and environmental persistence shape toxicokinetics, clinical presentation, biomarker formation and forensic interpretation. For each case we give the circumstances, the agent, the route, the clinical course, the treatment and the forensic confirmation in detail. We focus on acetylcholinesterase and butyrylcholinesterase inhibition, aging, protein adduct formation, dermal absorption and environmental persistence. We describe a recurring "toxicological paradox": greater control over exposure can reduce immediate lethality, but at the same time it increases diagnostic uncertainty and forensic complexity. The cases also show that mass and targeted use are not two separate historical stages. They coexist within the same period, sometimes even within one perpetrator organisation. This perspective has direct implications for emergency preparedness, biomarker development, antidotal treatment windows and international chemical incident response.
中文摘要:神经性毒剂中毒常与大规模伤亡事件相关。典型例子是战场使用或大型恐怖袭击。然而,过去数十年有记录的事件呈现出更广泛、更复杂的图景。本视角沿一系列有记录的病例展开。首先提到1978年伦敦Georgi Markov遭蓖麻毒素「雨伞」谋杀(并非神经性毒剂袭击,但具有历史重要性)。随后讨论松本(1994)和东京地铁(1995)的沙林袭击、奥姆真理教实施的VX暗杀(1994—1995)、2013年Ghouta沙林袭击,以及近年来针对Kim Jong-nam(2017)、Sergei和Yulia Skripal(2018)、Dawn Sturgess和Charlie Rowley(2018)及Alexei Navalny(2020)的定向投毒。我们借助这些病例说明暴露途径、剂量、剂型和环境持久性如何塑造毒代动力学、临床表现、生物标志物形成和法医学解释。对每个病例,我们详细给出事件情形、毒剂、途径、临床过程、治疗和法医学确认。重点关注乙酰胆碱酯酶和丁酰胆碱酯酶抑制、老化、蛋白加合物形成、皮肤吸收和环境持久性。我们描述一种反复出现的「毒理学悖论」:对暴露的控制增强可降低即时致死性,但同时增加诊断不确定性和法医学复杂性。这些病例还表明,大规模使用和定向使用并非两个相互分离的历史阶段。二者共存于同一时期,有时甚至存在于同一个施害者组织内。这一视角对应急准备、生物标志物开发、解毒治疗时间窗和国际化学事件应对具有直接意义。
Whereas attention-deficit/hyperactive disorder (ADHD) has consistently been shown to be correlated with later risk of depression, anxiety, and substance misuse, the relationship with other adverse health endpoints, particularly somatic conditions, is uncertain. In a full-nation birth cohort study, we used a phenotype-wide approach to explore the influence, if any, of a ADHD diagnosis in childhood/adolescence on later disease and injury. Comprising 52594 children (25463 females) born in a single year with non-missing data, the 1987 Finnish Birth Cohort was generated from linkage of routinely collected data. ADHD diagnosis was captured from in- and out-patient hospital records up to age 18 years and study members continued to be surveilled for other diagnoses until 2020 (aged 33). Pre-adulthood, 0.43% (N = 228) of study members were diagnosed with ADHD. In people with ADHD, relative to population controls, there was a heightened risk of developing all of the 17 health endpoints examined. Of these associations, however, eleven were statistically significant after adjustment for age and sex, and five after further control for birth weight, family socioeconomic circumstances, study members' educational performance, and multiple testing (odds ratio; 99.7%): neurotic disorders (2.11; 1.25, 3.41); substance abuse disorder (2.26; 1.27, 3.79); poisoning (2.30; 1.02, 4.52); mood disorders (2.45; 1.49, 3.88); and epilepsy (4.55; 1.82, 9.55). Repeating the main analyses following data imputation (N = 54045) confirmed these associations with the emergence of a connection between psychotic disorders and antecedent ADHD (2.63; 1.34, 5.18). Overall, young people with ADHD in the present cohort experienced an increased future burden of psychiatric and neurological conditions but seemingly not somatic disorders.
中文摘要:注意缺陷多动障碍(ADHD)已被反复证实与后续抑郁、焦虑和物质滥用风险相关,但其与其他不良健康结局尤其是躯体疾病的关系仍不确定。我们在一项全国出生队列研究中采用表型组范围方法,探讨儿童或青少年期ADHD诊断对后续疾病和损伤的影响(如有)。1987年芬兰出生队列通过链接常规收集数据生成,包含52594名同一年出生且数据完整的儿童(25463名女性)。ADHD诊断取自18岁前的住院和门诊病历,研究对象继续随访其他诊断至2020年(33岁)。成年之前,0.43%(N=228)的研究对象被诊断为ADHD。与人群对照相比,ADHD患者发生所检查的全部17种健康结局的风险均升高。调整年龄和性别后,其中11种关联具有统计学意义;进一步控制出生体重、家庭社会经济状况、研究对象教育表现及多重检验后,5种关联仍显著(比值比;99.7%):神经症性障碍(2.11;1.25, 3.41);物质滥用障碍(2.26;1.27, 3.79);中毒(2.30;1.02, 4.52);心境障碍(2.45;1.49, 3.88);癫痫(4.55;1.82, 9.55)。数据插补后(N=54045)重复主要分析,上述关联得到确认,并出现精神病性障碍与既往ADHD之间的关联(2.63;1.34, 5.18)。总体而言,本队列中ADHD年轻人在未来承受更多精神科和神经科疾病负担,但似乎未增加躯体疾病负担。
Methiodone (IC-26; 4-ethylsulfonyl-N,N-dimethyl-4,4-diphenylbutan-2-amine) is a synthetic opioid derivative of methadone that has recently emerged on the designer drug market. Data on its clinical toxicity and pharmacokinetics remain limited. We describe four cases of severe methiodone intoxication requiring intensive care unit (ICU) admission, taking place between July and November 2025. Clinical presentation, treatment, and outcomes were evaluated. In addition, systematic toxicological analysis was performed including Liquid Chromatography - High Resolution Mass Spectrometry (LC-HRMS) and targeted Liquid Chromatography - tandem Mass Spectrometry (LC-MS/MS). All patients presented with a classical opioid toxidrome, characterized by respiratory depression, miosis, and decreased consciousness. Naloxone administration resulted in clinical improvement in all cases. Methiodone plasma concentrations ranged from 0.20 to 0.64 mg/L. The elimination half-life in plasma was estimated at approximately 13 h based on one case. Metabolite analysis revealed N-dealkylation as an important metabolic pathway, with additional hydroxylation and limited glucuronidation. Methiodone was variably detected in routine immunoassays, depending on assay specificity. No electrocardiogram (ECG) clinically relevant abnormalities were observed, in contrast to observations in methadone intoxications. Methiodone is an emerging opioid capable of causing severe, but treatable, intoxication. Increased clinical and analytical awareness is essential, as further cases are likely to emerge with the ongoing evolution of the new psychoactive substance market.
中文摘要:甲硫酮(methiodone,IC-26;4-乙基磺酰基-N,N-二甲基-4,4-二苯基丁-2-胺)是美沙酮的一种合成阿片类衍生物,近期出现在设计药物市场上。其临床毒性与药代动力学资料仍然有限。报告2025年7月至11月间4例需入住重症监护病房(ICU)的重度甲硫酮中毒病例,对临床表现、治疗与结局进行了评估;同时开展系统毒理学分析,包括液相色谱-高分辨质谱(LC-HRMS)与靶向液相色谱-串联质谱(LC-MS/MS)。全部患者均表现为典型阿片中毒综合征,以呼吸抑制、瞳孔缩小和意识水平下降为特征。给予纳洛酮后各例临床均有改善。血浆甲硫酮浓度为0.20至0.64 mg/L;依据其中1例估算血浆消除半衰期约为13小时。代谢物分析显示N-脱烷基是重要代谢途径,另有羟基化以及有限的葡萄糖醛酸结合。常规免疫分析对甲硫酮的检出情况不一,取决于方法特异性。未观察到有临床意义的心电图异常,这一点与美沙酮中毒的观察结果不同。甲硫酮是一种新兴阿片类物质,可造成严重但可治疗的中毒。随着新精神活性物质市场不断演变,更多病例可能出现,提高临床与检测层面的警觉十分必要。
基础研究 (4篇)
Single-atom catalysts are promising for VOC abatement, but their application is limited by the trade-off between the stability of isolated atoms and the redox activity. Herein, we report a surface-confined Pt-Ov-Mn atomic interface constructed within the outer layer of Mn2O3 via thermal self-reconstruction. Oxygen vacancies trap isolated Pt atoms and electronically connect them with neighboring Mn centers, forming a vacancy-rich interfacial active center. For benzene oxidation, Pt1/Mn2O3 achieved a specific reaction rate of 45.70 μmol gPt-1 s-1 at 140 °C, which is 3.8 and 11.2 times those of the Pt nanocluster and nanoparticle counterparts, respectively. The catalyst also exhibited excellent thermal stability and enhanced tolerance to SO2 poisoning. Mechanistic studies reveal that the Pt-Ov-Mn interface enables electron-lattice-oxygen coupling: interfacial Pt 5d-Mn 3d electronic interaction upshifts the Pt d-band center, strengthening benzene π adsorption and promoting C-H activation and ring opening, while adjacent oxygen vacancies accelerate lattice-oxygen migration and replenishment through a Mars-van Krevelen cycle. This coupled pathway suppresses the accumulation of partially oxidized intermediates and drives deep mineralization to CO2. These findings identify surface-layer atomic interfaces as designable active centers for developing robust SACs toward hazardous VOC control.
中文摘要:单原子催化剂在VOC治理方面具有前景,但孤立原子稳定性与氧化还原活性之间的权衡限制了其应用。这里报道通过热自重构在Mn2O3外层构建的表面限域Pt-Ov-Mn原子界面。氧空位捕获孤立Pt原子,并使其与相邻Mn中心发生电子连接,形成富空位的界面活性中心。对于苯氧化,Pt1/Mn2O3在140 °C下达到45.70 μmol gPt-1 s-1的比反应速率,分别为Pt纳米团簇和纳米颗粒对应材料的3.8倍和11.2倍。该催化剂还表现出优异的热稳定性与增强的SO2中毒耐受性。机理研究表明,Pt-Ov-Mn界面可实现电子-晶格氧耦合:界面Pt 5d-Mn 3d电子相互作用使Pt d带中心上移,增强苯的π吸附并促进C-H活化和开环,同时相邻氧空位通过Mars-van Krevelen循环加速晶格氧迁移与补充。该耦合路径抑制部分氧化中间体的积累,并驱动深度矿化为CO2。这些发现表明表层原子界面可作为可设计的活性中心,用于开发面向危险VOC控制的稳健单原子催化剂。
Proton exchange membrane fuel cells (PEMFCs) hold great promise for low-carbon energy systems, yet their commercial viability is hindered by performance bottlenecks, particularly at the cathode catalyst layer (CCL). Central to the performance of PEMFCs is the triple-phase boundary (TPB), where the oxygen reduction reaction (ORR) occurs. However, achieving an ideal TPB is complicated by ionomer-induced poisoning, oxygen mass transport resistance, proton conduction discontinuities, and water management challenges. This review discusses the challenges associated with the TPB, focusing on ionomer poisoning, oxygen mass transport, proton conduction, and water management, and highlights the strategies to optimize each of these issues. It also covers recent advances in material strategies, including ionomer molecular engineering, surface functionalization of carbon supports, and catalyst design, aimed at improving TPB formation and maintaining optimal transport conditions. The study emphasizes the importance of optimizing the TPB for improving the efficiency and durability of PEMFCs, providing insights into designing next-generation low-Pt catalysts with enhanced performance.
中文摘要:质子交换膜燃料电池(PEMFCs)在低碳能源系统中具有很大潜力,但其商业化受性能瓶颈制约,阴极催化层(CCL)尤为突出。PEMFC性能的核心是三相边界(TPB),氧还原反应(ORR)在此发生。然而,离聚物诱导中毒、氧传质阻力、质子传导不连续以及水管理难题使理想TPB难以实现。综述讨论TPB相关挑战,聚焦离聚物中毒、氧传质、质子传导与水管理,并归纳针对各项问题的优化策略。文中还涵盖材料策略的最新进展,包括离聚物分子工程、碳载体表面功能化和催化剂设计,目标是改善TPB形成并维持最佳传输条件。该研究强调优化TPB对提升PEMFC效率与耐久性的重要性,并为设计性能增强的下一代低铂催化剂提供见解。
Personalized Federated Continual Learning (PFCL) requires that the server not only effectively integrate temporal knowledge accumulated across past tasks and spatial knowledge distributed among heterogeneous clients, but also ensure strong personalized performance of the global model for each client. Existing methods, whether in Personalized Federated Learning (PFL) or Federated Continual Learning (FCL), have overlooked the multi-granularity representation of knowledge, which can be utilized to overcome Spatial-Temporal Catastrophic Forgetting (STCF) and enable coarse-to-fine personalization. Furthermore, most approaches rely on local client-side personalization, increasing computational load and failing to address the risks posed by malicious or low-quality clients. To this end, we propose FedMGP+, which utilizes multi-granularity prompts to address these challenges, namely coarse-grained global prompt and fine-grained local prompt. The former focuses on efficiently transferring shared global knowledge without spatial forgetting, and the latter emphasizes specific learning of personalized local knowledge to overcome temporal forgetting. Visualization results and theoretical analyses further reveal that coarse-grained prompts primarily guide regional attention, whereas fine-grained prompts enrich object-level representations within those regions. Building upon this, Personalized Selective Prompt Fusion is designed to exclusively fuse coarse-grained knowledge on the server to generate client-specific global prompts, reducing local overhead and resisting poisoning attacks from malicious clients. Extensive experiments demonstrate that the proposed FedMGP+ effectively mitigates forgetting, significantly enhances personalized performance, and provides robust defense against poisoning and gradient leakage attacks.
中文摘要:个性化联邦持续学习(PFCL)要求服务器不仅有效整合过去任务积累的时间知识和异构客户端分布的空间知识,还要保证全局模型对每个客户端具有较强个性化性能。现有方法无论属于个性化联邦学习(PFL)还是联邦持续学习(FCL),都忽视了知识的多粒度表示,而这种表示可用于克服时空灾难性遗忘并实现由粗到细的个性化。此外,多数方法依赖客户端本地个性化,增加计算负担,也无法应对恶意或低质量客户端带来的风险。为此,提出FedMGP+,利用多粒度提示应对这些挑战,即粗粒度全局提示和细粒度局部提示。前者侧重高效迁移共享全局知识而不发生空间遗忘,后者强调个性化局部知识的特定学习以克服时间遗忘。可视化结果和理论分析进一步表明,粗粒度提示主要引导区域注意力,细粒度提示则丰富这些区域内对象级表示。在此基础上,设计个性化选择性提示融合,仅在服务器端融合粗粒度知识以生成客户端特定的全局提示,降低本地开销并抵御恶意客户端的投毒攻击。大量实验表明,FedMGP+有效缓解遗忘,显著提升个性化性能,并对投毒和梯度泄露攻击提供稳健防御。
Acetaminophen (APAP) overdose is the leading cause of acute liver failure in Western countries. However, the inflammatory mechanisms underlying APAP-induced liver injury (AILI) remain poorly understood. Interleukin (IL)-19 exerts its biological effects through binding to the IL-20 receptor complex (IL-20R1/IL-20R2). This study aimed to investigate the role of IL-19 in AILI. Il19-deficient mice and myeloid cell-specific Il20r2 knockout mice were generated and subjected to AILI. Single-cell RNA sequencing (ScRNA-seq) was performed to analyze hepatic macrophage subsets. Il19-deficient mice exhibited increased susceptibility to AILI, accompanied by a distinct transcriptional profile and a marked increase in proinflammatory macrophage infiltration. Treatment with recombinant IL-19 significantly suppressed proinflammatory macrophage infiltration and attenuated AILI. scRNA-seq analysis revealed that myeloid cell-specific Il20r2 deficiency exacerbated AILI and was associated with increased infiltration of S100A8/A9+ proinflammatory macrophages. Mechanistically, IL-19 downregulated CCAAT/enhancer-binding protein β (C/EBPβ) expression in macrophages by promoting its post-translational SUMOylation. This reduced C/EBPβ-mediated transcription of proinflammatory genes, including those regulating S100A8/A9 expression, thereby ameliorating AILI. IL-19 plays a key role in limiting proinflammatory macrophage infiltration and thereby ameliorates early-stage AILI. These findings suggest that IL-19 may represent a promising therapeutic target for AILI. Although IL-19 signals through the IL-20 receptor complex (IL-20R1/IL-20R2), its role in liver disease remains incompletely understood. Here, we show that IL-19 protects against APAP-induced liver injury by restricting the infiltration of S100A8/A9+ proinflammatory macrophages. Both Il19-deficient mice and myeloid cell-specific Il20r2-deficient mice displayed increased susceptibility to APAP hepatotoxicity and enhanced accumulation of S100A8/A9+ proinflammatory macrophages. Mechanistically, IL-19 promotes C/EBPβ SUMOylation, thereby suppressing proinflammatory gene expression. These findings identify IL-19 as a potential therapeutic target for acute liver injury.
中文摘要:对乙酰氨基酚(APAP)过量是西方国家急性肝衰竭的主要原因。然而,APAP诱导的肝损伤(AILI)背后的炎症机制仍不清楚。白细胞介素(IL)-19通过与IL-20受体复合物(IL-20R1/IL-20R2)结合发挥生物学效应。本研究旨在探讨IL-19在AILI中的作用。研究构建了Il19缺陷小鼠和髓系细胞特异性Il20r2敲除小鼠,并使其发生AILI。采用单细胞RNA测序(scRNA-seq)分析肝脏巨噬细胞亚群。Il19缺陷小鼠对AILI易感性增加,伴随独特的转录谱和促炎巨噬细胞浸润显著增加。给予重组IL-19可显著抑制促炎巨噬细胞浸润并减轻AILI。scRNA-seq分析显示,髓系细胞特异性Il20r2缺陷加重AILI,并与S100A8/A9+促炎巨噬细胞浸润增加相关。机制上,IL-19通过促进CCAAT/增强子结合蛋白β(C/EBPβ)的翻译后SUMO化,下调巨噬细胞中C/EBPβ表达。这减少了C/EBPβ介导的促炎基因转录,包括调控S100A8/A9表达的基因,从而改善AILI。IL-19在限制促炎巨噬细胞浸润、改善早期AILI中发挥关键作用。这些发现提示IL-19可能是AILI有前景的治疗靶点。尽管IL-19通过IL-20受体复合物(IL-20R1/IL-20R2)传递信号,但其在肝病中的作用仍未完全明确。本研究报告IL-19通过限制S100A8/A9+促炎巨噬细胞浸润,防止APAP诱导的肝损伤。Il19缺陷小鼠和髓系细胞特异性Il20r2缺陷小鼠均对APAP肝毒性更易感,并伴有S100A8/A9+促炎巨噬细胞聚集增强。机制上,IL-19促进C/EBPβ SUMO化,从而抑制促炎基因表达。这些发现将IL-19确定为急性肝损伤的潜在治疗靶点。
7心肺复苏与心脏骤停 (2篇)
临床研究 (2篇)
Extended embryo culture beyond Day-6 remains controversial. While a small subset of embryos reaches the blastocyst stage on Day-7, their developmental competence and reproductive potential remain uncertain. Data from previous studies have been limited and heterogeneous, particularly for meta-analytical evaluation of euploid embryo transfers. This systematic review and meta-analysis compared clinical pregnancy (CPR) and live birth rates (LBR), as well as implantation (IR), miscarriage (MR), and ongoing pregnancy rates (OPR), between Day-7 frozen blastocysts and those obtained on Day-5 and/or Day-6. Euploidy rates by day of blastocyst development and available perinatal outcomes were also assessed. Conducted according to PRISMA guidelines, this review included full-length English-language human studies, published up to 1 April 2026, comparing frozen transfers of Day-7 versus Day-5/6 blastocysts and reporting at least clinical pregnancy and/or live birth outcomes. Random-effects models were used to estimate pooled odds ratios (ORs) with 95% confidence intervals (95% CI). Obstetric and perinatal outcomes were analysed when available. A total of 17 retrospective studies were included. Across 2908 Day-7 transfers, CPR and LBR were significantly lower than for Day-5 (CPR: OR 0.26, 95% CI 0.19-0.35, I2: 76.2%, 16 studies, 2799 and 34 442 transfers at Day-7 and Day-5, respectively; LBR: OR 0.23, 95% CI 0.16-0.33, I2: 76.3%, 12 studies, 2687 and 31 630 transfers at Day-7 and Day-5, respectively) and Day-6 blastocysts (CPR: OR 0.38, 95% CI 0.31-0.48, I2: 54.4%, 16 studies, 2799 and 28 563 transfers at Day-7 and Day-6, respectively; LBR: OR 0.37, 95% CI 0.28-0.49, I2: 60.2%, 12 studies, 2687 and 26 687 transfers at Day-7 and Day-6, respectively). Similarly, IR and OPR were significantly lower in the Day-7 group than in the Day-5 or Day-6 groups, while MR was higher compared with Day-5 blastocysts (OR 1.54, 95% CI 1.04-2.30, I2: 51.1%, 14 studies, 685 and 18 609 pregnancies at Day-7 and Day-5, respectively). When considering only PGT-A euploid blastocysts, CPR and LBR remained significantly lower in the Day-7 group compared with Day-5 (CPR: OR 0.21, 95% CI 0.14-0.33, I2: 58.0%, 7 studies, 365 and 7064 transfers at Day-7 and Day-5, respectively; LBR: OR 0.21, 95% CI 0.17-0.28, I2: 0%, 6 studies, 364 and 5924 transfers at Day-7 and Day-5, respectively) and Day-6 (CPR: OR 0.36, 95% CI 0.28-0.46, I2: 40.8%, 7 studies, 365 and 4617 transfers at Day-7 and Day-6, respectively; LBR: OR 0.36, 95% CI 0.28-0.46, I2: 0%, 6 studies, 364 and 3782 transfers at Day-7 and Day-6, respectively), and MR was higher than Day-5 (OR 2.78, 95% CI 1.57-4.89, I2: 32.4%, 6 studies, 95 and 4018 pregnancies at Day-7 and Day-5, respectively). Euploid rates were also significantly reduced for Day-7 blastocysts compared with Day-5 and Day-6. Data on perinatal outcomes were limited but overall reassuring. The pooled analyses revealed low to high heterogeneity across studies. Despite lower success rates, including for euploid embryos, Day-7 blastocysts may still contribute to cumulative live birth rates, notably in poor-prognosis patients. Prospective studies are needed to better assess perinatal and long-term outcomes. PROSPERO (CRD420251114251).
中文摘要:体外延长培养至第6天以后仍存在争议。小部分胚胎在第7天达到囊胚阶段,其发育能力和生殖潜能仍不确定。既往研究数据有限且异质性较大,尤其缺乏对整倍体胚胎移植的荟萃分析评估。本系统综述和荟萃分析比较第7天冷冻囊胚与第5天和/或第6天获得的囊胚在临床妊娠率(CPR)、活产率(LBR)、种植率(IR)、流产率(MR)和持续妊娠率(OPR)方面的差异,并评估按囊胚发育天数计算的整倍体率及可获得的围产期结局。本综述按PRISMA指南开展,纳入截至2026年4月1日发表的英文全文人类研究,这些研究比较第7天与第5天/第6天冷冻囊胚移植,并报告至少临床妊娠和/或活产结局。采用随机效应模型估计合并比值比(OR)及95%置信区间(95% CI)。在有数据时分析产科和围产期结局。共纳入17项回顾性研究。在2908例第7天移植中,CPR和LBR显著低于第5天(CPR:OR 0.26,95% CI 0.19-0.35,I2:76.2%,16项研究,第7天和第5天分别为2799例和34442例移植;LBR:OR 0.23,95% CI 0.16-0.33,I2:76.3%,12项研究,第7天和第5天分别为2687例和31630例移植)和第6天囊胚(CPR:OR 0.38,95% CI 0.31-0.48,I2:54.4%,16项研究,第7天和第6天分别为2799例和28563例移植;LBR:OR 0.37,95% CI 0.28-0.49,I2:60.2%,12项研究,第7天和第6天分别为2687例和26687例移植)。同样,第7天组的IR和OPR显著低于第5天或第6天组,而MR高于第5天囊胚(OR 1.54,95% CI 1.04-2.30,I2:51.1%,14项研究,第7天和第5天分别为685例和18609例妊娠)。仅考虑PGT-A整倍体囊胚时,第7天组的CPR和LBR仍显著低于第5天(CPR:OR 0.21,95% CI 0.14-0.33,I2:58.0%,7项研究,第7天和第5天分别为365例和7064例移植;LBR:OR 0.21,95% CI 0.17-0.28,I2:0%,6项研究,第7天和第5天分别为364例和5924例移植)和第6天(CPR:OR 0.36,95% CI 0.28-0.46,I2:40.8%,7项研究,第7天和第6天分别为365例和4617例移植;LBR:OR 0.36,95% CI 0.28-0.46,I2:0%,6项研究,第7天和第6天分别为364例和3782例移植),且MR高于第5天(OR 2.78,95% CI 1.57-4.89,I2:32.4%,6项研究,第7天和第5天分别为95例和4018例妊娠)。与第5天和第6天相比,第7天囊胚的整倍体率也显著降低。围产期结局数据有限,但总体令人安心。合并分析显示研究间异质性为低至高度。尽管成功率较低,包括整倍体胚胎,第7天囊胚仍可能对累积活产率有贡献,尤其在预后较差患者中。需要前瞻性研究更好地评估围产期和长期结局。PROSPERO(CRD420251114251)。
During routine fertilization checks, the presence of two pronuclei (2PN) with two polar bodies is generally regarded as normal fertilization. Nonpronuclear (0PN) zygotes often suggest failed fertilization, but some do cleave and develop into viable embryos due to delayed appearances of pronuclei that were originally missed. Monopronuclear (1PN) zygotes may result from a lack of maternal or paternal pronuclei, fusion of pronuclei, or asynchronous appearance of pronuclei. These embryos may sometimes be transferred when no others are available. Current evidence on the euploidy rates (ER) and clinical outcomes of embryos derived from 0PN and 1PN zygotes is discordant across publications, resulting in conflicting conclusions regarding whether they are suitable for transfer. This review aims to present an updated synthesis of current knowledge regarding the potential adverse outcomes associated with 0PN and 1PN embryo transfers and to identify important gaps that should be addressed in future studies. CENTRAL, Embase, Fertility and Sterility, MEDLINE, and PubMed databases were searched on 10 November 2025 using the keywords '0PN embryo' and '1PN embryo'. All types of studies, except case reports and reviews, were included if they compared 0PN/1PN with 2PN zygotes in women of any age undergoing IVF/ICSI cycles, followed by single embryo transfer (SET) and/or preimplantation genetic testing for aneuploidy (PGT-A). Pronuclear status was assessed 16-18 h post insemination. Only data from SET cycles were included for embryo transfer outcomes. Eleven studies reporting on 37 240 SET cycles and 27 195 biopsied blastocysts were included. Compared to 2PN embryos, those derived from 0PN zygotes showed no significant differences in live birth rate (LBR) (OR = 0.94, 95% CI = 0.83-1.06, P = 0.33, I2 = 2%), clinical pregnancy rate (CPR) (OR = 0.96, 95% CI = 0.85-1.08, P = 0.48, I2 = 0%), miscarriage rate (MR) (OR = 1.04, 95% CI = 0.84-1.29, P = 0.70, I2 = 0%), malformation rate (OR = 1.05, 95% CI = 0.45-2.45, P = 0.91, I2 = 0%), and ER (OR = 0.86, 95% CI = 0.50-1.48, P = 0.59, I2=63%). However 0PN-derived embryos had a significantly lower blastulation rate (OR = 0.34, 95% CI = 0.17-0.68, P = 0.002; I2 = 99%). Compared to 2PN, 1PN embryos showed a significantly lower LBR (OR = 0.83, 95% CI = 0.70-0.98, P = 0.03, I2 = 12%), CPR (OR = 0.81, 95% CI = 0.68-0.96, P = 0.01, I2 = 22%), and blastulation rate (OR = 0.26, 95% CI = 0.14-0.48, P < 0.001; I2 = 96%), but a similar MR (OR = 1.34, 95% CI = 0.76-2.37, P = 0.31, I2 = 67%), malformation rate (OR = 0.46, 95% CI = 0.16-1.32, P = 0.15, I2 = 0%), and ER (OR = 1.05, 95% CI = 0.70-1.58, P = 0.80, I2 = 66%). In the meta-analysis, both 0PN- and 1PN-derived embryos showed no significant differences in rates of euploidy, miscarriage, and malformations compared to 2PN-derived embryos. However, clinical pregnancy and LBRs were significantly lower for 1PN, but not 0PN, embryos than for 2PN embryos. These findings suggest that 0PN-, and possibly even 1PN-, derived embryos, especially those that have undergone PGT-A, may represent a viable source for embryo transfer in certain clinical settings, particularly in cases where 2PN embryos are limited or unavailable. CRD42024546685.
中文摘要:常规受精检查中,出现两个原核并伴两个极体通常被视为正常受精。无原核(0PN)合子常提示受精失败,但部分合子因原核出现延迟而被漏检,仍可卵裂并发育为可移植胚胎。单原核(1PN)合子可能源于母源或父源原核缺失、原核融合或原核不同步出现;在无其他胚胎可用时,这类胚胎有时会被移植。现有关于0PN和1PN来源胚胎整倍体率及临床结局的证据并不一致,导致其是否适合移植的结论存在冲突。该综述旨在更新并整合当前知识,梳理0PN和1PN胚胎移植可能相关的不良结局,并指出未来研究需解决的重要空白。检索于2025年11月10日进行,数据库包括CENTRAL、Embase、Fertility and Sterility、MEDLINE和PubMed,关键词为「0PN embryo」和「1PN embryo」。纳入除病例报告和综述外的各类研究,条件为在任何年龄接受IVF/ICSI周期的女性中比较0PN/1PN与2PN合子,并随后进行单胚胎移植和/或胚胎植入前非整倍体遗传学检测。原核状态在授精后16-18小时评估。胚胎移植结局仅纳入单胚胎移植周期数据。共纳入11项研究,报告37240个单胚胎移植周期和27195个活检囊胚。与2PN胚胎相比,0PN合子来源胚胎的活产率(OR=0.94,95%CI=0.83-1.06,P=0.33,I2=2%)、临床妊娠率(OR=0.96,95%CI=0.85-1.08,P=0.48,I2=0%)、流产率(OR=1.04,95%CI=0.84-1.29,P=0.70,I2=0%)、畸形率(OR=1.05,95%CI=0.45-2.45,P=0.91,I2=0%)和整倍体率(OR=0.86,95%CI=0.50-1.48,P=0.59,I2=63%)均无显著差异;但0PN来源胚胎的囊胚形成率显著更低(OR=0.34,95%CI=0.17-0.68,P=0.002,I2=99%)。与2PN相比,1PN胚胎的活产率(OR=0.83,95%CI=0.70-0.98,P=0.03,I2=12%)、临床妊娠率(OR=0.81,95%CI=0.68-0.96,P=0.01,I2=22%)和囊胚形成率(OR=0.26,95%CI=0.14-0.48,P<0.001,I2=96%)显著更低,流产率(OR=1.34,95%CI=0.76-2.37,P=0.31,I2=67%)、畸形率(OR=0.46,95%CI=0.16-1.32,P=0.15,I2=0%)和整倍体率(OR=1.05,95%CI=0.70-1.58,P=0.80,I2=66%)相近。该荟萃分析中,0PN和1PN来源胚胎的整倍体率、流产率和畸形率与2PN来源胚胎均无显著差异;1PN胚胎的临床妊娠率和活产率显著低于2PN胚胎,0PN胚胎则未见此差异。这些结果提示,在特定临床情形下,尤其是2PN胚胎有限或不可用时,0PN来源胚胎以及可能包括1PN来源胚胎,特别是已接受胚胎植入前非整倍体遗传学检测者,可作为胚胎移植的可选来源。CRD42024546685。
8呼吸系统疾病 (1篇)
基础研究 (1篇)
Respiratory diseases remain major causes of morbidity and mortality; however, inadequate pulmonary drug exposure and systemic toxicity continue to limit treatment efficacy. Inhaled nanomedicines offer opportunities for localized, sustained, and targeted therapy. This review examines how disease biology informs pulmonary delivery design across pulmonary fibrosis, lung cancer, chronic obstructive pulmonary disease, pulmonary infections, and acute lung injury/acute respiratory distress syndrome. It outlines anatomical and biological barriers and compares liposomes, lipid nanoparticles, polymeric and hybrid systems, biomimetic carriers, and stimuli-responsive formulations. Particular attention is given to matching therapeutic cargo and carrier properties to fibroblasts, macrophages, tumor cells, and alveolar type II cells. Emerging approaches include mRNA delivery, siRNA-mediated gene silencing, antisense oligonucleotides, and CRISPR-based editing, alongside alveolar regeneration and biomarker-guided treatment. These strategies are evaluated in relation to their delivery requirements and stage of development. The review also addresses aerosol-device compatibility, manufacturing, repeated-dose safety, regulatory considerations, and clinical outcomes. By connecting delivery mechanisms with disease-specific applications and clinical evidence, this review identifies both therapeutic opportunities and barriers to translation. This integrated perspective can guide the development of inhaled nanomedicines with more reproducible pulmonary delivery, improved treatment efficacy, and acceptable safety.
中文摘要:呼吸系统疾病仍是发病和死亡的重要原因;肺部药物暴露不足和全身毒性继续限制治疗效果。吸入纳米药物为局部、持续和靶向治疗提供机会。本综述考察疾病生物学如何指导肺内递送设计,覆盖肺纤维化、肺癌、慢性阻塞性肺疾病、肺部感染以及急性肺损伤/急性呼吸窘迫综合征。文章概述解剖与生物学屏障,并比较脂质体、脂质纳米颗粒、聚合物与杂化系统、仿生载体和刺激响应制剂。重点关注将治疗载荷和载体特性匹配至成纤维细胞、巨噬细胞、肿瘤细胞和肺泡II型细胞。新兴方向包括mRNA递送、siRNA介导的基因沉默、反义寡核苷酸和基于CRISPR的编辑,以及肺泡再生和生物标志物指导的治疗。这些策略依据其递送需求和开发阶段接受评估。综述还讨论气溶胶装置兼容性、生产、重复给药安全性、监管考量与临床结局。通过将递送机制与疾病特异性应用及临床证据相连,综述识别治疗机会和转化障碍。这一整合视角可指导吸入纳米药物的开发,使其具有更可重复的肺部递送、更好的疗效和可接受的安全性。
9眼科影像筛查 (1篇)
临床研究 (1篇)
To externally validate a deep-learning (DL) algorithm detecting perimetric glaucoma on color fundus photographs (CFPs) in a population-based cohort. External validation in a prospective population-based cohort. Participants aged 50-80 years from three Rotterdam Study cohorts. We applied the winning Artificial Intelligence for Robust Glaucoma Screening (AIROGS) challenge algorithm, trained on 101,442 macula-centered CFPs to detect referable presumed perimetric glaucoma. Performance was assessed at eye and participant level, with participant-level cluster bootstrap confidence intervals. Misclassified cases underwent qualitative review. Longitudinal detection was evaluated by Kaplan-Meier analysis. Additionally, paired analyses compared macula- with disc-centered CFPs. A post-hoc analysis examined the effect of image quality on positive predictive value (PPV). Sensitivity at 95% specificity, area under the receiver operating characteristic curve (ROC-AUC), partial AUC (pAUC) for 90-100% specificity, PPV, and precision-recall AUC (PR-AUC). Among 19,088 eyes (9,837 participants), 201 eyes (1.1%) had perimetric glaucoma. At eye level, sensitivity at 95% specificity was 70.6% (95% CI: 63.8-76.8), with an ROC-AUC of 0.911 (95% CI: 0.887-0.934) and a PR-AUC of 0.343 (95% CI: 0.274-0.427). At participant level, sensitivity was 68.8% (95% CI: 61.8-75.9) and ROC-AUC 0.909 (95% CI: 0.882-0.934). Overall, this resulted in 5.1 referrals per detected glaucoma case. True positives showed more advanced visual field damage than false negatives (median mean deviation -10.8 vs -5.8 dB; P < 0.001). Among true positives with prior imaging, 33 of 61 (54%) were flagged before conversion, typically 4-7 years before diagnosis. Discrimination in the 90-100% specificity range was higher for disc- than macula-centered CFPs (pAUC 0.860 vs 0.802; P = 0.003). PPV improved substantially after excluding CFPs with incomplete optic nerve head (ONH) visibility. The DL-algorithm achieved meaningful discrimination for perimetric glaucoma in an external population-based dataset. Correctly identified cases were frequently flagged at an earlier examination, years before the perimetric diagnosis. Despite having been trained exclusively on macula-centered CFPs, the DL-algorithm showed no loss of discriminative performance on disc-centered CFPs. Incomplete ONH visibility was an important source of false positives. These findings support CFP-based deep learning as a scalable triage tool for glaucoma screening and highlight image acquisition standards for implementation.
中文摘要:在基于人群的队列中对一种在彩色眼底照片(CFP)上检测视野确诊青光眼的深度学习(DL)算法进行外部验证。研究为前瞻性基于人群队列的外部验证。参与者为来自三个鹿特丹研究队列的50至80岁人群。我们应用了AIROGS挑战赛获胜算法,该算法在101,442张以黄斑为中心的CFP上训练,用于检测可转诊的疑似视野确诊青光眼。在眼水平和参与者水平评估性能,参与者水平采用聚类自助法置信区间。对误分类病例进行定性复核。通过Kaplan-Meier分析评估纵向检出情况。另进行配对分析,比较以黄斑为中心与以视盘为中心的CFP。事后分析考察图像质量对阳性预测值(PPV)的影响。指标包括95%特异度下的敏感度、受试者工作特征曲线下面积(ROC-AUC)、90-100%特异度范围的部分AUC(pAUC)、PPV和精确率-召回率AUC(PR-AUC)。在19,088只眼(9,837名参与者)中,201只眼(1.1%)存在视野确诊青光眼。眼水平95%特异度下敏感度为70.6%(95% CI:63.8-76.8),ROC-AUC为0.911(95% CI:0.887-0.934),PR-AUC为0.343(95% CI:0.274-0.427)。参与者水平敏感度为68.8%(95% CI:61.8-75.9),ROC-AUC为0.909(95% CI:0.882-0.934)。总体而言,每检出1例青光眼对应5.1例转诊。真阳性者的视野损害程度高于假阴性者(平均偏差中位数-10.8 vs -5.8 dB;P < 0.001)。在有既往影像的真阳性者中,61例中有33例(54%)在转化前被标记,通常在诊断前4-7年。90-100%特异度范围内的区分能力在以视盘为中心的CFP上高于以黄斑为中心的CFP(pAUC 0.860 vs 0.802;P = 0.003)。排除视神经乳头(ONH)可见性不完整的CFP后,PPV显著提高。该DL算法在外部基于人群数据集中对视野确诊青光眼达到了有意义的区分能力。被正确识别的病例常在更早的检查中被标记,早于视野确诊青光眼诊断数年。尽管仅以黄斑为中心CFP训练,该DL算法在以视盘为中心CFP上未显示区分性能下降。ONH可见性不完整是假阳性的重要来源。这些发现支持基于CFP的深度学习作为青光眼筛查的可扩展分诊工具,并提示实施中的图像采集标准。
10暴力伤害预防 (1篇)
临床研究 (1篇)
Firearm violence is a leading cause of morbidity and mortality for US adolescents and emerging adults (A/EAs). Health care visits are an important opportunity to provide preventive counseling addressing risky firearm behaviors (RFBs), which increase fatal and nonfatal firearm injury risk, as well as associated negative health and social outcomes. To determine the efficacy of a technology-augmented behavioral counseling intervention addressing RFBs among A/EAs seeking emergency department (ED) treatment. This prospective, 2-arm randomized clinical trial was conducted at 2 US trauma center EDs in Michigan. A/EAs aged 16 to 30 years reporting past 3-month firearm carriage and smartphone ownership were enrolled from January 24, 2022, through October 25, 2024, and randomized to either IntERact or enhanced usual care (EUC). Follow-up surveys were conducted through April 2025, with data analysis conducted from May 2025 to November 2025. IntERact included (1) 3 sessions of trauma-informed behavioral counseling delivered by a telehealth health coach and integrating motivational interviewing and strengths-based care management; and (2) a smartphone application delivering additional tailored therapeutic content between counseling sessions. Both were delivered during the 30 days after an ED visit. EUC participants received an assessment-only application for 30 days. Participants in both groups received a resource brochure and gunlock(s). The primary outcome was self-reported RFBs evaluated at 3 and 6 months. Secondary outcomes included experiencing physical violence and nonfirearm physical aggression. Exploratory outcomes included violent injuries, violence consequences, criminal justice outcomes, substance use and consequences, mental health symptoms, and any firearm violence. A total of 373 patients were randomized to IntERact (n = 186) or EUC (n = 187). Mean (SD) age was 25.0 (3.7) years, 195 patients (52.3%) were female, and 278 of 371 patients (74.9%) reported past 3-month RFBs at baseline. Compared to EUC, IntERact participants demonstrated significantly greater reductions in RFBs at 6 months (IntERact: -57.4%; EUC: -25.4%; rate ratio [RR] = 0.51; 95% CI, 0.33-0.79). IntERact participants also demonstrated significantly greater reductions in experiencing physical violence at 3 months (RR = 0.46; 95% CI, 0.26-0.81) compared to EUC. Among exploratory outcomes, between-group comparisons demonstrated that compared to EUC, patients in the IntERact group showed greater reductions in violent injuries at 3 and 6 months, as well as violence consequences, substance use, anxiety, and depression outcomes at 6 months. Patients in the IntERact group also showed greater reductions in delinquency, violent offending, and any firearm violence at both 3 and 6 months. In this randomized clinical trial among A/EAs reporting firearm carriage, technology-augmented behavioral counseling showed promise reducing RFBs, as well as violence, criminal justice, substance use, and mental health outcomes. ClinicalTrials.gov Identifier: NCT05109325.
中文摘要:枪支暴力是美国青少年和新兴成年人(A/EAs)发病和死亡的主要原因。就医访问是提供预防性咨询的重要机会,这些咨询针对增加致命和非致命枪支伤害风险以及相关不良健康和社会结局的危险枪支行为(RFBs)。旨在确定一种针对寻求急诊科(ED)治疗的A/EAs中RFBs的技术增强行为咨询干预的效果。这项前瞻性、两臂随机临床试验在美国密歇根州2家创伤中心ED开展。2022年1月24日至2024年10月25日纳入年龄16至30岁、报告过去3个月携带枪支且拥有智能手机的A/EAs,并随机分配至IntERact或增强常规照护(EUC)。随访调查持续至2025年4月,数据分析于2025年5月至2025年11月进行。IntERact包括:(1)由远程医疗健康教练提供的3次创伤知情行为咨询,整合动机性访谈和基于优势的照护管理;(2)在咨询间期提供额外个体化治疗内容的智能手机应用。两者均在ED就诊后30天内提供。EUC参与者接受为期30天的仅评估应用。两组参与者均获得资源手册和枪锁。主要结局为3个月和6个月时自我报告的RFBs。次要结局包括经历身体暴力和非枪支身体攻击。探索性结局包括暴力伤害、暴力后果、刑事司法结局、物质使用及其后果、精神健康症状和任何枪支暴力。共373例患者随机分配至IntERact(n=186)或EUC(n=187)。平均(SD)年龄25.0(3.7)岁,195例患者(52.3%)为女性,371例患者中278例(74.9%)在基线报告过去3个月RFBs。与EUC相比,IntERact参与者在6个月时RFBs减少更显著(IntERact:-57.4%;EUC:-25.4%;率比[RR]=0.51;95%CI 0.33-0.79)。与EUC相比,IntERact参与者在3个月时经历身体暴力的减少也更显著(RR=0.46;95%CI 0.26-0.81)。在探索性结局中,组间比较显示,与EUC相比,IntERact组患者在3个月和6个月时暴力伤害减少更明显,6个月时暴力后果、物质使用、焦虑和抑郁结局也减少更明显。IntERact组患者在3个月和6个月时违法行为、暴力犯罪和任何枪支暴力也显示更大减少。在这项报告携带枪支的A/EAs随机临床试验中,技术增强行为咨询在减少RFBs以及暴力、刑事司法、物质使用和精神健康结局方面显示出前景。ClinicalTrials.gov标识符:NCT05109325。
11循环液体管理 (1篇)
临床研究 (1篇)
To evaluate the mechanistic specificity of capillary leak clinical indices by testing their performance in a heart failure population as a negative control. Retrospective observational study. Tertiary-care academic medical center. Adults with chronic heart failure (both stable outpatients and those with acute decompensation) undergoing clinically indicated blood volume analysis. None. Clinical capillary leak indices, Sequential Organ Failure Assessment score, Capillary Leak Index, Vascular Leak Index, and Hematocrit-Albumin Difference, were calculated and compared with the transcapillary escape rate of albumin (TERalb) by Spearman correlation. Across analyses, indices showed weak or absent correlation with TERalb, indicating a lack of mechanistic specificity outside acute inflammatory illness. Clinical capillary leak indices do not accurately reflect true capillary permeability in a cohort of patients with chronic and acute-on-chronic heart failure, suggesting that they should be interpreted as context-dependent markers rather than as general measures of endothelial permeability.
中文摘要:旨在通过以心力衰竭人群作为阴性对照,检验毛细血管渗漏临床指标的机制特异性。采用回顾性观察性研究,在三级学术医疗中心开展。对象为接受临床指征性血容量分析的成人慢性心力衰竭患者,包括稳定的门诊患者和急性失代偿患者。无干预。计算临床毛细血管渗漏指标、序贯器官衰竭评估评分、毛细血管渗漏指数、血管渗漏指数及血细胞比容-白蛋白差值,并与白蛋白跨毛细血管逃逸率(TERalb)进行Spearman相关分析。各项分析中,这些指标与TERalb呈弱相关或无相关,提示其在急性炎症性疾病之外缺乏机制特异性。在慢性及慢性基础上急性加重的心力衰竭患者队列中,临床毛细血管渗漏指标不能准确反映真实的毛细血管通透性,应将其视为依赖背景的标志物,而非内皮通透性的通用测量。
12创伤与急诊外科 (1篇)
基础研究 (1篇)
Hemorrhage is a leading cause of mortality in humans, responsible for approximately two million deaths annually worldwide. The contraction of blood clots is a robust process that occurs intravascularly to reduce the size of pathological thrombi. However, it is not clear if clot contraction contributes to hemostasis. Here we show that blood clots in laceration wounds contract, and the forces can decrease the size of wounds by up to 80%. Clots contracted after penetrating injuries in swine, as revealed by scanning electron microscopy. Contraction was robust throughout hemorrhagic shock in two swine models, with ex vivo clots becoming 20-40% of their initial volume (60-80% contraction) at sustained rates of ∼1.5% of clot volume min-1. In two models of laceration, one using a synthetic gel and the other using ex vivo lacerated livers, contraction decreased the size of wounds in a platelet-dependent response, generating forces up to approximately 0.5 N. A ten-fold increase in platelet count increased the closure by ∼22%. A mechanics-based computational model representing the clot as a tunable biomaterial composed of fibrin fibers and platelet motors replicated and confirmed this phenomenon. Thus, platelet-driven clot contraction is an important component of the hemostatic response to severe injury, and contraction is a tunable process that may be useful for improving biomaterials for hemostasis.
中文摘要:出血是人类死亡的主要原因之一,全球每年约造成两百万人死亡。血凝块收缩是一种强健的过程,发生在血管内,可缩小病理性血栓的体积。但血凝块收缩是否有助于止血尚不清楚。在裂伤创口中,血凝块会收缩,其产生的力可使创口尺寸缩小至多80%。扫描电子显微镜显示,猪穿透伤后血凝块发生收缩。在两种猪模型中,失血性休克全程收缩均很显著,离体血凝块体积降至初始体积的20-40%(收缩60-80%),并持续以约每分钟1.5%血凝块体积的速率进行。在两种裂伤模型中,一种使用合成凝胶,另一种使用离体裂伤肝脏,收缩以血小板依赖的方式缩小创口,产生的力可达约0.5 N。血小板计数增加十倍使闭合程度提高约22%。一个以力学为基础的计算模型将血凝块表示为由纤维蛋白纤维和血小板马达组成的可调生物材料,复现并证实了这一现象。因此,血小板驱动的血凝块收缩是严重损伤后止血反应的重要组成部分,收缩是一个可调过程,可能有助于改进用于止血的生物材料。
13其他 (15篇)
临床研究 (11篇)
Coronary Care Units (CCUs) were at the forefront of the development of intensive care in the 1960s and 1970s. The development of CCUs, and intensive care more broadly, was enabled by the interplay of expanding medical technology and the evolving role of nurses vis-à-vis physicians. This paper examines the history the CCU at New York Hospital, the teaching hospital of Cornell University School of Medicine and School of Nursing, with a particular focus on role of nurses in the unit's success. Drawing from historical archives of New York Hospital and the Cornell University School of Nursing, this paper argues that that nurses were co-creators, alongside physicians, of the NYH CCU, and demonstrates how nurses drew from the NYH CCU experience to expand critical care services at the local and national level, including by advocating for the creation of the NYH medical intensive care unit (MICU), leading a CCU nurse training program to expand regional CCU capability, and contributing expertise to a federally-sponsored national conference on CCUs. A close reading of this history offers lessons and insights as intensive care medicine moves into an uncertain future, chief among them that work of caring for critically ill patients requires the thoughtful integration of new technologies with hands on care.
中文摘要:冠心病监护病房(CCU)处在20世纪60至70年代重症监护发展的前沿。CCU以及更广泛重症监护的发展,得益于医学技术扩展与护士相对医生角色演变之间的相互作用。本文考察康奈尔大学医学院与护理学院的教学医院纽约医院CCU的历史,重点聚焦护士在该病房成功中的作用。依据纽约医院与康奈尔大学护理学院的历史档案,本文提出护士与医生共同创造了纽约医院CCU,并说明护士如何借助该CCU经验在地方与全国层面扩展重症监护服务,包括推动创建纽约医院医疗重症监护病房(MICU)、领导CCU护士培训项目以提升区域CCU能力,以及为联邦资助的全国CCU会议贡献专业经验。对这段历史的细读,在重症监护医学走向不确定未来之际提供了经验与启示,其中首要的一点是,照护危重患者的工作需要把新技术与直接床旁照护审慎地结合起来。
Understanding how neonatal functional connectivity at birth is associated with later cognitive performance in infants born very preterm (VPT) may help identify early neuroimaging markers of neurodevelopment. To examine the associations between functional connectivity at birth and cognitive performance at age 2 and 3 years in children born VPT. This prospective cohort study included infants born VPT (gestational age ≤32 weeks) from 5 level III and IV neonatal intensive care units in the greater Cincinnati, Ohio, area between September 16, 2016, and November 19, 2019. Maternal, pregnancy, delivery, and infant clinical data were collected from birth through discharge from the neonatal intensive care unit. Participants underwent magnetic resonance imaging at full-term-equivalent age at Cincinnati Children's Hospital using the same scanner. Image preprocessing and statistical analyses for this study were conducted between January 25, 2025, and July 30, 2026. Cognitive outcomes were assessed at corrected age 2 and 3 years using the Bayley Scales of Infant and Toddler Development, Third Edition and the Differential Ability Scales, Second Edition, respectively. Functional connectivity was measured within and between the default mode network (DMN), somatomotor network (SMN), dorsal attention network (DAN), frontoparietal control network, visual network (VIS), and cingulo-opercular network (CO). Associations between neonatal functional connectivity and longitudinal cognitive outcomes were examined using a bayesian hierarchical linear mixed-effects model. A total of 257 infants born VPT (mean [SD] gestational age, 29.2 [2.5] weeks; 132 male [51.4%]) were included in the final longitudinal analysis. Stronger neonatal connectivity involving the DMN was positively associated with cognitive performance, including intra-DMN (0.23; 95% credible interval [CrI], 0.06-0.39) and DMN connections with the frontoparietal control network (0.24; 95% CrI, 0.07-0.40), SMN (0.20; 95% CrI, 0.02-0.37), VIS (0.32; 95% CrI, 0.13-0.51), and CO (0.39; 95% CrI, 0.21-0.56). Positive associations were also observed for SMN-VIS (0.27; 95% CrI, 0.12-0.43) and SMN-CO (0.26; 95% CrI, 0.09-0.44) connectivity. The SMN-VIS was the only connection showing a difference between assessments, with a less pronounced association at 3 years than at 2 years (interaction, -0.09; 95% CrI, -0.20 to <0.01). In this cohort study of infants born VPT, neonatal functional network organization was associated with cognitive performance at corrected age 2 and 3 years. The findings highlight the relevance of distributed connectivity involving the DMN and SMN to later cognitive outcomes and support further investigation of neonatal functional connectivity as an early marker of neurodevelopment.
中文摘要:了解极早产儿出生时新生儿功能连接与后期认知表现的关联,可能有助于识别神经发育的早期神经影像标志物。考察出生时功能连接与极早产儿2岁和3岁时认知表现的关联。这项前瞻性队列研究纳入2016年9月16日至2019年11月19日期间在俄亥俄州大辛辛那提地区5个III级和IV级新生儿重症监护病房出生的极早产儿(胎龄≤32周)。收集从出生至出院期间的母亲、妊娠、分娩和婴儿临床数据。参与者在Cincinnati Children's Hospital使用同一台扫描仪,在相当于足月龄时接受磁共振成像。本研究的图像预处理和统计分析于2025年1月25日至2026年7月30日进行。认知结局分别在矫正年龄2岁和3岁时评估,使用Bayley Scales of Infant and Toddler Development第三版和Differential Ability Scales第二版。功能连接测量默认模式网络(DMN)、感觉运动网络(SMN)、背侧注意网络(DAN)、额顶控制网络、视觉网络(VIS)和扣带-岛盖网络(CO)内部及网络间连接。使用贝叶斯分层线性混合效应模型分析新生儿功能连接与纵向认知结局的关联。最终纵向分析纳入257名极早产儿(平均[SD]胎龄29.2[2.5]周;132名男性[51.4%])。涉及DMN的更强新生儿连接与认知表现呈正相关,包括DMN内部连接(0.23;95%可信区间[CrI],0.06-0.39)以及DMN与额顶控制网络(0.24;95% CrI,0.07-0.40)、SMN(0.20;95% CrI,0.02-0.37)、VIS(0.32;95% CrI,0.13-0.51)和CO(0.39;95% CrI,0.21-0.56)的连接。SMN-VIS(0.27;95% CrI,0.12-0.43)和SMN-CO(0.26;95% CrI,0.09-0.44)连接也观察到正相关。SMN-VIS是唯一在两次评估间存在差异的连接,3岁时的关联不如2岁时明显(交互作用,-0.09;95% CrI,-0.20至<0.01)。在这项极早产儿队列研究中,新生儿功能网络组织与矫正年龄2岁和3岁时的认知表现相关。研究结果强调涉及DMN和SMN的分布式连接与后期认知结局相关,并支持进一步研究新生儿功能连接作为神经发育早期标志物。
Children with airway hyperresponsiveness face higher risks of perioperative respiratory adverse events. Although the use of supraglottic airway devices (SADs) is associated with fewer perioperative respiratory adverse events than tracheal intubation in selected paediatric populations, evidence remains limited regarding induction-phase airway management in children with airway hyperresponsiveness. We aimed to investigate the association between SAD placement (vs tracheal intubation) and respiratory adverse events during induction-phase airway management in children with airway hyperresponsiveness using propensity score-based inverse probability of treatment weighting. This multicentre retrospective cohort study was conducted at 12 tertiary-care institutions (six paediatric and six mixed adult-paediatric university hospitals) in the Japan Paediatric Difficult Airway in Anaesthesia registry between July 2022 and February 2025. We included children aged <18 yr undergoing general anaesthesia who had an active upper respiratory tract infection, an upper respiratory tract infection within the preceding 14 days, asthma exacerbation, or household smoking exposure. The primary outcome was the occurrence of respiratory adverse events. Of the 27 844 encounters, 4878 were analysed (tracheal intubation 3005 of 4878 [61.6%]; SAD 1873 of 4878 [38.4%]). After adjustment, SAD placement was associated with a lower risk of respiratory adverse events (adjusted risk ratio [aRR] 0.41; 95% confidence interval [CI] 0.19-0.62; P<0.001), airway management-related adverse events (aRR 0.32; 95% CI 0.19-0.45; P<0.001), and severe oxygen desaturation (aRR 0.47; 95% CI 0.19-0.75; P<0.001). Overall, supraglottic airway device use during induction of anaesthesia was associated with a lower risk of adverse respiratory events in children with airway hyperresponsiveness. These findings support consideration of supraglottic airway devices when clinically appropriate while acknowledging potential residual confounding.
中文摘要:气道高反应性患儿围术期呼吸不良事件风险较高。在部分儿科人群中,使用声门上气道装置(SAD)与较气管插管更少的围术期呼吸不良事件相关,但气道高反应性患儿诱导期气道管理方面的证据仍有限。该研究旨在采用基于倾向评分的逆概率治疗加权,探讨气道高反应性患儿诱导期气道管理中放置SAD(相较于气管插管)与呼吸不良事件之间的关联。这项多中心回顾性队列研究纳入日本儿科麻醉困难气道(J-PEDIA)注册研究中2022年7月至2025年2月期间12家三级医疗机构(6家儿科医院和6家成人儿科混合大学医院)的病例。研究对象为接受全身麻醉、年龄<18岁,且存在活动性上呼吸道感染、既往14天内上呼吸道感染、哮喘急性发作或家庭吸烟暴露的儿童。主要结局为呼吸不良事件的发生。在27,844例次记录中,4,878例次纳入分析(气管插管3005/4878[61.6%];SAD 1873/4878[38.4%])。校正后,放置SAD与较低的呼吸不良事件风险相关(校正风险比[aRR]0.41;95%置信区间[CI]0.19-0.62;P<0.001),与较低的气道管理相关不良事件风险相关(aRR 0.32;95% CI 0.19-0.45;P<0.001),并与较低的严重氧饱和度下降风险相关(aRR 0.47;95% CI 0.19-0.75;P<0.001)。总体而言,麻醉诱导期使用声门上气道装置与气道高反应性患儿较低的呼吸不良事件风险相关。这些结果支持在临床合适时考虑使用声门上气道装置,同时需承认可能存在残余混杂。
To investigate associations between polyendocrine metabolic ovarian syndrome (PMOS) and maternal and neonatal outcomes and explore interactions with BMI and ethnicity. This was a prospective nested cohort study of pregnant women with risk factors for hyperglycemia enrolled in an international, multicenter, randomized controlled trial of gestational diabetes mellitus (GDM) treatment. We compared baseline and pregnancy characteristics, evaluated adverse maternal and neonatal outcomes by PMOS status, and used multivariable regression models to evaluate factors (maternal age, baseline BMI, ethnicity, parity, smoking, and level of education) that independently affected maternal and neonatal outcomes. Of 3,645 participants, PMOS prevalence was 17.1% (95% CI 15.9, 18.3). At booking visits, women with PMOS (vs. without) were younger (30.6 ± 4.7 vs. 31.3 ± 5.2 years; P < 0.001) and had higher median (interquartile range) BMI at baseline (29.8 [25.1-35.7] vs. 28.1 [24.1-33.9] kg/m2; P < 0.001), and more were primigravid (30.2% [n = 188] vs. 25.7% [n = 778]; P = 0.022). There were positive associations between PMOS and early GDM, with an adjusted odds ratio (aOR) of 1.37 (95% CI 1.10, 1.72), a composite of adverse neonatal outcomes (aOR 1.28 [95% CI 1.04, 1.58]), admission to a neonatal special care nursery or neonatal intensive care unit (aOR 1.32 [95% CI 1.05-1.65]), and negative associations between PMOS and gestational age at birth (-1.60 days [95% CI -2.82, -0.39]) and birth length (-0.33 cm [95% CI -0.61, -0.04]). No interactions were found with baseline BMI and ethnicity. PMOS was associated with higher odds of early GDM, and neonatal outcomes were poorer on adjusted analyses, highlighting independent pregnancy risks in PMOS and the need to identify, monitor, and treat women with PMOS to mitigate risks of adverse pregnancy outcomes.
中文摘要:探讨多内分泌代谢性卵巢综合征(PMOS)与孕产妇及新生儿结局之间的关联,并探索其与BMI和种族的交互作用。这是一项前瞻性巢式队列研究,对象为参加一项国际多中心妊娠期糖尿病(GDM)治疗随机对照试验、具有高血糖风险因素的孕妇。比较基线和妊娠特征,按PMOS状态评估不良孕产妇和新生儿结局,并使用多变量回归模型评估独立影响孕产妇和新生儿结局的因素(母亲年龄、基线BMI、种族、产次、吸烟和教育水平)。在3645名参与者中,PMOS患病率为17.1%(95% CI 15.9, 18.3)。首次就诊时,PMOS女性(与无PMOS者相比)更年轻(30.6 ± 4.7 vs. 31.3 ± 5.2岁;P < 0.001),基线BMI中位数(四分位距)更高(29.8 [25.1-35.7] vs. 28.1 [24.1-33.9] kg/m2;P < 0.001),初产妇更多(30.2% [n = 188] vs. 25.7% [n = 778];P = 0.022)。PMOS与早期GDM呈正相关,调整后比值比(aOR)为1.37(95% CI 1.10, 1.72),与不良新生儿结局复合终点(aOR 1.28 [95% CI 1.04, 1.58])、入住新生儿特殊护理病房或新生儿重症监护病房(aOR 1.32 [95% CI 1.05-1.65])呈正相关,与出生时胎龄(-1.60天 [95% CI -2.82, -0.39])和出生身长(-0.33 cm [95% CI -0.61, -0.04])呈负相关。未发现与基线BMI和种族的交互作用。PMOS与早期GDM的更高几率相关,调整分析中新生儿结局更差,突出PMOS独立的妊娠风险,以及识别、监测和治疗PMOS女性以降低不良妊娠结局风险的必要性。
Cluster randomized trials (CRTs) are useful for evaluating system-level interventions in critical care but raise complex ethical and methodological issues that are amplified in this setting. We aimed to describe ethical and methodological features of CRTs in critical care settings. We performed a systematic literature search in MEDLINE and Embase. We included primary reports of CRTs in critical care settings published from 2004 to 2022 in English. Two reviewers independently extracted data from each CRT, resolving any discrepancies by consensus. Among 102 CRTs, 77 CRTs (78%) reported trial registration and 101 CRTs (99%) reported research ethics committee review; five CRTs (5%) were exempted from review. Common designs were parallel-arm (48, 47%), two-period crossover (23, 23%), stepped-wedge (20, 20%), and multi-period crossover (8, 8%). A justification for using cluster randomization was provided in 47 CRTs (46%). Patients and caregivers were identified as research participants in 99 CRTs (97%). Of these, 74 CRTs (75%) reported on consent, which was most commonly waived consent (36, 49%). Healthcare providers were identified as research participants in 48 CRTs (47%). Of these, 11 CRTs (23%) reported on consent. Most (82, 80%) reported a sample size or power calculation, with 67 CRTs (82%) accounting for the intracluster correlation; 77 CRTs (76%) accounted for the intracluster correlation in the primary analysis. Among 85 CRTs with fewer than 40 clusters, 11 CRTs (13%) reported a small sample correction. Ethical and methodological shortcomings persist in CRTs. Enhanced reporting standards and adherence to established ethical frameworks, including the Ottawa Statement , are needed to ensure both scientific and ethical integrity in this essential design in critical care research.
中文摘要:集群随机试验(CRTs)适用于评价重症监护中的系统层面干预,但其伦理与方法学问题在该场景中被放大。研究旨在描述重症监护环境中CRTs的伦理与方法学特征。检索MEDLINE和Embase,纳入2004至2022年以英文发表的重症监护环境CRTs原始报告。两名评价者独立提取每项CRT的数据,分歧通过共识解决。102项CRTs中,77项(78%)报告试验注册,101项(99%)报告研究伦理委员会审查,5项(5%)获豁免审查。常见设计为平行组(48项,47%)、两周期交叉(23项,23%)、阶梯楔形(20项,20%)和多周期交叉(8项,8%)。47项CRTs(46%)说明采用集群随机的理由。99项CRTs(97%)将患者和照护者确定为研究参与者;其中74项(75%)报告知情同意情况,最常见为免除知情同意(36项,49%)。48项CRTs(47%)将医护人员确定为研究参与者;其中11项(23%)报告知情同意情况。多数(82项,80%)报告样本量或把握度计算,67项(82%)考虑集群内相关性;77项(76%)在主要分析中考虑集群内相关性。85项集群数少于40的CRTs中,11项(13%)报告小样本校正。CRTs仍存在伦理与方法学不足。需要改进报告标准并遵循既有伦理框架(包括渥太华声明),以确保这一重症监护研究重要设计兼具科学性与伦理完整性。
Clinical practice guidelines and consensus statements are increasingly influential in anaesthesia, perioperative medicine, pain medicine, and critical care. Despite drawing upon similar evidence bases, recommendations frequently differ across countries, professional societies, and healthcare systems. Such variation may reflect differences in methodology, evidence appraisal, resource availability, patient populations, health policy, cultural context, and stakeholder priorities. To address this challenge, the British Journal of Anaesthesia is launching a new series that will systematically compare and synthesise international guideline documents, using structured appraisal frameworks.
中文摘要:临床实践指南和共识声明在麻醉学、围手术期医学、疼痛医学和重症监护中的影响力日益增强。尽管依据相似证据基础,不同国家、专业学会和医疗体系之间的推荐意见却经常不同。这种差异可能反映方法学、证据评价、资源可及性、患者人群、卫生政策、文化背景和利益相关方优先事项的不同。为应对这一挑战,《英国麻醉学杂志》将推出一个新系列,采用结构化评价框架系统比较和综合国际指南文件。
This study was designed to explore the effect of intraoperative corticosteroid administration at antiemetic doses on postoperative pulmonary complications in adult patients undergoing major surgery. We designed a post hoc analysis of two clinical trials conducted across 30 hospitals that included adult patients undergoing major abdominal or thoracic surgeries. Patients who received intraoperative corticosteroids were identified and balanced with those who did not receive corticosteroids using inverse probability of treatment weighting based on preoperative confounders. The primary outcome was a composite of postoperative pulmonary complications within 30 days after surgery. Generalised mixed-effects models with random intercepts at each hospital were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). A total of 1963 patients were included. Before weighting for potential confounders, the incidence of severe postoperative pulmonary complications was lower in those who received corticosteroids than those who did not (9.3% [107/1142] vs 14.0% [113/821], P=0.002). After weighting, intraoperative corticosteroids were not associated with a significant reduction in the incidence of postoperative pulmonary complications (OR 0.86, 95% CI 0.62-1.18, P=0.347), but there was a modest improvement in partial pressure of oxygen in arterial blood-to-fraction of inspired oxygen ratios in the PACU in those who received intraoperative corticosteroids compared with those who did not (adjusted mean difference 19.9 mm Hg, 95% CI 0.64-39.1, corrected P=0.043). Corticosteroid administration at antiemetic doses in adult patients having major abdominal or thoracic surgery was not associated with a lower incidence of postoperative pulmonary complications. Postoperative pulmonary gas exchange marginally improved in patients receiving intraoperative corticosteroids. NCT03182062 and NCT02798133.
中文摘要:本研究旨在探讨成人大型手术中给予止吐剂量的糖皮质激素对术后肺部并发症的影响。我们设计了两项在30家医院开展的临床试验的事后分析,纳入接受腹部或胸部大型手术的成年患者。识别术中接受糖皮质激素的患者,并基于术前混杂因素采用逆概率治疗加权,使其与未接受糖皮质激素的患者达到平衡。主要结局为术后30天内肺部并发症的复合终点。采用以医院为随机截距的广义混合效应模型计算比值比(OR)及95%置信区间(CI)。共纳入1963例患者。加权前,接受糖皮质激素者严重术后肺部并发症发生率低于未接受者(9.3%[107/1142]对14.0%[113/821],P=0.002)。加权后,术中糖皮质激素与术后肺部并发症发生率显著降低无关(OR 0.86,95%CI 0.62-1.18,P=0.347),但接受术中糖皮质激素者在麻醉后监护室(PACU)的动脉血氧分压与吸入氧分数比值有轻度改善(校正均差19.9 mmHg,95%CI 0.64-39.1,校正P=0.043)。在接受腹部或胸部大型手术的成年患者中,给予止吐剂量的糖皮质激素与术后肺部并发症发生率降低无关。接受术中糖皮质激素的患者术后肺气体交换有边缘性改善。NCT03182062和NCT02798133。
To review how the human microbiome impacts management of the critically ill or injured patient. English-language manuscripts were sourced from PubMed and OVID from inception to August 2025. Manuscripts addressing the mammalian microbiome, microbiome characterization, microbiome derangement, microbiome restoration, critical care interventions, the ICU, and organ system outcomes related to the human microbiome. Gray literature was excluded. Data that informed microbiome characterization, derangement, support, manipulation, as well as the impact of the microbiome on critical care medicine interventions or outcomes were abstracted. Humans demonstrate a variety of unique microbiomes spanning eyes, skin, oropharynx, lung, bladder, and gastrointestinal tract. The most identifiable active outside of the lifecycles of resident microbiota is the gastrointestinal microbiome. The gastrointestinal microbiome plays a critical role in health maintenance as well as the physiologic recovery-or failure-of the critically ill or injured. Microbial balance disruption is common in ICU patients due to index admission disease processes as well as rescue or management therapeutics. Understanding how disease-modulated and therapy-driven microbiome changes occur-as well as their impact-may reveal strategies to improve critical care outcomes. The gastrointestinal microbiome serves as a lens through which microbial actions and host-microbe-regulated functions may be understood. Based on the impact of the human microbiome on critical care-relevant interventions and outcomes, the ICU clinician will benefit from understanding: 1) microbiome evaluation fundamentals, 2) microbiome adaptive or maladaptive alteration by disease process as well as therapeutic agents, and 3) current and emerging interventions to mitigate pathobiome induction and restore homeostasis to improve outcomes.
中文摘要:综述人类微生物组如何影响危重或创伤患者的管理。检索PubMed与OVID自建库至2025年8月的英文文献,纳入讨论哺乳动物微生物组、微生物组特征描述、微生物组紊乱、微生物组恢复、重症监护干预、ICU以及与人类微生物组相关的器官系统结局的稿件,排除灰色文献。提取用于说明微生物组特征、紊乱、支持、调控以及微生物组对重症医学干预或结局影响的数据。人类的眼、皮肤、口咽、肺、膀胱和胃肠道存在多种独特微生物组。除常住微生物生命周期之外最可识别的活跃部分为胃肠道微生物组。胃肠道微生物组在健康维持以及危重或创伤患者的生理恢复或失败中起关键作用。ICU患者常因入院原发疾病过程及抢救或管理治疗而出现微生物平衡破坏。理解疾病调节和治疗驱动的微生物组变化及其影响,可能揭示改善重症监护结局的策略。胃肠道微生物组可作为理解微生物作用及宿主-微生物调控功能的视角。基于人类微生物组对重症监护相关干预和结局的影响,ICU临床医生将受益于理解:1)微生物组评估基础;2)疾病过程及治疗药物导致的微生物组适应性或适应不良性改变;3)当前和新兴的干预措施,以减轻致病微生物组诱导并恢复稳态以改善结局。
Physician orders for life-sustaining treatment (POLST) and advance directives (AD) aim to honor patient autonomy. However, the impact of the signatory's identity-whether the patient or a surrogate-on clinical trajectories in the ICU remains poorly characterized. The aim was to evaluate the association of signatory identity with terminal care intensity and hospitalization costs among adult patients in the ICU. This nationwide population-based cohort study utilized the South Korean National Health Insurance Service database, including 1 189 042 adult ICU admissions between 2020 and 2023. Statistical analyses employed high-dimensional fixed-effects models to account for institutional variability across 417 hospitals. Among 1 189 042 patients, surrogate-determined POLST (SD-POLST) was more than 3 times as prevalent as patient-determined POLST (PD-POLST). Among 90-day decedents, PD-POLST was associated with significantly reduced odds of invasive terminal care (OR, 0.43; 95% CI, 0.43-0.54). Conversely, SD-POLST more than doubled the odds (OR, 2.16; 95% CI, 1.98-2.35). Notably, even patients with proactive ADs experienced increased care intensity once a surrogate signed the final order (OR, 1.69; 95% CI, 1.51-1.89), indicating a phenomenon of "AD erosion." SD-POLST also was associated with significantly higher daily hospitalization costs (cost ratio, 1.04; 95% CI, 1.02-1.06) compared with no documentation. The clinical efficacy of POLST in limiting nonbeneficial care depends fundamentally on the signatory. Surrogate-led decisions were associated with paradoxically higher care intensity and costs, potentially overriding prior patient wishes. These findings highlight the critical importance of early, patient-led discussions to ensure goal-concordant end-of-life care in the ICU.
中文摘要:生命维持治疗医嘱(POLST)与预立医疗指示(AD)旨在尊重患者自主权,但签署者身份为患者本人或代理决策者时,对ICU临床轨迹的影响仍缺乏充分描述。本研究评估签署者身份与成人ICU患者终末期治疗强度及住院费用之间的关联。这项全国性人群队列研究使用韩国国民健康保险服务数据库,纳入2020年至2023年间1,189,042例成人ICU住院。统计分析采用高维固定效应模型,以解释417家医院间的机构差异。在1,189,042例患者中,由代理决策者确定的POLST(SD-POLST)流行程度超过由患者本人确定的POLST(PD-POLST)3倍。在90天内死亡者中,PD-POLST与有创终末期治疗几率显著降低相关(OR 0.43;95% CI 0.43-0.54)。相反,SD-POLST使该几率增加一倍以上(OR 2.16;95% CI 1.98-2.35)。即便患者已有主动AD,一旦由代理决策者签署最终医嘱,其治疗强度仍会增加(OR 1.69;95% CI 1.51-1.89),呈现「AD侵蚀」现象。与无相关文书相比,SD-POLST还与更高的每日住院费用显著相关(费用比1.04;95% CI 1.02-1.06)。POLST限制无益医疗的临床效果根本上取决于签署者。代理决策主导的决定与 paradoxically 更高的治疗强度和费用相关,可能覆盖患者先前的意愿。这些发现凸显了早期开展以患者为主导的讨论、以确保ICU中目标一致性的终末期照护至关重要。
To assess the relationship between restricted weight gain or weight loss (defined as weight gain <5 kg) and perinatal outcomes in pregnant individuals with type 2 diabetes. This was a retrospective cohort study of 954 pregnant individuals with type 2 diabetes from two academic health centers. Maternal demographics, health care utilization, glycemia, and diabetes therapies were compared between groups. Weight gain <5 kg occurred in 327 (34.3%) of all pregnancies. Logistic regression analyses were used to compare perinatal outcomes between those with <5 kg weight gain and ≥5 kg weight gain, adjusted for covariates. Weight gain <5 kg was associated with a significant reduction in the risk for multiple perinatal outcomes, including large-for-gestational-age birth weight (adjusted odds ratio [aOR] 0.42, 95% CI 0.29-0.59), neonatal intensive care unit admission (aOR 0.74, 95% CI 0.55-0.98), hypertensive disorders of pregnancy (aOR 0.56, 95% CI 0.42-0.75), and cesarean delivery (aOR 0.66, 95% CI 0.48-0.91). We did not detect a significant increase in small-for-gestational-age birth weight (aOR 1.61, 95% CI 0.96-2.71) or preterm birth (aOR 0.92, 95% CI 0.67-1.25) in pregnancies with maternal weight gain <5 kg. Weight gain <5 kg was associated with significantly lower rates of several adverse perinatal outcomes. Future interventional studies are needed to assess whether lifestyle or pharmacologic interventions can limit weight gain and improve both short- and long-term maternal and child outcomes in pregnant individuals with type 2 diabetes.
中文摘要:评估2型糖尿病孕妇体重增长受限或体重下降(定义为体重增长<5 kg)与围产结局之间的关系。这项回顾性队列研究纳入来自两个学术健康中心的954例2型糖尿病孕妇,比较两组孕产妇人口学特征、医疗保健利用情况、血糖和糖尿病治疗。全部妊娠中327例(34.3%)体重增长<5 kg。采用Logistic回归分析,在调整协变量后比较体重增长<5 kg与≥5 kg者的围产结局。体重增长<5 kg与多种围产结局风险显著降低相关,包括大于胎龄儿出生体重(调整比值比aOR 0.42,95%CI 0.29-0.59)、新生儿重症监护病房入住(aOR 0.74,95%CI 0.55-0.98)、妊娠期高血压疾病(aOR 0.56,95%CI 0.42-0.75)和剖宫产分娩(aOR 0.66,95%CI 0.48-0.91)。在体重增长<5 kg的妊娠中,未发现小于胎龄儿出生体重(aOR 1.61,95%CI 0.96-2.71)或早产(aOR 0.92,95%CI 0.67-1.25)显著增加。体重增长<5 kg与若干不良围产结局发生率显著降低相关。未来需要干预性研究评估生活方式或药物干预能否限制体重增长,并改善2型糖尿病孕妇及其子女的短期和长期结局。
The acute-on-chronic liver failure (ACLF) multisociety harmonisation initiative represents a global collaborative effort to establish a unified, evidence-based framework for the definition, diagnosis, grading, and management of ACLF. Building on the strengths of existing regional definitions and integrating diverse international perspectives, this consensus provides a pragmatic, globally applicable foundation for clinical practice, research, and education. It also establishes a common framework for patient stratification, organ dysfunction and failure assessment, critical care management, liver transplantation, and the design of future phase II/III trials. Standardised, regulatory-aligned endpoints are expected to improve cross-study comparability, strengthen collaboration, and accelerate development of effective ACLF therapies.
中文摘要:慢加急性肝衰竭(ACLF)多学会协调倡议是一项全球协作,旨在建立统一、循证的框架,用于ACLF的定义、诊断、分级和管理。该共识在现有区域定义优势的基础上,整合不同国际视角,为临床实践、研究和教育提供务实且全球适用的基础。它还建立了患者分层、器官功能障碍与衰竭评估、重症监护管理、肝移植以及未来II/III期试验设计的共同框架。标准化且与监管要求对齐的终点有望提高跨研究可比性,加强协作,并加快有效ACLF疗法的开发。
基础研究 (4篇)
Low-molecular weight heparin (LMWH) remains clinically indispensable for the prevention and treatment of thrombosis in cardiovascular surgery, hemodialysis, and other critical care settings. However, LMWH is constrained by heparin-induced thrombocytopenia (HIT) and supply chain vulnerabilities of animal-derived sources. This study used chemoenzymatic synthesis to engineer homogeneous dodecasaccharide 12G-2, decoupling anticoagulant efficacy from HIT risk via dual structural modulation. Substitution with 2-O-sulfated glucuronic acid conferred conformational rigidity, and engineered sulfation attenuated platelet factor 4 (PF4) binding, whereas the antithrombin-binding domain remained intact. 12G-2 exhibited nanomolar anti-Factor Xa (FXa) activity in vitro, enoxaparin-equivalent venous antithrombotic efficacy, and superior arterial antithrombotic activity in murine thrombosis models, and it showed diminished PF4 binding, attenuated pathological β sheet formation, and minimal recognition by HIT-related antibodies in vitro. Both in vitro and in a murine tail-bleeding model, 12G-2 demonstrated high protamine reversibility, exceeding standard LMWH enoxaparin neutralization efficiency. In washed human platelets, 12G-2-PF4 complexes with the HIT-mimicking antibody KKO failed to induce integrin αIIbβ3 activation or P-selectin release and elicited minimal platelet spreading comparable to resting controls. Safety assessments in mice showed no hepatotoxicity at tested doses and low immunogenicity in a murine PF4-heparin immunization model. In PF4-heparin antibody-positive mice, 12G-2 attenuated platelet activation while exerting stronger FXa inhibition than enoxaparin. These findings established 12G-2 as an alternative to LMWH.
中文摘要:低分子肝素在心血管手术、血液透析及其他重症监护场景中仍是预防和治疗血栓不可替代的药物,但受制于肝素诱导的血小板减少症(HIT)以及动物来源供应链的脆弱性。本研究采用化学酶法合成均一十二糖12G-2,通过双重结构调控使抗凝效力与HIT风险解耦。引入2-O-硫酸化葡萄糖醛酸赋予构象刚性,工程化硫酸化修饰减弱血小板因子4(PF4)结合,而抗凝血酶结合域保持完整。12G-2在体外表现纳摩尔级抗Xa因子活性,在鼠血栓模型中静脉抗血栓效力与依诺肝素相当,动脉抗血栓活性更优;体外显示PF4结合减少、病理性β折叠形成减弱、HIT相关抗体识别极少。在体外及小鼠尾部出血模型中,12G-2均表现出高鱼精蛋白可逆性,中和效率超过标准低分子肝素依诺肝素。在洗涤人血小板中,12G-2-PF4复合物与HIT模拟抗体KKO未能诱导整合素αIIbβ3活化或P选择素释放,引起的血小板铺展极少,与静息对照相当。小鼠安全性评估显示测试剂量下无肝毒性,在小鼠PF4-肝素免疫模型中免疫原性低。在PF4-肝素抗体阳性小鼠中,12G-2减轻血小板活化,同时Xa因子抑制作用强于依诺肝素。这些结果确立12G-2作为低分子肝素的替代选择。
Large language models (LLMs) are increasingly being integrated into anaesthesia, perioperative medicine, and critical care, creating new opportunities to improve communication, decision support, and access to healthcare knowledge. Realising these opportunities equitably depends not only on model capability but also on how LLMs are developed, implemented, used, and governed within healthcare systems. This editorial introduces the Bias Pyramid, a conceptual framework that explains how inequity can emerge across global knowledge ecosystems, institutional information environments, and individual clinical workflows, and identifies opportunities for equitable implementation. By incorporating reinforcing feedback, the framework conceptualises equity as an evolving property of learning healthcare systems that can either amplify existing inequities or progressively improve equity over successive learning cycles. The Bias Pyramid provides a practical implementation framework to guide governance, education, and coordinated action before LLMs become embedded in routine perioperative and critical care practice.
中文摘要:大型语言模型正日益进入麻醉、围手术期医学和重症监护,为改善沟通、决策支持和医疗知识获取带来新机会。能否公平实现这些机会,不仅取决于模型能力,也取决于LLM在医疗系统中如何开发、实施、使用和治理。这篇社论提出「偏见金字塔」这一概念框架,解释不公平如何在全球知识生态、机构信息环境和个人临床工作流程中产生,并指出公平实施的机会。该框架纳入强化反馈,将公平视为学习型医疗系统的一种演化属性,它可能在连续学习周期中放大既有不公平,也可能逐步改善公平。偏见金字塔提供了一个可操作的实施框架,用于在LLM嵌入常规围手术期和重症监护实践之前指导治理、教育和协调行动。
To investigate whether gender disparity in authorship of critical care scientific publications is greater in studies originating from low- and middle-income countries (L/MICs) compared with those from high-income countries (HICs). Cross-sectional bibliometric analysis. Original research publications, including observational studies and randomized controlled trials, published from 2018 to 2022 in the ten critical care journals with the highest 2022 impact factors as reported by Clarivate Analytics Journal Citation Reports. A total of 4,982 publications, 4,479 from HICs, and 503 from L/MICs, comprising 50,357 authors. None. We evaluated the proportion of women authors overall, and in first and senior positions; proportions of coauthors; differences by country income classification; temporal trends; and subgroup analyses stratified by funding type. Women accounted for 31.3% of all authors, 35.4% of first authors, and 21.4% of senior authors. Women's representation was higher in L/MICs than in HICs (38.2% vs. 30.6%; p < 0.01). The proportion of women in first (40.7% vs. 34.7%; p < 0.01) and senior (27.6% vs. 20.7%; p < 0.01) positions was also higher in publications from L/MICs. Coauthorships (i.e., the dyad of first and senior authors) involving at least one woman accounted for less than 30% across all publications. There were temporal increases in overall and senior woman authorship in HICs ( p < 0.01 for both) and in overall authorship in L/MICs ( p = 0.02). Women authors were more frequently represented among funded publications from L/MICs. Among high-impact critical care journals, substantial gender disparities persisted in authorship of publications. Women are better represented in publications from L/MICs, and there was an increase in women's authorship over time in both HICs and L/MICs from 2018 to 2022.
中文摘要:调查危重症医学科学出版物作者性别差异在低收入和中等收入国家(L/MICs)来源的研究中是否高于高收入国家(HICs)。横断面文献计量分析。纳入2018至2022年发表于Clarivate Analytics Journal Citation Reports所报告2022年影响因子最高的十种危重症医学期刊的原创研究论文,包括观察性研究和随机对照试验。共4,982篇论文,其中4,479篇来自HICs,503篇来自L/MICs,涉及50,357名作者。无干预。评估女性作者总体比例、第一作者和资深作者比例;共同作者比例;按国家收入分类的差异;时间趋势;按资助类型分层的亚组分析。女性占全部作者的31.3%,第一作者的35.4%,资深作者的21.4%。L/MICs中女性代表性高于HICs(38.2% vs. 30.6%;p < 0.01)。L/MICs论文中女性第一作者(40.7% vs. 34.7%;p < 0.01)和资深作者(27.6% vs. 20.7%;p < 0.01)比例也更高。至少包含一名女性的共同作者关系(即第一作者与资深作者配对)在所有论文中不足30%。HICs中女性总体作者和资深作者比例随时间增加(两者p < 0.01),L/MICs中女性总体作者比例随时间增加(p = 0.02)。L/MICs获资助论文中女性作者更常见。在高影响力危重症医学期刊中,作者性别差异仍然显著。L/MICs论文中女性代表性更好,2018至2022年HICs和L/MICs女性作者比例均增加。
Acute kidney injury (AKI) is associated with central neurologic complications, notably in critical care, the mechanisms of which are poorly understood. Blood-brain barrier (BBB) disruption is a central mechanism associated with cognitive impairment in chronic kidney disease. The objectives of this study were to characterize the influence of AKI on brain alteration and BBB permeability in a preclinical model. We performed a mouse model of unilateral renal ischemia-reperfusion injury without or with AKI (obtained by removing the contralateral kidney before ischemia). All animals were 7-week-old male C57Bl/6J mice, randomly assigned to groups: AKI, kidney ischemia-reperfusion alone, or control. We assessed neurologic impairment using the modified neurologic severity score and motricity evaluations, quantified BBB disruption by cerebral extravasation of Evans blue and positron emission tomography (PET)/CT imaging with Gallium-68 diethylenetriaminepentaacetic acid ( 68 Ga-DTPA), and performed immunohistochemistry and electron microscopy on brain sections. In mice with AKI, we found neurologic impairment, decreased spontaneous motricity, and cerebral extravasation of Evans blue, which were not observed in mice with renal ischemia-reperfusion without nephrectomy. Cerebral 68 Ga-DTPA PET/CT imaging with imaging confirmed the BBB disruption. In addition, we observed more extracellular vesicles in cerebral endothelial cells by electron microscopy in AKI mice compared with controls. AKI-induced neurologic complications are associated with an early increase in BBB permeability and transcytosis of extracellular vesicles in cerebral endothelium.
中文摘要:急性肾损伤(AKI)与中枢神经系统并发症相关,在重症监护中尤为突出,其机制尚不清楚。血脑屏障(BBB)破坏是慢性肾脏病相关认知障碍的核心机制。本研究旨在在临床前模型中描述AKI对脑改变和BBB通透性的影响。我们建立小鼠单侧肾缺血再灌注损伤模型,分为伴或不伴AKI(缺血前切除对侧肾)等。所有动物为7周龄雄性C57Bl/6J小鼠,随机分为AKI组、单纯肾缺血再灌注组和对照组。采用改良神经功能严重程度评分和运动能力评估评价神经功能损害,通过伊文思蓝脑外渗和镓-68二乙烯三胺五乙酸(68Ga-DTPA)PET/CT成像定量BBB破坏,并对脑切片进行免疫组化和电镜检查。在AKI小鼠中观察到神经功能损害、自发运动能力下降和伊文思蓝脑外渗,而未切除肾脏的肾缺血再灌注小鼠未见这些表现。脑68Ga-DTPA PET/CT成像证实BBB破坏。与对照组相比,AKI小鼠脑内皮细胞中细胞外囊泡增多。AKI所致神经并发症与BBB通透性早期升高及脑内皮细胞外囊泡跨细胞转运相关。